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A B S T R A C T
Background
Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor
compliance. The benefits gained by long-acting preparations, however, may be offset by a higher incidence of adverse effects.
Objectives
To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for
individuals with schizophrenia in terms of clinical, social and economic outcomes.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (February 2011 and October 16, 2013), which is based on regular
searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials.
Selection criteria
Weconsidered all relevant randomised controlled trials (RCTs) focusing onpeoplewith schizophrenia comparingfluphenazine decanoate
or enanthate with placebo or oral anti-psychotics or other depot preparations.
Data collection and analysis
We reliably selected, assessed the quality, and extracted data of the included studies. For dichotomous data, we estimated risk ratio (RR)
with 95% confidence intervals (CI). Analysis was by intention-to-treat. We used the mean difference (MD) for normal continuous
data. We excluded continuous data if loss to follow-up was greater than 50%. Tests of heterogeneity and for publication bias were
undertaken. We used a fixed-effect model for all analyses unless there was high heterogeneity. For this update. we assessed risk of bias of
included studies and used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to create
a ’Summary of findings’ table.
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Main results
This review now includes 73 randomised studies, with 4870 participants. Overall, the quality of the evidence is low to very low.
Compared with placebo, use of fluphenazine decanoate does not result in any significant differences in death, nor does it reduce relapse
over six months to one year, but one longer-term study found that relapse was significantly reduced in the fluphenazine arm (n = 54, 1
RCT, RR 0.35, CI 0.19 to 0.64, very low quality evidence). A very similar number of people left the medium-term studies (six months
to one year) early in the fluphenazine decanoate (24%) and placebo (19%) groups, however, a two-year study significantly favoured
fluphenazine decanoate (n = 54, 1 RCT, RR 0.47, CI 0.23 to 0.96, very low quality evidence). No significant differences were found
in mental state measured on the Brief Psychiatric Rating Scale (BPRS) or in extrapyramidal adverse effects, although these outcomes
were only reported in one small study each. No study comparing fluphenazine decanoate with placebo reported clinically significant
changes in global state or hospital admissions.
Fluphenazine decanoate does not reduce relapse more than oral neuroleptics in the medium term (n = 419, 6 RCTs, RR 1.46 CI 0.75
to 2.83, very low quality evidence). A small study found no difference in clinically significant changes in global state. No difference in
the number of participants leaving the study early was found between fluphenazine decanoate (17%) and oral neuroleptics (18%), and
no significant differences were found in mental state measured on the BPRS. Extrapyramidal adverse effects were significantly less for
people receiving fluphenazine decanoate compared with oral neuroleptics (n = 259, 3 RCTs, RR 0.47 CI 0.24 to 0.91, very low quality
evidence). No study comparing fluphenazine decanoate with oral neuroleptics reported death or hospital admissions.
No significant difference in relapse rates in the medium term between fluphenazine decanoate and fluphenazine enanthate was found
(n = 49, 1 RCT, RR 2.43, CI 0.71 to 8.32, very low quality evidence), immediate- and short-term studies were also equivocal. One
small study reported the number of participants leaving the study early (29% versus 12%) and mental state measured on the BPRS
and found no significant difference for either outcome. No significant difference was found in extrapyramidal adverse effects between
fluphenazine decanoate and fluphenazine enanthate. No study comparing fluphenazine decanoate with fluphenazine enanthate reported
death, clinically significant changes in global state or hospital admissions.
Authors’ conclusions
There are more data for fluphenazine decanoate than for the enanthate ester. Both are effective antipsychotic preparations. Fluphenazine
decanoate produced fewer movement disorder effects than other oral antipsychotics but data were of low quality, and overall, adverse
effect data were equivocal. In the context of trials, there is little advantage of these depots over oral medications in terms of compliance
but this is unlikely to be applicable to everyday clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Depot fluphenazine decanoate and enanthate for schizophrenia
People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment for
these symptoms of schizophrenia are antipsychotic drugs, which can be taken bymouth (tablet) or by an injection (depot). Fluphenazine
was one of the first antipsychotic to be produced in depot form. The depot comes in two forms (decanoate and enanthate). Depot
injections are often used for people who refuse or forget to take tablets (showing poor compliance or adherence with medication).
Fluphenazine is an older antipsychotic drug that is very effective in the treatment of schizophrenia. However, when compared to newer
antipsychotic drugs, fluphenazine may have serious side effects (such as involuntary shaking, tremors, muscle stiffness and the inability
to sit still) and is known to lower people’s mood.
This review aimed to investigate the effects of fluphenazine (decanoate and enanthate) for schizophrenia. Searches for relevant ran-
domised controlled trials was run in February 2011 and October 16, 2013. Authors could include and extract data from 73 studies with
a total of 4870 participants. There were more studies on fluphenazine decanoate than enanthate.The review authors rated the quality of
the evidence in the included trials to be low or very low. A long-term result from only one trial indicated fluphenazine decanoate reduces
the rate of relapse when compared with placebo (‘dummy treatment’). Three studies found that fluphenazine decanoate produced
fewer general movement disorders than oral antipsychotics. However, other results showed, overall, the effects and outcomes, including
adverse effects for fluphenazine (decanoate and enanthate) are similar to other oral and depot antipsychotics. Important outcomes and
information about use of services, going into hospital, satisfaction with care and costs were not reported in any study.
Depot injections may offer an advantage over tablets (oral medication) in terms of people taking their medication (complying and
adhering to treatment). However, this needs to be balanced with the likelihood of serious side effects, such as involuntary shaking,
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muscle stiffness, the inability to sit still and lowering in people’s mood. Results did not show any strong evidence that depot fluphenazine
produced more adverse effects than other antipsychotics.
This should be addressed in future large scale and high quality studies.
This plain language summary has been written by a consumer Ben Gray from Rethink Mental Illness.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: hospital and community
Intervention: FLUPHENAZINE DECANOATE
Comparison: PLACEBO
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
PLACEBO FLUPHENAZINE DE-
CANOATE
Death
Follow-up: 2 years
0 per 1000 0 per 1000
(0 to 0)
RR 5
(0.25 to 99.51)
54
(1 study)
⊕©©©
very low1,2,3
Relapse
Fol-
low-up: medium term (6
months to 1 year)
673 per 1000 418 per 1000
(162 to 1000)
RR 0.62
(0.24 to 1.6)
196
(3 studies)
⊕©©©
very low3,4,5,6
Clinically significant
change in global state -
not reported
See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Hospital admission -
not reported
See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Leaving the study early
Fol-
low-up: medium term (6
months to 1 year)
185 per 1000 241 per 1000
(143 to 406)
RR 1.3
(0.77 to 2.19)
216
(4 studies)
⊕©©©
very low3,4,6
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M ental state
BPRS
Follow-up: 9 months
The mean mental state
in the intervent ion
groups was
2.03 lower
(4.51 lower to 0.45
higher)
16
(1 study)
⊕©©©
very low3,6,7
Extrapyra-
midal adverse effects -
tardive dyskinesia
Follow-up: 2 years
852 per 1000 707 per 1000
(528 to 946)
RR 0.83
(0.62 to 1.11)
54
(1 study)
⊕©©©
very low1,2,3
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: serious - This study had an unclear risk of bias for randomisat ion, allocat ion concealment and blinding.
2 Imprecision: very serious - There were few part icipants and few events; the conf idence intervals are wide.
3 Publicat ion bias: strongly suspected - Four studies or fewer reported data for this outcome.
4 Risk of bias: serious - The studies had an unclear risk of bias for randomisat ion, allocat ion concealment and blinding of
part icipants.
5 Inconsistency: very serious - There is very high heterogeneity.
6 Imprecision: serious - There are wide conf idence intervals.
7 Risk of bias: very serious - This study had a high risk of bias for incomplete outcome data, and an unclear risk of bias for
randomisat ion, allocat ion concealment and blinding.
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B A C K G R O U N D
Description of the condition
One in every 10,000 people per year are diagnosed with
schizophrenia, with a lifetime prevalence of about 1% (Jablensky
1992). It often runs a chronic course with acute exacerbations
and often partial remissions. The neuroleptic group of drugs is
the mainstay treatment for this illness (Dencker 1980). These
are generally regarded as highly effective, especially in controlling
such symptoms as hallucinations and fixed false beliefs (delusions)
(Kane 1986). They seem to reduce the risk of acute relapse.
Anti-psychotic drugs are usually given orally (Aaes-Jorgenson
1985), but compliance with medication given by this route may
be difficult to quantify. Problems with treatment adherence are
common throughout medicine (Haynes 1979). Those who suffer
from long-term illness such as schizophrenia are less likely to take
medication regularly if experiencing adverse effects (Kane 1998),
or if they experience cognitive impairments (David 1994) and ero-
sion of insight. The development of depot injections in the 1960s
and initial clinical trials (Hirsch 1973b) gave rise to extensive use
of depots as a means of long-term maintenance treatment.
Description of the intervention
Fluphenazine was one of the first oral antipsychotics to be pro-
duced in a depot form. Two forms of the depot, a decanoate (Mod-
ecate) and an enanthate (Moditen) are available. The decanoate is
more commonly prescribed (Marder 1990) and lasts about four
to six weeks in the body, while a single dose of the enanthate is
shorter acting (one to three weeks). Evidence also suggests that
the decanoate may produce slightly less adverse effects than its
enanthate counterpart (Kurland 1970). However, in comparison
with newer depot formulations fluphenazine decanoate has been
reported to cause greater extrapyramidal adverse effects (Knights
1979) and to significantly lower mood (De Alarcon 1969a).
How the intervention might work
Depots mainly consist of an ester of the active drug held in an oily
suspension. This is injected intramuscularly and is slowly released.
Depots may be given every one to six weeks. Individuals may be
maintained in the communitywith regular injections administered
by community psychiatric nurses, sometimes in clinics set up for
this purpose (Barnes 1994). The use of depots eradicates covert
non-compliance.
Why it is important to do this review
A systematic review undertaken over a decade ago suggested that,
for those with serious mental illness, stopping anti-psychotics re-
sulted in 58% of people relapsing, whereas only 16% of those
who were still on the drugs became acutely ill within a one-year
period (Davis 1986). Evidence also points to the fact that experi-
encing a relapse of schizophrenia lowers a person’s level of social
functioning and quality of life (Curson 1985). Relapse prevention
has also enormous financial implications. For example, within the
UK, a Department of Health burden of disease analysis in 1996
indicated that schizophrenia accounted for 5.4% of all National
Heath Service inpatient expenditure, placing it behind only learn-
ing disability and stroke in magnitude (DoH 1996).
O B J E C T I V E S
To assess the effects of fluphenazine decanoate and enanthate ver-
sus oral anti-psychotics and other depot neuroleptic preparations
for individuals with schizophrenia in terms of clinical, social and
economic outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials. If a trial had been de-
scribed as ’double blind’ but implied randomisation, we would
have included such trials in a sensitivity analysis (see Sensitivity
analysis). If their inclusion did not result in a substantive differ-
ence, they would have remained in the analyses. If their inclusion
did result in statistically significant differences, we would not have
added the data from these lower quality studies to the results of
the better trials, but presented such data within a subcategory.
We excluded quasi-randomised studies, such as those allocating
by alternate days of the week. Where people were given additional
treatments with fluphenazine decanoate or fluphenazine enan-
thate, we only included data if the adjunct treatment was evenly
distributed between groups and it was only the fluphenazine de-
canoate or fluphenazine enanthate that was randomised.
Types of participants
Adults, however defined, with schizophrenia or related disorders,
including schizophreniform disorder, schizoaffective disorder and
delusional disorder, again, by any means of diagnosis.
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We are interested in making sure that information is as relevant to
the current care of people with schizophrenia as possible so pro-
posed to clearly highlight the current clinical state (acute, early
post-acute, partial remission, remission) as well as the stage (pro-
dromal, first episode, early illness, persistent) and as to whether
the studies primarily focused on people with particular problems
(for example, negative symptoms, treatment-resistant illnesses).
Types of interventions
1. Fluphenazine decanoate: any dose.
2. Fluphenazine enanthate: any dose.
3. Oral anti-psychotics (with the exception of fluphenazine
hydrochloride): any dose.
4. Other depot preparations: any dose.
5. Placebo.
Types of outcome measures
Outcomes were grouped into immediate (zero to five weeks), short
term (six weeks to five months), medium term (six months to one
year) and longer term (over 12 months)
Primary outcomes
1. Death and all causes of mortality
2. Clinical global state
2.1 Relapse
2.2 Clinically significant change in global state - as defined by each
of the studies
3. Leaving the study early
4. Service utilisation outcomes
4.1 Hospital admission
Secondary outcomes
1. Clinical global state
1.1 Mean score/change in global state
2. Behaviour*
3. Mental state
3.1 Clinically significant change in psychotic symptoms - as de-
fined by each of the studies
3.2 Mean score/change in psychotic symptoms
3.3 Clinically significant change in positive symptoms - as defined
by each of the studies
3.4 Mean score/change in positive symptoms
3.5 Clinically significant response in negative symptoms - as de-
fined by each of the studies
3.6 Mean score/change in negative symptoms
4. Extrapyramidal adverse effects
4.1 Incidence of use of antiparkinson drugs
4.2Clinically significant extrapyramidal adverse effects - as defined
by each of the studies
4.3 Mean score/change in extrapyramidal adverse effects
5. Other adverse effects, general and specific
6. Service utilisation outcomes
6.1 Days in hospital
7. Economic outcomes
8. Quality of life/satisfaction with care for either recipients of
care or carers
8.1 Significant change in quality of life/satisfaction - as defined by
each of the studies
8.2 Mean score/change in quality of life/satisfaction.
9. ’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2008) and used GRADE profiler to import data from RevMan 5
(Review Manager) to create ’Summary of findings’ tables. These
tables provide outcome-specific information concerning the over-
all quality of evidence from each included study in the compar-
ison, the magnitude of effect of the interventions examined, and
the sum of available data on all outcomes we rated as important
to patient-care and decision making. We selected the following
main outcomes at medium-term follow-up for inclusion in the
’Summary of findings’ table.
1. Death and all causes of mortality
2. Relapse
3. Clinically significant change in global state
4. Hospital admission
5. Leaving the study early
6. Mental state
7. Extrapyramidal adverse effects
* additional outcome
Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group’s Trials Register
The Trials Search Co-ordinator (TSC) searched the Cochrane
Schizophrenia Group’s Registry of Trials (February 2011 and Oc-
tober 16, 2013) using the following search strategies which have
been developed based on literature review and consulting the au-
thors of the review:
((*anaten* or *Cardilac* or *Cenilene* or *dapotum* or *De-
cafen* or *decazate* or *Decentan* or *enanthate* or *eutimox* or
*Fludeca* or *flufen* or *flunanthate* or *fluphen* or *Idazoxan*
or *Lyogen * or *lyoridin* or *Mirenil* or *modec* or *moditen*
or *Omca* or *Oxyprothepin* or *Pacinol* or *Permitil* or *phen-
athiazine* or *piperazine* or *prolixin* or *Prolongatum* or *Rx
781094* or *sediten* or *selecten* or *Sevinol* or *sinqualone*
or *siqualone* or *trancin*) and (*decanoat* or *depot* or *long?
act* or *delayed?act*)):ti,ab,kw of REFERENCE or (*fluphenaz*
and *depot*):sin of STUDY
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The Cochrane Schizophrenia Group’s Registry of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE,MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group
Module). There is no language, date, document type, or publica-
tion status limitations for inclusion of records into the register.
For previous searches, see Appendix 1.
Searching other resources
1. Reference searching
We also inspected the references of all identified trials for more
studies. We sought each of the included studies as a citation on
the SCISEARCH database. Then we inspected reports of articles
that had cited these studies in order to identify further trials.
2. Personal contact
We tried to contact the first author of each included study for in-
formation regarding unpublished trials. We contacted companies
producing depots and made requests for reports of published and
unpublished trials. Where authors responded, this is noted in the
Characteristics of included studies.
Data collection and analysis
This is an update of the original review (David 2004). Methods
used in data collection and analysis for this update are below, for
previous methods please see Appendix 2.
Selection of studies
For the update screening, two members of the Enhance Reviews
team (NM and RA) independently inspected citations from the
2011 and 2013 searches and identified relevant abstracts. A ran-
dom 20% sample was independently re-inspected by a senior re-
searcher in the team to ensure reliability. Where disputes arose,
the full report was acquired for more detailed scrutiny. If citations
met inclusion criteria, we obtained full reports of the papers for
more detailed inspection. Again, a random 20% of reports were
re-inspected by a senior researcher in the team in order to ensure
reliable selection. Where it was not possible to resolve disagree-
ment by discussion, we attempted to contact the authors of the
study for clarification.
Data extraction and management
1. Extraction
For this update, review author NM extracted data from included
studies and RA checked the data.We extracted data presented only
in graphs and figures whenever possible, but only included if two
review authors had the same results. When further information
was necessary, we contacted authors of studies in order to obtain
missing data or for clarification. No studies were multi-centre;
had there been, we would have extracted data relevant to each
component centre separately where possible.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument has not been written or modified by
one of the trialists for that particular trial.
2.3 Endpoint versus change data
There are advantages to both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difficult in
unstable and difficult tomeasure conditions such as schizophrenia.
We decided primarily to use endpoint data, and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we used mean differences (MD)
rather than standardised mean differences throughout (Higgins
2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aimed to apply the following
standards to all data before inclusion: a) standard deviations and
means are reported in the paper or obtainable from the authors;
b) when a scale starts from the finite number zero, the standard
deviation, when multiplied by two, is less than the mean (as oth-
erwise the mean is unlikely to be an appropriate measure of the
centre of the distribution (Altman 1996)); c) if a scale started from
a positive value (such as the Positive and Negative Syndrome Scale
(PANSS), Kay 1986), which can have values from 30 to 210), we
modified the calculation described above to take the scale starting
point into account. In these cases skew is present if 2 SD > (S-S
min), where S is the mean score and S min is the minimum score.
Endpoint scores on scales often have a finite start and end point
and these rules can be applied. We entered skewed endpoint data
from studies of fewer than 200 participants in ’other tables’ within
the data and analyses section rather than into a statistical analysis.
Skewed data pose less of a problem when looking at mean if the
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sample size is large; we entered such data from studies with over
200 participants into syntheses.
When continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difficult
to tell whether data are skewed or not; we entered skewed change
data into analyses.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962)
or the Positive and Negative Syndrome Scale (PANSS, Kay 1986),
this could be considered as a clinically significant response (Leucht
2005; Leucht 2005a). If data based on these thresholds were not
available, we used the primary cut-off presented by the original
authors.
2.7 Direction of graphs
We entered data in such a way that the area to the left of the line of
no effect indicated a favourable outcome for fluphenazine esters.
Assessment of risk of bias in included studies
For this 2013 update, the Enhanced Reviews team used the crite-
ria described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) to assess trial quality. This new set of
criteria is based on evidence of associations between overestimate
of effect and high risk of bias of the article such as sequence gener-
ation, allocation concealment, blinding, incomplete outcome data
and selective reporting.
We have noted the level of risk of bias in both the text of the
review and in the Summary of findings for the main comparison,
Summary of findings 2 and Summary of findings 3.
Measures of treatment effect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive (Boissel 1999) than odds ratios
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). The Number Needed to Treat/Harm (NNT/H)
statistic with its confidence intervals is intuitively attractive to
clinicians but is problematic both in its accurate calculation in
meta-analyses and interpretation (Hutton 2009). Therefore, we
did not present NNTs.
2. Continuous data
For continuous outcomes, we estimated mean difference (MD)
between groups. We prefer not to calculate effect size measures
(standardised mean difference SMD). However, if scales of very
considerable similarity were used, we presumed there was a small
difference in measurement, and we calculated effect size and trans-
formed the effect back to the units of one or more of the spe-
cific instruments. Where trials reported mean data adjusted for
baseline and standard error using ANCOVA, we entered this data
using the generic inverse variance according to section 9.4.5.2 of
the Cochrane Handbook (Higgins 2011).
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Authors often fail to account for in-
tra-class correlation in clustered studies, leading to a ’unit of anal-
ysis’ error (Divine 1992) whereby P values are spuriously low, con-
fidence intervals unduly narrow and statistical significance overes-
timated. This causes type I errors (Bland 1997; Gulliford 1999).
None of the trials we included were cluster trials. Had there been,
where clustering was not accounted for in primary studies, we
would have presented data in a table, with a (*) symbol to indicate
the presence of a probable unit of analysis error. In subsequent
versions of this review, we would seek to contact first authors of
studies to obtain intra-class correlation coefficients (ICCs) for their
clustered data and to adjust for this by using accepted methods
(Gulliford 1999). Where clustering had been incorporated into
the analysis of primary studies, we would have presented these
data as if from a non-cluster randomised study, but adjusted for
the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’de-
sign effect’. This is calculated using the mean number of partici-
pants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC]
(Donner 2002). If the ICC was not reported we would have as-
sumed it to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed taking into ac-
count ICCs and relevant data documented in the report, synthe-
sis with other studies would have been possible using the generic
inverse variance technique.
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2. Cross-over trials
Some included studies used a cross-over design. A major concern
of cross-over trials is the carry-over effect. It occurs if an effect (e.g.
pharmacological, physiological or psychological) of the treatment
in the first phase is carried over to the second phase. As a conse-
quence, on entry to the second phase the participants can differ
systematically from their initial state despite a wash-out phase. For
the same reason cross-over trials are not appropriate if the condi-
tion of interest is unstable (Elbourne 2002). As both effects are
very likely in severe mental illness, we only used data of the first
phase of cross-over studies.
3. Studies with multiple treatment groups
For the included studies with more than two treatment arms, we
presented the additional treatment arms in comparisons. Where
data were binary, we simply added these and combined them
within the two-by-two table.Where datawere continuouswe com-
bined data following the formula in section 7.7.3.8 (Combining
groups) of the Handbook (Higgins 2011). Where the additional
treatment arms were not relevant, we did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility
(Xia 2009). We chose that, for any particular outcome, where
more than 30% of those randomised were lost to follow-up by six
months, or 50% of data by beyond that time be unaccounted for,
we did not reproduce these data or use them within analyses.
2. Continuous
2.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50% and completer-only data were reported, we repro-
duced these.
2.2 Standard deviations
If standard deviations (SDs) were not reported, we first tried to
obtain the missing values from the authors. If not available, where
there are missing measures of variance for continuous data, but
an exact standard error (SE) and confidence intervals available for
group means, and either P value or T value available for differ-
ences in mean, we can calculate them according to the rules de-
scribed in the Handbook (Higgins 2011): When only the SE is
reported, SDs are calculated by the formula SD = SE * square root
(n). Chapters 7.7.3 and 16.1.3 of the Handbook (Higgins 2011)
present detailed formulae for estimating SDs from P values, T or
F values, confidence intervals, ranges or other statistics. If these
formulae do not apply, we would calculate the SDs according to
a validated imputation method which is based on the SDs of the
other included studies (Furukawa 2006). Although some of these
imputation strategies can introduce error, the alternative would
be to exclude a given study’s outcome and thus to lose informa-
tion. We nevertheless examined the validity of the imputations in
a sensitivity analysis excluding imputed values.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying people or situations which we had
not predicted would arise. When such situations or participant
groups arose, we fully discussed these.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arose,
we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 method alongside the Chi2 P value. The I2 provides an estimate
of the percentage of inconsistency thought to be due to chance
(Higgins 2003). The importance of the observed value of I2 de-
pends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi2 test, or a
confidence interval for I2). an I2 estimate greater than or equal to
around 50% accompanied by a statistically significant Chi2 statis-
tic was interpreted as evidence of substantial levels of heterogene-
ity (Higgins 2011). When substantial levels of heterogeneity were
found in the primary outcome, we explored reasons for hetero-
geneity (see Subgroup analysis and investigation of heterogeneity).
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Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section10of theHandbook (Higgins 2011).
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects.We did not use funnel plots for outcomes where there were
10 or fewer studies, or where all studies were of similar sizes. In
other cases, where funnel plots were possible, we sought statistical
advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies, even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We chose the fixed-effect model for all analyses, unless there was
high heterogeneity (see Assessment of heterogeneity), in which
case we used the random-effects model. The reader is, however,
able to choose to inspect the data using the random-effects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses - only primary outcomes
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview of
the effects of fluphenazine esters for people with schizophrenia in
general. In addition, however, we tried to report data on subgroups
of people in the same clinical state, stage andwith similar problems.
In order to do subgroup analyses, we needed to have at least six
studies for an outcome.
Sensitivity analysis
We aimed to apply all sensitivity analyses to the primary outcomes
of this review, again, if there were at least six studies with data for
a particular outcome.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way so as to imply randomisation. For the pri-
mary outcomes, we would have included these studies and if there
was no substantive difference when the implied randomised stud-
ies were added to those with better description of randomisation,
then we would have entered all data from these studies.
2. Assumptions for lost binary data
If assumptions had to be made regarding people lost to follow-up
and missing SDs data (see Dealing with missing data), we would
have compared the findings on primary outcomes when we used
our assumption compared with completer data only. We would
have undertaken a sensitivity analysis to test how prone results
were to change when ’completer’ data only were compared to the
imputeddata using the above assumption. If therewas a substantial
difference, we would have reported results and discussed them,
but continued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that were judged to be
at high risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further details available):
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome. If the exclusion of trials at
high risk of bias did not substantially alter the direction of effect
or the precision of the effect estimates, thenwe included data from
these trials in the analysis.
4. Imputed values
If we had included cluster trials, we also would have completed
a sensitivity analysis to assess the effects of including data from
trials if we needed to use imputed values for ICC in calculating
the design effect in cluster randomised trials.
If we had noted substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we would not have pooled data from the excluded trials with the
other trials contributing to the outcome, but would have presented
them separately.
5. Fixed-effect and random-effects
We synthesised data using a fixed-effect model.
6. Dose
We tested the sensitivity of the primary outcomes as to whether
high (250 mg) or low (25 mg) dose of fluphenazine decanoate was
used or whether the trials used an intermediate/high (0.5 mg) or
low (0.25 mg) dose of fluphenazine enanthate.
R E S U L T S
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Description of studies
Please see Characteristics of included studies, Characteristics
of excluded studies and Characteristics of studies awaiting
classification.
Results of the search
The original search yielded 982 citations using the search strategy.
Twohundred and forty-eight citationswere related tofluphenazine
decanoate or enanthate but only 62 referred to controlled clinical
trials (all published in journals). The review was also updated in
May 2002, a further electronic search yielded 247 citations from
which we obtained 124 articles for further inspection.
The 2013 update search identified 44 potential studies and af-
ter screening we added four new studies (Ju 2000; Kane 1978;
Khazaie 2005; Shenoy 1981) to the included studies. Two pre-
viously included studies, Marder 1984 and Marder 1987, were
found to include the same participants, and so were added as the
same study. The total number of included studies is now 73 ran-
domised controlled trials with a total of 90 reports.
For overall screening from the three searches see Figure 1.
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Figure 1. Study flow diagram.
13Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
1. Length of trials
The duration for all the studies ranged between two weeks (Kane
1978) to three years (Dencker 1973).
2. Participants
The diagnoses of all participants were schizophrenia or some other
similar psychotic disorder. Most of the studies included people of
both sexes, although seven studies (Albert 1980; Asarnow 1988;
Kurland 1966; Marder 1987;McCreadie 1980; McCreadie 1982)
included only men and 16 trials failed to mention the sex of par-
ticipants. Ages ranged between 13 and 81 years, but most people
were in the 18 to 65 age range. Most trial participants had long
histories of schizophrenia, although many studies (n = 44) failed
to mention the length of time people had been ill. Researchers
frequently used operational criteria for diagnoses (RDC, Schnei-
der’s first rank symptoms, Hay& Forrest 1972 criteria, PSE, Krae-
pelinian, ICD -9, DSM-II/III, Bleuler’s criteria, Feighner 1972
criteria, Chinese Classification of Mental Disorders and Huang-
shan council schizophrenia standard), although 31 (43%) trials
did not specify which diagnostic criteria were used.
3. Setting
The trials were both community- and hospital-based. People in
two studies (Schooler 1980;Wistedt 1984) were given the first two
injections whilst in hospital and after whichmedication continued
to be administered in the community. Both Dencker 1973 and
Wistedt 1984 studied people initially in a hospital setting followed
by a continuation in the community. Several studies involved
people from both hospital and community settings (Dencker
1973; Donlon 1976; Kaneno 1991; Magnus 1979; Marder 1987;
McCreadie 1980; Rifkin 1977; Schooler 1997; Simon 1978). A
surprisingly large number (11) of studies did not mention the set-
ting used (Albert 1980; Javed 1991; Kissling 1985;McKane 1987;
Odejide 1982; Quitkin 1978; Russell 1982; Schneider 1981;
Schlosberg 1978; Sharma 1991; Wistedt 1983). Thirty-one trials
were conducted in North America and another 29 in Europe, 10
in Asia, one in Africa; and two did not report the country.
4. Study size
The largest study was by Schooler 1997 who randomised 313
people, whereas Altamura 1985 only included 11. The majority
randomised between 30 and 60 people.
5. Interventions
Six of the included trials compared fluphenazine decanoate with
placebo (Dotti 1979; Hirsch 1975; Jolley 1990; Odejide 1982;
Rifkin 1977; Shenoy 1981) and one study compared fluphenazine
enanthate with placebo (Van Praag 1970). Ten studies compared
fluphenazine decanoate with enanthate (Altamura 1985; Asarnow
1988; Chouinard 1978; Chouinard 1982; Donlon 1976; Kane
1978; Keskiner 1971; Kurland 1966; MacCrimmon 1978; Van
Praag 1973). Fourteen studies compared fluphenazine esters with
oral antipsychotics. Thirty-five trials compared fluphenazine de-
canoate or enanthate with other depot formulations. There were
10 dosage studies - nine comparing fluphenazine decanoate and
one comparing fluphenazine enanthate (Goldstein 1978). Of the
73 included trials, 66 used fluphenazine decanoate as an interven-
tion.
6. Outcomes
6.1 Outcome reporting
Many of the trials presented their findings in graphs or using P
values alone. Graphical presentation made it impossible to acquire
raw data for synthesis. Requests for raw data from authors have so
far failed with the exception of Pinto 1979 and Quitkin 1978. It
was also common to use P values as a measure of association be-
tween intervention and outcomes instead of showing the strength
of the association.
6.2 Missing outcomes
No study reported on hospital and service outcomes or com-
mented on participants’ overall satisfaction during or after the trial.
Economic outcomes were not reviewed by any of the included
studies.
6.1 Outcome scales
Scales that provided usable data are listed below.We listed data that
were not usable in the Characteristics of included studies under
outcomes, ’unable to use’.
6.1.1 Global functioning
a) Clinical Global Impression - CGI (Guy 1976)
This is a three-item rating instrument commonly used in
schizophrenia studies. It enables clinicians to quantify the sever-
ity of illness and overall clinical improvement during therapy. A
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seven-point scoring system is usually used with low scores indicat-
ing decreased severity and/or greater recovery.
b) Global Assessment Scale - GAS (Endicott 1976)
This is an observer-rated scale for evaluating the overall function-
ing of an individual during a specified time period on a continuum
from psychological or psychiatric sickness to health. Score ranges
from zero to 100, where a higher score indicates better function-
ing.
6.1.2 Mental state
a) Brief Psychiatric Rating Scale - BPRS (Overall 1962)
The BPRS is an 18-item scale measuring positive symptoms, gen-
eral psychopathology and affective symptoms. The original scale
has 16 items, but a revised 18-item scale is commonly used. Scores
can range from zero to 126. Each item is rated on a seven-point
scale, with high scores indicating more severe symptoms.
b) Comprehensive Psychopathological Rating Scale - CPRS
(Asberg 1978)
The scale is designed to measure psychopathology over time via a
clinical interview. It contains 67 items, including one global rating
and one item documenting the reliability of the interview. The
majority of the items (40) are based upon reported symptoms.
Assumed reliability of the rating is scored as zero (very poor), one
(fair), two (good) or three (very good).
c) Krawiecka Scale (Krawiecka 1977)
This mental state scale encompasses both positive and negative
symptoms of schizophrenia. It is used to evaluate the mental state
and behaviour in chronic psychotic people with higher scores in-
dicating greater severity. It is also known as the Manchester Scale.
d) Scale for the Assessment of Negative Symptoms - SANS
(Andreasen 1983)
This scale allows a global rating of the following negative symp-
toms: alogia (impoverished thinking), affective blunting, avoli-
tion-apathy, anhedonia-asociality, and attention impairment. As-
sessments are made on a six-point scale from zero (not at all) to
five (severe). Higher scores indicate more symptoms.
e) Scale for the Assessment of Positive Symptoms - SAPS
(Andreasen 1984)
This six-point scale gives a global rating of positive symptoms
such as delusions, hallucinations and disordered thinking. Higher
scores indicate more symptoms.
6.1.3 Behaviour
a) Nurses Observational Scale of Inpatients Evaluation - NOSIE
(Honigfeld 1962).
This is an 80-item scale with items rated on a five-point scale from
zero (not present) to four (always present). Ratings are based on
behaviour over the previous three days. The seven headings are
social competence, social interest, personal neatness, co-operation,
irritability, manifest psychosis and psychotic depression. The total
score ranges from zero to 320 with high scores indicating a poor
outcome.
6.1.4 Adverse effects
a) Abnormal Involuntary Movement Side Effects Scale - AIMS
(Guy 1976)
This is a 12-item scale designed to record the occurrence of dysk-
inetic movements. Ten items of this scale have been used to assess
tardive dyskinesia, a long-term drug-induced movement disorder.
A five-point scoring system (from zero - none to four - severe) has
been used to rate each of the 10 items. Using this scale in short-
term treatment may be helpful in assessing some short-term ab-
normal movement disorders. A low score indicates low levels of
dyskinetic movements.
b) Dosage Record and Treatment Emergent Symptoms Scale -
DOTES (Guy 1976)
This adverse effect tool seems less of a scale, where the degree and
severity of a symptom is recorded, and more of a checklist. The
DOTES seems to record the presence or absence of a list of adverse
effects.
c) Extrapyramidal Symptom Rating Scale - ESRS (Chouinard
1980)
This consists of a questionnaire relating to parkinsonian symp-
toms (nine items), a physician’s examination for parkinsonism and
dyskinetic movements (eight items), and a clinical global impres-
sion of tardive dyskinesia. High scores indicate severe levels of
movement disorder.
d) Simpson and Angus Scale - SAS (Simpson 1970b)
The SAS is a 10-item scale, used to evaluate the presence and
severity of drug-induced parkinsonian symptomatology. The ten
items focus on rigidity rather than bradykinesia, and do not assess
subjective rigidity or slowness. Items are rated for severity on a
zero to four scale, with a scoring system of zero to four for each
item. This scale is referred to as the RSESE in Ju 2000. A low score
indicates low levels of parkinsonism.
e)UKUSide Effects Rating Scale -UKU-SERS (Lingjaerde 1987).
The UKU rates four major topics: psychological adverse effects
(10 items), neurological adverse effects (eight items), autonomic
adverse effects (11 items) and other adverse effects (19 items). Each
item is defined by means of a four-point scale where zero means
not present or doubtfully present. Scoring range zero to144.
f ) Treatment Emergent Symptom Scale -TESS (Guy 1976)
This checklist assesses a variety of characteristics for each adverse
event, including severity, relationship to the drug, temporal char-
acteristics (timing after a dose, duration and pattern during the
day), contributing factors, course, and action taken to counteract
the effect. Symptoms can be listed a priori or can be recorded as
observed by the investigator. High scores indicate worse symp-
toms.
g) Symptom Checklist 90 - SCL-90 (Derogatis 1977)
15Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
This is a self-report scale of physical symptoms.
h) Maryland Psychiatric Research Center Involuntary Movement
Scale (Cassady 1997)
TheMPRC rates the severity of tardive dyskinesia. It gives a global
rating of dyskinesia in 11 body areas and two ratings during gait. It
is rated on an eight-point scale (zero to seven), with higher scores
indicating worse symptoms.
6.1.5 Quality of life
a) Quality of life scale - QLS (Heinrich 1984)
This 21-item scale is based on a semi-structured interview pro-
viding information on symptoms and functioning during the pre-
ceding four weeks. There are seven severity steps (zero to six; six
being adequately functioning and zero being deficient). Four item
categories have been identified by factor analysis i) interpersonal
relationships (seven items), ii) instrumental role (four items), iii)
intrapsychic function (seven items) and iv) common place objects
and activities. Higher scores indicate better quality of life.
Excluded studies
We excluded 201 studies, mainly because they were not ran-
domised controlled trials (RCTs), or controlled clinical trials
(CCTs), because neither fluphenazine decanoate nor fluphenazine
enanthate were included in the interventions or because trialists
did not report any usable data. In the latter case, we contacted au-
thors requesting raw data but we have, in most cases, received no
reply.Other reasons for exclusion were that the two drugs were not
analysed (Crawford 1974; Wistedt 1983a) or clinical outcomes
were not measured (Landmark 1994; Leff 1973; Marder 1990a;
Marder 1991a; Stevens 1973).
Awaiting assessment
Six studies await assessment. del Giudice 1970; Jue 1996; Kabes
1984; Ravanic 1996 are reports for which we have citations but
no papers. These are currently being sought. Two papers await
translation (Angst 1973; Ushakov 1990a).
Ongoing studies
We have not identified any ongoing studies.
Risk of bias in included studies
See also ’Risk of bias’ tables in Characteristics of included studies,
and Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Since the last version of this review was published, themethods for
assessing the risk of bias of studies has changed. All studies were
re-assessed for risk of bias in the current version of this review. The
risk of bias has not been fully assessed for two studies as they are
not reported in English and we were not able to translate them
(Kaneno 1991; Rossi 1990), although Kaneno 1991 had a section
in English and the risk of bias has been completed based on this.
Allocation
All included studies were reported as randomised, but only five de-
scribed the method of randomisation: Kissling 1985 used a coin-
throwing method, Frangos 1978 a randomisation code, Magnus
1979 a pre-arranged prescribing list, andWistedt 1984 a randomi-
sation list. Leong 1989 described the method of randomisation
as the next available study number in the numerical sequence.
However only Kissling 1985 was rated as low risk, Leong 1989
was rated to be a high risk and the other studies were all rated as
unclear risk of bias for sequence generation.
Three other studies did not report method of randomisation but
did describe allocation concealment (Kelly 1977; Kurland 1966;
McClelland 1976). In these three trials the allocation codes were
known only to the hospital pharamcists or nurses involved in the
trial, and were rated as low risk of bias; the remaining studies were
rated as unclear risk of bias.
Blinding
Most studies reported using double-blind methodology, although
the technique used was not described in themajority of these stud-
ies. Seven studies were rated low risk of bias for blinding of partic-
ipants and personnel, and stated blindness was achieved through
use of identical injections of medication (Albert 1980; Chouinard
1982; Crawford 1974; Donlon 1976;McClelland 1976;McLaren
1992; Van Praag 1970).
Only 14 studies described outcome assessors as being blinded
to treatment and were rated low risk of bias (Altamura 1985;
Chouinard 1982; Dencker 1973; Frangos 1978; Goldstein 1978;
Kane 1978; Leong 1989; McClelland 1976; Odejide 1982; Pinto
1979; Russell 1982; Van Praag 1970; Van Praag 1973; Wistedt
1983). Magnus 1979 and Simon 1978 were open label trials and
Leong 1989 described using a ’partially-blinded’ method where
only outcome assessors were blinded. The remaining studies were
of unclear risk of bias as no information on blinding of outcome
assessors was provided.
Incomplete outcome data
Twenty-nine studies were rated as low risk of bias for incomplete
outcome data and 25 studies had an unclear risk of bias. Seventeen
studies were rated as high risk of bias, for two of these it was due to
more than 50% of losses to follow-up (Jain 1975; Kissling 1985),
and only data for the outcome “Leaving the study early” was used
for these studies.
Selective reporting
Only 12 studies were of low risk of bias with regard to selective re-
porting, and five were unclear. The remaining studies were of high
risk of bias, mainly due to poor data reporting. Continuous data
were particularly problematic as many studies presented findings
without standard deviations or any other measure of variance, in
graphs, in percentiles or by inexact P values. Furthermore, many
pre-planned outcomes were not reported at all.
Other potential sources of bias
McKane 1987 and McLaren 1992 were subject to other biases as
theywere funded by the pharmaceutical industry. Eighteen studies
were rated as low risk of bias for other potential sources of bias,
and the remaining had an unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
FLUPHENAZINE DECANOATE compared with PLACEBO
for schizophrenia; Summary of findings 2 FLUPHENAZINE
DECANOATE compared with ORAL NEUROLEPTICS for
schizophrenia; Summary of findings 3 FLUPHENAZINE
DECANAOTE compared to FLUPHENAZINE ENANTHATE
for schizophrenia
We calculated risk ratios (RR) for dichotomous data and estimated
mean differences (MD) for continuous data, with their respective
95% confidence intervals (CIs) throughout.
COMPARISON 1: FLUPHENAZINE DECANOATE
versus PLACEBO
1.1 Death
The only study reporting mortality was Jolley 1990 where two
deaths occurred in the treatment group (fluphenazine decanoate)
compared to none in the placebo group (n = 54, RR 5.00, CI 0.30
to 99.51). Nevertheless, the result was not statistically significant
(Analysis 1.1).
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1.2 Global state
Heterogeneous data from three studies (Hirsch 1975; Odejide
1982; Rifkin 1977) found relapse rates to be equivocal over six
months to one year for the fluphenazine decanoate group com-
paredwith people receiving placebo (n = 196, 3RCTs, RR0.62, CI
0.24 to 1.60). Shenoy 1981 reported no relapses in the short term
at six weeks. Relapse rates for longer-term studies (Jolley 1990) at
two years significantly favoured fluphenazine decanoate (n = 54,
RR 0.35, CI 0.19 to 0.64) compared to placebo (Analysis 1.2).
Furthermore, one short-term study of six weeks found no signif-
icant difference between treatment group when global state was
measured on the Global Assessment Scale (GAS) (Analysis 1.3).
1.3 Leaving the study early
Four trials in which 216 people had been randomised to
fluphenazine decanoate or placebo had, in total, 21% attrition
(Analysis 1.4). No significant difference was found in people leav-
ing the study early between groups (RR 1.30, CI 0,77 to 2.19).
Shenoy 1981 reported short-term data at six weeks and also found
no significant difference between treatment groups. Jolley 1990 re-
ported longer-termdata at two years for leaving the study early that
significantly favoured depot fluphenazine compared to placebo (n
= 54, RR 0.47, CI 0.23 to 0.96).
1.4 Mental state
Only one trial (Dotti 1979) reported general mental state on the
Brief Psychiatric Rating Scale (BPRS), the results were equivocal
(Analysis 1.5). The single study by Odejide 1982 reporting on de-
pression showed equivocal results between fluphenazine decanoate
and placebo (Analysis 1.6).
1.5 Adverse effects
Limited data were available. Jolley 1990 reported equivocal data
for incidence of tardive dyskinesia (Analysis 1.7). Rifkin 1977 re-
ported on toxicity (no further details reported), which was signif-
icantly higher in the depot fluphenazine group (n = 45 RR, 7.65,
CI 1.04 to 56.26; Analysis 1.8).
COMPARISON 2: FLUPHENAZINE DECANOATE
versus ORAL NEUROLEPTICS
2.1 Death
There were no reports of death in any of the studies comparing
depot fluphenazine versus other oral neuroleptics.
2.2 Global state
Using the negative outcome, ’no clinically important global
change’ Adamson 1973 and Curry 1972 produced results favour-
ing fluphenazine decanoate at 0 to 5 weeks (n = 74, 2 RCTs, RR
0.61 CI 0.46 to 0.81; Analysis 2.1). Song 1993 reported on out-
comes at 6 months to one year, with equivocal findings (n = 102,
RR 0.85, CI 0.56 to 1.27). Using the CGI scale, Shu 1983 also
reported equivocal findings (n = 34, MD at 6 weeks -0.10 CI -
2.79 to 2.59; Analysis 2.3). There was no significant difference
between those taking fluphenazine decanoate and people on oral
neuroleptics for relapse at 6 months to one year (n = 419, 6 RCTs,
RR 1.46, CI 0.75 to 2.83); relapse data recorded at more than one
year were also not significant (n = 216, 3 RCTs, RR 1.25 0.81 to
1.95; Analysis 2.2).
2.3 Leaving the study early
Nine trials reported no significant difference between the number
of people who left the study early over six months to one year in
either the fluphenazine decanoate group or the oral antipsychotic
group (n = 887, RR 0.96, CI 0.73 to 1.25; Analysis 2.4). Studies
by Curry 1972 (at 28 days), Shu 1983 (at six weeks) and Falloon
1978 and Simon 1978 (at more than one year) were also equivocal.
2.4 Behaviour
Simon 1978 found no difference in Nurses Observational Scale
of Inpatients Evaluation (NOSIE) scale scores between groups (n
= 120, MD -0.56, CI -6.92 to 5.80; Analysis 2.5). Barnes 1983
reported a significant difference for change in disturbed behaviour
(n = 36); these data are skewed (Analysis 2.6).
2.5 Mental state
Only Simon 1978, reported on mental state (BPRS endpoint
scores) and found no significant difference between groups (n =
120, MD -0.75, CI -5.75 to 4.25; Analysis 2.7). Schooler 1979
and Falloon 1978 reporting on depression found no significant
difference between those receiving fluphenazine decanoate and
oral neuroleptics (n = 214, RR six months to one year 0.89, CI
0.60 to 1.32; n = 44, RRmore than one year 1.53,CI 0.91 to 2.57;
Analysis 2.8).
2.6 Adverse effects
Three studies, McCreadie 1980, McCreadie 1982 and Schooler
1980, report homogenous data for general movement disor-
ders (six months to one year), which significantly favoured
fluphenazine decanoate compared to oral neuroleptics (n = 259,
RR 0.47, CI 0.24 to 0.91; Analysis 2.9). The single longer-term
study by Falloon 1978 found no significant difference for in-
cidence of movement disorders (n = 44, RR 0.40, CI 0.12 to
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1.28). Rifkin 1977 reported on akathisia at one year. Akathisia
was significantly lower in the oral fluphenazine group (n = 51,
RR 20.54 CI 1.25 to 337.94; Analysis 2.10). Trials reported lim-
ited data for the outcome ’needing anticholinergic drugs’ and all
findings were equivocal (Analysis 2.11). McCreadie 1982 found
tardive dyskinesia to be significantly less common for those allo-
cated fluphenazine decanoate compared with people on pimozide
(n = 28, RR medium term 0.62, CI 0.41 to 0.93; Analysis 2.12).
The other study that reported on tardive dyskinesia was Simon
1978. Trialists did not find any difference between fluphenazine
decanoate and oral neuroleptic (n = 120, RR at 18 months 0.16,
CI 0.01 to 2.99). Shu 1983, using the Simpson and Angus Scale
(SAS) reported no significant difference at six weeks between
fluphenazine decanoate andpenfluridol (n =32,MD1.30,CI 0.01
to 2.59; Analysis 2.14). Adamson 1973 (immediate), McCreadie
1982 and Schooler 1980 (medium term) reported general adverse
effects. Outcomes are equivocal (Analysis 2.17). Falloon 1978 was
the only longer-term study to report on tremor, with equivocal
results for depot fluphenazine and pimozide (n = 44, RR 0.80,
CI 0.26 to 2.45; Analysis 2.13). Schooler 1976 reports equivocal
data for the adverse effect of blurred vision (Analysis 2.15). Rifkin
1977 also reported on toxicity (no further details), whichwasmore
frequent for the depot fluphenazine group (n = 51, RR 4.87, CI
1.14 to 20.72; Analysis 2.16).
COMPARISON 3: FLUPHENAZINE DECANOATE
versus OTHER DEPOT NEUROLEPTICS
3.1 Death
McKane 1987 reported one death occurring in the treatment
group (fluphenazine decanoate) compared to none in the haloperi-
dol decanoate group (n = 38, RR 3.0, CI 0.13 to 69.31; Analysis
3.1). Nevertheless, the result was not statistically significant.
3.2 Global state
Eleven studies reported the outcome of ’relapse’ at six months to
one year. We found no statistically significant difference between
the fluphenazine decanoate group and the other depot groups (n
= 581, RR 0.82, CI 0.56 to 1.18). Longer studies (more than
one year) also found no difference between interventions (n =
252, RR 1.22, CI 0.77 to 1.92). Wistedt 1984 did report relapse
data at 20 weeks but, again, results were equivocal (Analysis 3.3).
Outcomes for ’no clinically important global change’ at sixmonths
to one year reported byDencker 1973, Leong 1989 andSchlosberg
1978 were not significant for the fluphenazine decanoate and other
depot neuroleptic groups (n = 187, RR 1.04, CI 0.96 to 1.12;
Analysis 3.2); Ju 2000 also reported short-termdata and also found
no significant difference. Leong 1989 supported this result by
reporting no significant differences in the number of people who
became severely ill in the comparison of fluphenazine decanoate
with other depot drugs (n = 60, RR 1.07, CI 0.94 to 1.23; Analysis
3.4).
Chouinard 1984 and Schlosberg 1978 report continuous data at
six months to one year on clinical global impression. There is no
clear advantage between fluphenazine decanoate and other depot
neuroleptics (n = 90, MD -0.10, CI -0.41 to 0.21; Analysis 3.7).
These findings were confirmed by Chouinard 1984 and Cookson
1986 who reported no significant difference in needing additional
antipsychotics at six months to one year between the depot groups
(n = 91, RR0.53, CI 0.14 to 1.96; Analysis 3.5). Frangos 1978 also
reported the outcome of ’not improved’ (n =50,RRat fourmonths
RR 2.50, CI 0.53 to 11.70) and Leong 1989, at seven months (n
= 60, RR 0.75, CI 0.18 to 3.07) (Analysis 3.8). Finally, Wistedt
1984 reported non-significant data for clinical global impression
at zero to five weeks. These data are skewed so are not displayed
graphically (Analysis 3.6).
3.3 Leaving the study early
Fifteen included trials found no significant difference in the num-
ber of people who left the study early in either the fluphenazine
decanoate group or the other depot group (n = 775, RR medium
term 1.13, CI 0.89 to 1.44). Studies found no differences across
any time period from the immediate to those lasting longer than
one year (Analysis 3.9).
3.4 Behaviour
Simon 1978 supported this outcome by reporting no difference
in NOSIE-30 scores between the groups (n = 118, MD - -5.21 -
10.85 to 0.43; Analysis 3.10).
3.5 Mental state
We found short- and medium-term studies assessing mental state
(BPRS endpoint scores) to significantly favour ’other depot neu-
roleptics’ for the short term (n = 203, 2 RCTsMD1.11, CI 0.86 to
1.36) and medium term (n = 162, 3 RCTs, MD 1.20, CI 1.10 to
1.30) (Analysis 3.11). Longer-term studies (McKane 1987, Simon
1978) did not show any differences for mental state in either inter-
vention (n = 141, MD 0.85 CI -2.32 to 4.03; Analysis 3.11). Di-
chotomised medium-term BPRS data reported by Dencker 1973
found no significant difference between depot fluphenazine and
pipothiazine palmitate (Analysis 3.12). The only study reporting
on the outcome of depression was Dencker 1973 who found no
significant difference between fluphenazine decanoate and pipoth-
iazine palmitate (n = 67, RR medium term 1.02, CI 0.81 to
1.28; Analysis 3.13). Ju 2000 reported data for positive and nega-
tive symptoms on the Scale for the Assessment of Positive Symp-
tom(SAPS) and SANS, respectively, from sixweeks to fivemonths,
but these data are skewed so are not displayed graphically (Analysis
3.14).
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3.6 Adverse effects
The occurrence of dyskinetic movements in general was the same
across short-, medium- and longer-term studies (Analysis 3.15).
Feng 1990 reporting on a small, short-term study found no sig-
nificant difference between fluphenazine decanoate and haloperi-
dol decanoate (n = 30 RR 2.00, CI 0.43 to 9.32). Dencker 1973,
Leong 1989 and Schlosberg 1978 (comparing fluphenazine de-
canoate with pipothiazide palmitate) andMcLaren 1992 (compar-
ing with bromperidol decanoate) found no significant difference
in the occurrence of dyskinestic movements (n = 234, RR at six
months to one year 1.08, CI 0.86 to 1.34). Longer-term studies
also found no significant difference with movement disorders be-
tween fluphenazine decanoate and other depot neuroleptics. For
the outcome of ’needing anticholinergic medication’, eight stud-
ies, when synthesised, found in favour of other depots by one
year (n = 448, RR 1.24 0.93 to 1.64 ). However, these data were
heterogeneous and using the random-effects model (as per pro-
tocol), the result was not statistically significant (Analysis 3.16).
For the same outcome, three longer-term studies were equivo-
cal but significantly favoured the ’other depot neuroleptics’ group
when analysed with a fixed-effect model (n = 220, RR 1.28, CI
1.08 to 1.51). Outcomes such as dry mouth, tardive dyskinesia
and parkinsonism were not significantly different between depot
fluphenazine and other depot neuroleptics (Analysis 3.22; Analysis
3.18; Analysis 3.17, respectively). Tremor (short term, 2 RCTs and
medium term, 3 RCTs) was not more common for people given
the depot flupenthixol (Analysis 3.19). Ju 2000 reported data for
movement disorders from six weeks to five months on the TESS
and RSESE, but these data are skewed so are not displayed graph-
ically (Analysis 3.20). When reporting blurred vision, the results
of one medium term trial were not significant, but one longer-
term study, Pinto 1979, did report significant results (P = 0.04)
favouring flupenthixol decanoate (n = 64, RR 17.88, CI 1.08 to
294.82; Analysis 3.21). General adverse effects (short-term data)
were reported by Frangos 1978 and Javed 1991 and favoured other
depot neuroleptics (n = 88, RR 1.36, CI 1.07 to 1.74). However,
medium-term data (n = 249, six months to one year) were equiv-
ocal (Analysis 3.23).
COMPARISON 4: FLUPHENAZINE DECANOATE -
DOSAGE STUDIES (HIGH DOSE versus
STANDARD DOSE)
4.1 Global state
McClelland 1976 and Kreisman 1988 reported no significant
difference in relapse scores (medium term) between either de-
pot group (n = 182, RR 2.11, CI 0.30 to 14.91; Analysis 4.1).
Also, McClelland 1976 reported no significant difference in need-
ing additional antipsychotics (six months to one year) between
fluphenazine decanoate (high dose) group and the standard dosage
groups (n = 50, 1 RCTs, RR 1.67, CI 0.45 to 6.24; Analysis 4.2).
Outcomes for global improvement ’not improved’ were reported
by Lehmann 1980 (nurse and psychiatrist rated) at six months to
one year (Analysis 4.3). Results for nurse rated outcomes signif-
icantly favoured the standard dosage group (n = 40, 1 RCT, RR
1.58, CI 1.09 to 2.30). However, results for psychiatrist rated were
not significant for either dosage intervention at six months (n =
40, 1 RCT, RR 1.15, CI 0.77 to 1.74).
4.2 Leaving the study early
Lehmann 1980 and McClelland 1976 reported no difference in
the number leaving the study (six months to one year) for either
intervention (n = 90, 2 RCTs, RR 0.60, CI 0.15 to 2.36; Analysis
4.4).
4.3 Mental state
McClelland 1976 further reported no difference in BPRS end-
point score (n = 50, 1 RCT,MD -0.03, CI -5.79 to 5.73) for either
the high or standard dosage group (Analysis 4.5).
4.4 Adverse effects
McClelland 1976 reported no difference between the groups for
those needing anticholinergic medication (n = 50, RR 1.67, CI
0.45 to 6.24) at six months to one year, suggesting the incidence
of adverse effects is comparable between the groups, as the use of
anticholinergic drugs is considered to be a direct measure of the
severity of adverse effects due to medication (Analysis 4.6).
COMPARISON 5: FLUPHENAZINE DECANOATE -
DOSAGE STUDIES - (LOWDOSE versus
STANDARD DOSE)
5.1 Global state
Relapse data, assessed over six months to one year were equiv-
ocal. Longer-term studies (more than one year) reported by
Asarnow 1988, Hogarty 1988 and Marder 1987 were also equiv-
ocal (Analysis 5.1).
5.2 Leaving the study early
Asarnow 1988, Hogarty 1988, and Marder 1987 reported no dif-
ference in the number of people who left the study early in each
dosage group after more than one year of medication (n = 172,
RR 0.67, CI 0.33 to 1.36; Analysis 5.2).
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5.3 Mental state
The data obtained for mental state (e.g. BPRS score etc.) were
skewed and therefore could not be included in the analyses.
5.4 Adverse effects
Marder 1987 reported that there was no significant difference in
the number of people requiring additional anticholinergic drugs
at six months to one year (n = 50, RR 2.55, CI 0.72 to 9.05).
Kane 1983 supported this finding by reporting that the number
of people with tardive dyskinesia (n = 126, RR 0.52, CI 0.10 to
2.72) at six months to one year, was not significantly different
between the groups receiving low doses of fluphenazine decanoate
and standard dosage fluphenazine. Kane 1983, however, did report
a statistically significant (P = 0.03) difference at endpoint analysis
with the Simpson Dyskinesia Scale (n = 126), which favoured
low-dose fluphenazine decanoate, although data were skewed and
therefore not graphically reported (Analysis 5.3).
COMPARISON 6: FLUPHENAZINE ENANTHATE
versus PLACEBO
6.1 Adverse effects - at eight weeks
Only Van Praag 1973 reported for this comparison. This small
trial reported no significant difference in the number of people
needing anticholinergic drugs in the fluphenazine enanthate and
placebo groups (n = 25, RR 9.69, CI 0.58 to 163.02; Analysis
6.1).
COMPARISON 7. FLUPHENAZINE ENANTHATE
versus ORAL NEUROLEPTICS
7.1 Global state
Chien 1973 reported no significant difference in global change
(immediate term, zero to five weeks) between fluphenazine enan-
thate and chlorpromazine (n = 31, RR 0.67, CI 0.27 to 1.66;
Analysis 7.1).
7.2 Adverse effects
Reports of adverse effects, again from the same study and for the
immediate term were all not significantly different (n = 31, RR
movement disorders 2.34, CI 0.53 to 10.30; RR general adverse
effects 2.81, CI 0.94 to 8.45; RR parkinsonism 6.56, CI 0.91 to
47.21; Analysis 7.2).
COMPARISON 8: FLUPHENAZINE ENANTHATE
versus OTHER DEPOT NEUROLEPTICS
8.1 Global state
Albert 1980 and Chouinard 1978 reported no significant dif-
ference in needing additional antipsychotics (at six months to
one year) for fluphenazine enanthate compared with other depot
groups (n = 65, RR 0.50, CI 0.24 to 1.05; Analysis 8.1). Both
Malm 1974, at six weeks to five months (n = 57, RR 2.38, CI
0.66 to 8.61) and Chouinard 1978, at six months to one year (n
= 32, RR 0.33, CI 0.04 to 2.87) reported no statistically signif-
icant differences in relapse rates between the fluphenazine enan-
thate group and the other depot (pipothiazine palmitate) groups
(Analysis 8.2).
8.2 Leaving the study early
Only Jain 1975 provided data for numbers leaving the study early
(zero to five weeks). These data significantly favoured fluphenazine
enanthate compared with the other depot neuroleptics - pipoth-
iazine palmitate (n = 30, RR 0.09, CI 0.01 to 0.62). However,
this outcome should be interpreted with caution given the limited
number of participants. The number of people who left the study
early by six weeks to five months, in the single study by Malm
1974 using fluspirilene as a control, was not significant (n = 57, RR
2.38, CI 0.66 to 8.61). Similarly, Chouinard 1978 found no dif-
ference between the fluphenazine enanthate group and the other
depot neuroleptic group - pipothiazine palmitate at six months to
one year (n = 32, RR 0.33, CI 0.04 to 2.87) (Analysis 8.3).
8.3 Mental state
Singh 1979 reported general BPRS scores and found a significant
difference between the twogroups favouring the other depot group
(n = 30, MD 0.40, CI 0.34 to 0.46; Analysis 8.4). Specific scores
on, for example, depression found no difference between the two
groups (Singh 1979, n = 30, RR 7.00, CI 0.39 to 124.83; Analysis
8.5).
8.4 Adverse effects
Findings were equivocal for outcomes of ’movement disorders’
(medium term: n = 63, 2RCTs, RR1.52, CI 0.75 to 3.07; Analysis
8.6), tardive dyskinesia (medium term: n=32, 1RCT,RR0.89,CI
0.46 to 1.71; Analysis 8.8), tremor (medium term: n = 95, 3 RCTs,
RR 1.24, CI 0.82 to 1.87; Analysis 8.9), blurred vision (medium
term: n = 30, 1 RCT, RR 3.00, CI 0.13 to 68.26; Analysis 8.10)
and dry mouth (medium term: n = 62, 2 RCTs, RR 0.80, CI 0.36
to 1.76; Analysis 8.11). Malm 1974 reported that those receiving
fluspirilene required significantly less anticholinergic drugs at six
weeks to five months than the fluphenazine enanthate group (n =
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57, RR 2.86, CI 1.16 to 7.06). The numbers of people needing
additional anticholinergic drugs at six months to one year were
found (Albert 1980; Chouinard 1978) to be equivocal (n = 65, RR
1.02, CI 0.76 to 1.35) for the fluphenazine enanthate and other
depot neuroleptic groups (Analysis 8.7).
COMPARISON 9: FLUPHENAZINE ENANTHATE -
DOSAGE STUDIES (LOWDOSE versus
INTERMEDIATE/HIGH DOSE)
9.1 Global state
A single study by Goldstein 1978 reported the global outcome
of relapse at six weeks to five months (Analysis 9.1). Trial-
ists found statistically significant differences favouring the high-
dosage fluphenazine enanthate group compared with low-dosage
fluphenazine enanthate (n = 104, RR 9.35, CI 2.28 to 38.29).
For every fourth person administered a low dose of fluphenazine
decanoate, one would relapse. However, this result must be treated
with caution as only one study is involved.
9.2 Leaving the study early
Goldstein 1978 found no significant difference in the number of
people who left the study early (six weeks to five months) whilst
receiving either high or low dosages of fluphenazine enanthate (n
= 104, RR 3.12, CI 0.66 to 14.74; Analysis 9.2).
COMPARISON 10: FLUPHENAZINE DECANOATE
versus FLUPHENAZINE ENANTHATE
10.1 Global state
Van Praag 1973 reported data for ’needing additional antipsy-
chotic treatment’ at zero to five weeks (Analysis 10.1). This trial
found a significant difference between the fluphenazines (de-
canoate and enanthate) (n = 33, RR 0.39, CI 0.18 to 0.86).
Chouinard 1982 was the only study to report the numbers of peo-
ple requiring additional antipsychotic treatment at six months to
one year and found no significant difference.
The number of people who relapsed whilst receivingmedication at
zero to five weeks was not significant for the two studies available
(n =44, 2RCTs,RR0.66,CI 0.18 to 2.43).Donlon 1976 reported
no significant difference in relapse rates at six weeks to five months
between the fluphenazine decanoate group and the fluphenazine
enanthate group (n=30,RR2.29,CI 0.70 to 7.48).MacCrimmon
1978, reporting on relapse over the medium term (six months to
one year) found no significant difference (n = 49, RR 2.43, CI
0.71 to 8.32) (Analysis 10.2).
10.2 Leaving the study early
The number of people leaving the study early (Analysis 10.3)
at zero to five weeks was not significantly different between the
fluphenazine decanoate and enanthate groups (n = 44, 2RCTs, RR
0.66,CI 0.18 to 2.43). Short termoutcomes (6weeks to 5months)
were also not significantly different between the fluphenazine ester
groups (n = 42, 2 RCTs, RR 2.29 CI 0.70 to 7.48). Medium-term
data (six months to one year) were consistent with the results of
the two shorter study periods, finding no difference in the number
of people leaving the study early for the two fluphenazine ester
groups (n = 49, 1 RCT, RR 2.43, CI 0.71 to 8.32).
10.3 Mental state
Only one study by MacCrimmon 1978 reported on mental state,
using BPRS endpoint scores at one year. They found no significant
difference between the fluphenazine esters (n = 39, MD 0.00, CI
-3.93 to 3.93; (Analysis 10.4).
10.4 Adverse effects
The number of people in these studies reporting movement dis-
orders for immediate (zero to five weeks) or short term (six
weeks to five months) was not significantly different between
the fluphenazine esters (Analysis 10.5). Reports of adverse ef-
fects (zero to five weeks), parkinsonism (six weeks to five months)
and akathisia (zero to five weeks) were equivocal for fluphenazine
decanoate and enanthate groups (Analysis 10.9; Analysis 10.7;
Analysis 10.8, respectively).
The number of people needing anticholinergic drugs at zero to
five weeks was found by Van Praag 1973 to be significantly lower
for the fluphenazine decanoate group (n = 33, RR 0.29, CI 0.12
to 0.70). For longer-term studies (six weeks to five months and six
months to one year) there were no significant differences in the
number of people needing anticholinergic drugs (Analysis 10.6).
COMPARISON 11: FLUPHENAZINE DECANOATE
EVERY TWOWEEKS versus EVERY SIX WEEKS
We found only one relevant trial (Khazaie 2005) that compared
the use of fluphenazine decanoate every two weeks with every six
weeks.
11.1 Global state
There was no significant difference between fluphenazine de-
canoate every two weeks and every six weeks in the number of
participants relapsing (n = 37, RR 0.89, CI 0.55 to 1.44; Analysis
11.1).
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11.2 Leaving the study early
The number of participants leaving the study early also did not dif-
fer significantly between fluphenazine decanoate every two weeks
and every six weeks (n = 37, RR 1.17, CI 0.46 to 2.98; Analysis
11.2).
11.3 Mental state
Total BPRS scores were not significantly different between
fluphenazine decanoate every two weeks and every six weeks (n =
37, MD 2.72, CI -1.16 to 6.60, Analysis 11.3), nor was the BPRS
sub-scale for thought disorder (n = 37, MD -0.39, CI -1.51 to
0.73; Analysis 11.3).
11.4 Adverse effects
There was no significant difference between fluphenazine de-
canoate every twoweeks and every sixweeks in parkinsonian symp-
toms (n = 37, MD 1.30, CI -0.03 to 2.63) and dyskinesia (n = 37,
MD 2.40, CI -1.77 to 6.57) measured on the Maryland Psychi-
atric Research Center Involuntary Movement Scale (MPRC) scale
(Analysis 11.4).
11.5 Quality of life
We did not find any difference between fluphenazine decanoate
every two weeks and every six weeks in the quality of life of par-
ticipants (n = 37, MD 1.42, CI -9.68 to 12.52, Analysis 11.5).
12. Subgroup analyses
The only primary outcome with enough studies (at least six) to
warrant subgroup analysis was relapse from Comparison 2 and
Comparison 3. However, studies either included chronic patients,
amix of chronic and acute, or did not report the stage of the illness,
therefore, it was not possible to undertake any subgroup analyses.
13. Sensitivity analysis
The only primary outcome with enough studies (at least six) to
warrant sensitivity analysis was relapse from Comparison 2 and
Comparison 3.
13.1 Implication of randomisation
All trials were described as randomised in the review.
13.2 Assumptions for lost binary data
We did not make any assumptions about lost binary data.
13.3 Risk of bias
For relapse at medium term in Comparison 2 (Analysis 3.3), only
Leong 1989 had a high risk of bias for randomisation. The results
remained non-significant with the removal of this trial. For this
outcome, all trials had a high risk of bias for selective reporting
except, again, for Leong 1989 and results were unchanged.
For relapse at medium term in Comparison 3 (Analysis 2.2), all
studies had unclear risk of bias for randomisation and all had a
high or unclear risk of bias for selective reporting.
13.4 Imputed values
We did not have any cluster randomised trials and did not impute
any data.
13.5 Dose
Themeandaily dose of fluphenazine decanoate at endpoint ranged
from 0.3 to 300 mg and for fluphenazine enanthate ranged from
2.35 to 387.5 mg. Two studies, Cookson 1986 and Curry 1972,
did not specify the average dose. The way data were reported did
not permit any more sensitivity analyses than those which have
already been presented.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: hospital and community
Intervention: FLUPHENAZINE DECANOATE
Comparison: ORAL NEUROLEPTICS
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
ORAL NEUROLEPTICS FLUPHENAZINE DE-
CANOATE
Death - not reported See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Relapse
Fol-
low-up: medium term (6
months to 1 year)
423 per 1000 618 per 1000
(317 to 1000)
RR 1.46
(0.75 to 2.83)
419
(6 studies)
⊕©©©
very low1,2,3
No clinically important
global change
Fol-
low-up: medium term (6
months to 1 year)
519 per 1000 441 per 1000
(291 to 659)
RR 0.85
(0.56 to 1.27)
102
(1 study)
⊕©©©
very low3,4,5
Hospital admission -
not reported
See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Leaving the study early
Fol-
low-up: medium term (6
months to 1 year)
184 per 1000 177 per 1000
(134 to 230)
RR 0.96
(0.73 to 1.25)
937
(10 studies)
⊕⊕©©
low3,6,7
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M ental state
BPRS endpoint score
Follow-up: (longer term
- more than 1 year)
The mean mental state
in the intervent ion
groups was
0.75 lower
(5.75 lower to 4.25
higher)
120
(1 study)
⊕©©©
very low3,5,8
Extrapyramidal ad-
verse effects - general
Fol-
low-up: medium term (6
months to 1 year)
137 per 1000 64 per 1000
(33 to 125)
RR 0.47
(0.24 to 0.91)
259
(3 studies)
⊕©©©
very low3,5,9
Studies also reported
equivocal results for
akathisia, needing an-
t icholinergic drugs, tar-
dive dyskinesia, tremor,
and symptoms on the
Simpson Angus scale
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: serious - Studies had an unclear risk of bias for randomisat ion, allocat ion concealment and blinding. One study
had a high risk of bias for incomplete outcome data.
2 Inconsistency: serious - There is high heterogeneity.
3 Imprecision: serious - There are wide conf idence intervals.
4 Risk of bias: serious - This study had an unclear risk of bias for randomisat ion, allocat ion concealment, blinding and
incomplete outcome data.
5 Publicat ion bias: strongly suspected - Three studies or fewer reported data for this outcome.
6 Risk of bias: serious - Studies had an unclear risk of bias for randomisat ion, allocat ion concealment and blinding, although
one study had a low risk of bias for blinding of part icipants. One study had a high risk of bias for incomplete outcome data.
7 Publicat ion bias: undetected - It seems that larger trials have not been performed, see Figure 4.
8Risk of bias: very serious - This study had a high risk of bias for blinding as it is an open label study. It has an unclear risk of
bias for randomisat ion and allocat ion concealment.
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9 Risk of bias: serious - Studies had an unclear risk of bias for randomisat ion, allocat ion concealment and blinding.
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FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: hospital and community
Intervention: FLUPHENAZINE DECANAOTE
Comparison: FLUPHENAZINE ENANTHATE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
FLUPHENAZINE ENAN-
THATE
FLUPHENAZINE DE-
CANAOTE
Death - not reported See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Relapse
Fol-
low-up: medium term (6
months to 1 year)
120 per 1000 292 per 1000
(85 to 998)
RR 2.43
(0.71 to 8.32)
49
(1 study)
⊕©©©
very low1,2,3
Clinically significant
change in global state -
not reported
See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Hospital admission -
not reported
See comment See comment Not est imable - See comment No studies reported
data for this outcome.
Leaving the study early
Fol-
low-up: medium term (6
months to 1 year)
120 per 1000 292 per 1000
(85 to 998)
RR 2.43
(0.71 to 8.32)
49
(1 study)
⊕©©©
very low1,2,3
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M ental State
BPRS
Fol-
low-up: medium term (6
months to 1 year)
The mean mental state
in the intervent ion
groups was
0 higher
(3.93 lower to 3.93
higher)
39
(1 study)
⊕©©©
very low1,3,4
Extrapyra-
midal adverse effects -
general
Follow-up: short term (6
weeks to 5 months)
538 per 1000 614 per 1000
(425 to 883)
RR 1.14
(0.79 to 1.64)
49
(2 studies)
⊕©©©
very low3,4,5
Stud-
ies also reported equiv-
ocal results for Parkin-
sonism, akathisia and
needing ant icholinergic
drugs
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: serious - This study had an unclear risk of bias for randomisat ion, allocat ion concealment and blinding.
2 Imprecision: very serious - There were few part icipants and few events; the conf idence intervals are wide.
3 Publicat ion bias: strongly suspected - Fewer than three studies reported data for this outcome.
4 Imprecision: serious - There are wide conf idence intervals.
5 Risk of bias: serious - The studies had an unclear risk of bias for randomisat ion and blinding of outcome assessors. One
was low risk of bias for allocat ion concealment and the other for blinding of part icipants.
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D I S C U S S I O N
Summary of main results
Seventy-three trials including 4870 participants were included
in the review. The summary below reflects the outcomes chosen
for Summary of findings for the main comparison, Summary of
findings 2 and Summary of findings 3, and are considered the
main findings of this review. Overall, the quality of the evidence
was rated as low to very low.
1. Fluphenazine decanoate versus placebo
1.1 Death
Only one, small study (Jolley 1990) reported on death and no
significant differences were observed.
1.2 Global state
1.2.1 Clinically significant change in global state
No studies reported data for this outcome.
1.2.2 Relapse
Very lowquality evidence from three studies showed thatmedium-
term relapse rates were not significantly lower in the fluphenazine
decanoate group (43%) compared with placebo (67%). Only
longer-term data from one small trial (Jolley 1990) significantly
reduced relapse.
1.3 Hospital admission
No studies reported data for this outcome.
1.4 Leaving the study early
The numbers of people leaving the study early in the fluphenazine
decanoate (24%) and placebo (19%) groups were very similar,
however, the quality of the evidence was very low. This figure
could be higher in clinical practice because rigorous adherence
to protocols in these randomised studies may decrease attrition,
although the opposite could also be true. Although adherence
to protocol improves internal validity, it can potentially decrease
the external validity and applicability of results. The single two-
year study significantly favoured fluphenazine decanoate com-
pared with placebo (Jolley 1990).
1.5 Mental state
One very small study (Dotti 1979) found no difference in mental
state measured on the BPRS.
1.6 Extrapyramidal adverse effects
The occurrence of tardive dyskinesia (long term) was not signifi-
cantly different, although the quality of the evidence is very low
and data were again from a single small study (Jolley 1990).
2. Fluphenazine decanoate versus oral neuroleptics
2.1 Death
No studies reported data for this outcome.
2.2 Relapse
Very low quality evidence from six studies showed that medium-
term rates of relapse were not significantly different in the
fluphenazine decanoate group (49%) compared with oral neu-
roleptics (42%).
2.3 Clinically significant change in global state
One small study (Song 1993) found no difference in the number
of participants showing a clinically significant change in global
state.
2.4 Hospital admission
No studies reported data for this outcome.
2.5 Leaving the study early
Low-quality evidence showed no difference in the number of par-
ticipants leaving the study early for fluphenazine decanoate (17%)
versus oral neuroleptics (18%).
2.6 Mental state
Very low quality evidence from one study (Simon 1978) found no
difference in mental state measured on the BPRS.
2.7 Extrapyramidal adverse effects
Three small studies showed that general extrapyramidal adverse
effects were lower in the fluphenazine decanoate group (7%) com-
pared to oral neuroleptics (14%). However, the quality of the evi-
dence was judged to be very low, and there was no difference with
longer-term data. The outcome of ’needing additional anticholin-
ergic drug’ was equivocal over short-, medium- and longer-term,
suggesting oral neuroleptics and fluphenazine decanoate are sim-
ilar in their ability to induce movement disorders. Also, tardive
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dyskinesia was significantly lower for the fluphenazine decanoate
group during medium-term evaluation, but was not different to
oral neuroleptics with longer-term data.
3. Fluphenazine decanoate versus other depot
antipsychotics
3.1 Death
One study did report a death in fluphenazine decanoate treatment
group, however, this did produce an effect with no significant
differences between groups for death.
3.2 Global state
Eleven studies reported equivocal data fro the outcome of ’relapse’
at six months to one year. Other global state outcomes such as sig-
nificant clinical improvement, clinical global impression, needing
additional antipsychotics and ’not improved’ were also equivocal.
3.3 Leaving the study early
Fifteen included trials found people were no more likely to leave
the study early if they were receiving fluphenazine decanoate or
other depot antipsychotics.
3.4 Behaviour
Only one study reported equivocal data.
3.5 Mental state
Short- and medium-term studies assessing mental state (BPRS
endpoint scores) to significantly favour ’other depot neuroleptics’
for the short term and medium term. Long-term studies did not
find such difference in mental state. One study reported on the
outcome of depression; Dencker 1973, found no significant dif-
ference between fluphenazine decanoate and pipothiazine palmi-
tate.
3.6 Adverse effects
The occurrence of dyskinetic movements in general was the same
across short-, medium- and longer-term studies. Outcomes such
as dry mouth, tardive dyskinesia and parkinsonism were not sig-
nificantly different between depot fluphenazine and other depot
neuroleptics. When reporting blurred vision, the results of one
medium-term trial were not significant, but one longer-term study,
Pinto 1979, did report significant results favouring flupenthixol
decanoate. General adverse effects (short-term data) were reported
by Frangos 1978 and Javed 1991 and favoured other depot neu-
roleptics. However, medium-term data were equivocal.
4. Fluphenazine decanoate versus fluphenazine
enanthate
4.1 Death
No studies reported data for this outcome.
4.2 Relapse
Very low quality evidence from only one small study (
MacCrimmon 1978) found no significant difference in the num-
ber of participants experiencing relapse in the medium term. Re-
sults were also equivocal for immediate- and short-term studies.
4.3 Clinically significant change in global state
No studies reported data for this outcome.
4.4 Hospital admission
No studies reported data for this outcome.
4.5 Leaving the study early
No difference in the number of participants leaving the study
early was found between fluphenazine decanoate (29%) and
fluphenazine enanthate (12%), but this is based on one small study
(MacCrimmon 1978) and considered to be very low quality evi-
dence.
4.6 Mental state
BPRS data were only available from one small trial (MacCrimmon
1978). This study reported identical scores for both of the
fluphenazine depots groups.
4.7 Extrapyramidal adverse effects
Very low evidence from two very small studies showed that two
preparations caused roughly equal incidences of generalmovement
disorders. Results were also equivocal for parkinsonism, akathisia
and needing additional anticholinergics in the short and immedi-
ate term.
Overall completeness and applicability of
evidence
Trials were based mainly in the community, or combined both
hospital and community settings. Ages ranged between 13 and 81
years, butmost people were in the 18 to 65 age range. The duration
of illness was long in most participants in the studies that reported
this. Included trials were conducted around the world, although
the majority (56) were based in North America and Europe and
none were based in Australia or South America. There is a broad
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mixture of participants, settings and clinical applicability of the
interventions which should increase generalisability.The dosages
of fluphenazine decanoate and enanthate reflected current clinical
practice. Outcomeswere, however, limited. No trials reported data
on service utilisation, hospital admission and economic outcomes.
It is a shame that so few outcomes were included.
Quality of the evidence
The quality of the evidence is low to very low based on GRADE
(Schünemann 2008). Although all studies were reported as ran-
domised, only five reported the method of randomisation and an-
other three the method of allocation concealment. For the ma-
jority of studies the method of blinding was not reported despite
most stating that they were double blind. In 83% of studies, the
risk of bias for selective reporting was rated as high; many pre-
planned outcomes were not reported and continuous data were
often reported as mean without standard deviation, only as P val-
ues, or graphically. Poor presentation of data meant that a lot of
potentially informative data were lost.
Potential biases in the review process
A thorough search strategy was used in this review. There may
still be gaps in the search strategy such as unpublished data (grey
literature), which are difficult to obtain. Futhermore, when assess-
ing the risk of bias of studies previously included in this review,
we were unable to assess the risk of bias for one study in Italian.
However, this study did not contribute to any outcomes in the
’Summary of findings’ tables and therefore the omission of this
one study did not affect the overall quality judgement.
For most outcomes we are not able to tell if there was publication
bias, as no more than 10 trials reported data for these, and a funnel
plot could not be performed. For leaving the study early in the
comparison of fluphenazine decanoate versus oral neuroleptics,
there does appear to be publicationbias, as the funnel plot indicates
that larger trials have not been performed.
Agreements and disagreements with other
studies or reviews
We do not know of any other systematic reviews on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
When compared with either placebo or oral neuroleptics,
fluphenazine decanoate does not appear to have a clinically impor-
tant effect in terms of improving relapse rates based on medium-
term (six months to one year) data. Longer-term data, however, do
support the use of fluphenazine decanoate to reduce relapse when
compared to placebo, but not when compared to oral neurolep-
tics. Relapse data for fluphenazine enanthate were limited and no
data comparing it with placebo or oral neuroleptics were available.
Fluphenazine depot preparations, especially the decanoate, seem
equivalent to oral medications and may even cause less adverse
effects.
2. For clinicians
The data on the effects of fluphenazine decanoate are clearer than
for fluphenazine enanthate.Within the highly unusual setting of a
randomised trial, the decanoatemay have some advantages over the
oral antipsychotics. In clinical life there may be greater advantages
in terms of compliance. There are no data to support the claim that
depots cause more adverse effects than oral preparations. There
are also no data to support the use of high doses.
3. For managers or policy makers
Studies did not report data relating to service utilisation and care
management. Outcomes relating to use of hospitals and services,
satisfaction with care and economics were not reported in any
study. This deficiency remains and should be addressed in real
world randomised studies.
Implications for research
1. General
Trialists involved in future studies should implement the CON-
SORT statement (Moher 2001) to ensure that outcomes are more
relevant. Inclusion of hospital and services outcomes, satisfaction
with care and economic outcomes would provide valuable data for
people with schizophrenia, clinicians and policy makers.
2. Specific
A recurring failure to report the exact methodology of allocation
was evident throughout the included trials. Only five studies stated
the randomisation process used; Kissling 1985 used a coin-throw-
ing method, Frangos 1978 a randomisation code, Magnus 1979 a
pre-arranged prescribing list, and Wistedt 1984 a randomisation
list and Leong 1989 allocated to the next available study number.
Allocation concealment is essential to ensure that selection bias is
kept to a minimum.
Only 14 studies described outcome assessors as being blinded
to treatment and were rated low risk of bias (Altamura 1985;
Chouinard 1982; Dencker 1973; Frangos 1978; Goldstein 1978;
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Kane 1978; Leong 1989; McClelland 1976; Odejide 1982; Pinto
1979; Russell 1982; Van Praag 1970; Van Praag 1973; Wistedt
1983). Magnus 1979 and Simon 1978 were open label trials and
Leong 1989 described using a ’partially-blinded’ method where
only outcome assessors were blinded. The remaining studies were
of unclear risk of bias as no information on blinding of outcome
assessors was provided. Although most studies were stated to be
double blind, only 14 studies described outcome assessors as being
blinded to treatment and were rated low risk of bias (Altamura
1985; Chouinard 1982; Dencker 1973; Frangos 1978; Goldstein
1978; Kane 1978; Leong 1989; McClelland 1976; Odejide 1982;
Pinto 1979; Russell 1982; Van Praag 1970; Van Praag 1973;
Wistedt 1983). This is an important strategy for avoiding per-
formance and detection bias. Odejide 1982 included participants
who were unaccounted for after randomisation was undertaken.
This study did not specify from which groups this withdrawal had
occurred. In 12 trials the number of people who left the study
was not reported. It is important to know how many, and from
which groups, people were withdrawn in order to evaluate ex-
clusion bias. Studies included both community-based and hospi-
talised people but 16 failed to report the setting (Albert 1980; Feng
1990; Hranov 1998; Javed 1991; Kissling 1985; Kreisman 1988;
Lehmann 1980; McKane 1987; Odejide 1982; Quitkin 1978;
Rossi 1990; Russell 1982; Schlosberg 1978; Schneider 1981;
Sharma 1991;Wistedt 1983). A few studies, all using fluphenazine
decanoate as an intervention, involved people in hospital at the be-
ginning of the trial but these people were later discharged into the
community (Dencker 1973;Donlon 1976;Magnus 1979;Marder
1987; McCreadie 1980; Rifkin 1977; Schooler 1980; Schooler
1997; Simon 1978;Wistedt 1984). More community-based stud-
ies would be welcome.
This review highlights the need for good controlled clinical trials
to address the effects of fluphenazine decanoate and fluphenazine
enanthate and to assess their clinical suitability in certain situa-
tions. Despite the many studies that are in existence, we do think
that more studies are required in each category but particularly in
the case of fluphenazine enanthate where data were particularly
few. We realise that such design needs a great deal of planning but
suggest a simple outline in Table 1.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adamson 1973
Methods Allocation: randomised.
Blindness: double.
Duration: 28 days.
Design: cross-over x2.
Country: UK.
Participants Diagnosis: schizophrenia.
N = 37 (in phase II).
Age: 24-65 years.
Sex: 22M, 15F.
History: all in hospital for > 1 year.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose 12.5 mg/IM day one, 25 mg/IM day 7. N = 19.
2. Chloropromazine: dose 50-100 mg/bid. N = 18.
Outcomes Behaviour: leaving the study early. Adverse effects: various side effects
Unable to use -
Mental state: BPRS (no data).
Behaviour: WWBRS (no data).
Notes No usable continuous data.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Divided randomly”, “matched for sex,
mean age, mean weight and mean plasma
chlorpromazine concentrations”
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, no further details re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”, no further details re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up reported.
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Adamson 1973 (Continued)
Selective reporting (reporting bias) High risk Not all outcomes fully reported, no data
reported for BPRS and WWBRS
Other bias Unclear risk Source of funding not reported.
Albert 1980
Methods Allocation: randomised.
Blindness: double.
Duration: 39 weeks.
Design: drug stabilisation period 2 months, treatment 3 months.
Country: Canada.
Participants Diagnosis: schizophrenia.
N = 33.
Age: approximate age mid 40s.
Sex: all male.
History: average duration spent in hospital 16-20 years.
Setting: hospital.
Interventions 1. Fluphenazine enanthate: dose mean 50mg/IM/biweekly. N = 11.
2. Pipothiazine palmitate: dose mean 100mg/IM or 150 mg/IM*/monthly. N = 11
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: Evaluation Scale.
Unable to use -
Global state: CGI (no SD).
Mental state: BPRS (no SD).
Adverse effects: NOSIE (no SD).
Notes * 2 different dosage groups for PP.
Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “patients were randomly assigned”.
Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The identity of the medications was
masked and the double blind character of
the study preserved by inserting an identi-
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Albert 1980 (Continued)
cal placebo injection at two week intervals”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The identity of the medications was
masked and the double blind character of
the study preserved by inserting an iden-
tical placebo injection at two week inter-
vals”. Blinding of outcome assessment not
specifically reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients randomised to each
group have been reported. However, it is
unclear if all participants completed the
study
Selective reporting (reporting bias) High risk Standard deviations and information on
Serious Adverse Events have not been re-
ported
Other bias Unclear risk Source of funding not reported.
Altamura 1985
Methods Allocation: randomised.
Blindness: double.
Duration: 2-3 week (2 periods).
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia (PSE- DSM III).
N = 11.
Age: 35-60 years.
Sex: 2M, 9F.
History: duration illness < 2 yrs.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25 mg/IM every 3-4 weeks. N = 6.
2. Fluphenazine enanthate: dose 25 mg/IM every 3-4 weeks. N = 5
Outcomes Behaviour: leaving the study early.
Adverse effects: various side effects.
Unable to use -
Mental state: CPRS (no data).
Physiological: (various measures, blood tests - non-clinical outcomes, data unusable).
Cognitive: handwriting (non-clinical outcomes, data unusable)
Notes No usable continuous data.
Authors contacted.
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Altamura 1985 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The assignment of order of treatments was
randomised”. Method not reported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk An uninvolved person administered the
doses and the ampules were not seen by the
patients or rater. Other involved personnel
might have been unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An uninvolved person administered the
doses and the ampules were not seen by the
rater
Incomplete outcome data (attrition bias)
All outcomes
High risk 4/11 participants left early. Reasons are
not reported per intervention group. Losses
to follow-up/missing data imbalanced in
numbers across intervention groups. 2/5 vs
2/6. The study was terminated due to to
high incidence of side effects
Selective reporting (reporting bias) High risk Results for “unwanted effects” not reported
separately (akinesia, involuntary move-
ment, autonomic disturbances and drowsi-
ness) and only part of the rating scale was
used. “only two scores on the four point
rating scale were... used... absent and maxi-
mum...no attempt could be made to derive
a figure representing a grading of effect”.
Although this is mainly a safety study, pres-
ence/absence of Serious Adverse Events not
reported
Other bias Unclear risk Source of funding not reported.
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Asarnow 1988
Methods Allocation: randomised.
Blindness: double.
Duration: 2 years.
Design: dosage study.
Country: United States.
Participants Diagnosis: schizophrenia.
N = 36.
Age: 34-41 years.
Sex: all male.
History: stabilised for < 2 months, informed consent given.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25mg/IM (standard) biweekly. N = 14.
2. Fluphenazine decanoate: dose 5mg/IM (low) biweekly. N = 22
Outcomes Behaviour: leaving the study early.
Unable to use -
Mental state: BPRS (no SD).
Cognitive: information-processing skills (non-clinical outcomes, data unusable)
Notes Very little usable data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reported data for drop-outs is unclear.
“two patients in the GSLD and PSLD
groups and one patient each in the GSSD
andPSLDgroups dropped out before com-
pletion...”
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Asarnow 1988 (Continued)
Selective reporting (reporting bias) High risk Although the results for stated outcomes
have been reported, the results are not pre-
sented as useful data (i.e. mean, SD). Also,
not all expected outcomes were reported (e.
g. presence/absence adverse events, serious
adverse events)
Other bias Low risk The study seems to be free of other sources
of bias.
Barnes 1983
Methods Allocation: assigned to two groups by independent statistician.
Blindness: double.
Duration: 1 year.
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia (PSE).
N = 36.
Age: mean ~ 49 years.
Sex: 18M, 18F.
History: not stated.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25 mg/IM biweekly. N = 19.
2. Pimozide: dose 8 mg biweekly. N = 17.
Outcomes Behaviour: leaving the study early.
Unable to use -
Behaviour: SBAS (non-clinical outcomes, data unusable).
Notes Analysis: last observation carried forward.
No continuous outcomes measured.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were assigned to two groups by
an independent statistician, matched on
the basis of age, sex and calculated weekly
fluphenazine dose”
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
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Barnes 1983 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind...double dummy” Blinding
details not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk In “the 1-year follow-up results of all pa-
tients who had begun the trial, includ-
ing drop-outs, withdrawals and relapsers,
were involved in the analysis...Unfortu-
nately, the SBAS data were incomplete for
one relapsed patient who was abroad from
the time of relapse to the end of the trial.”
Selective reporting (reporting bias) High risk Results for SBAS have been reported as per-
centages, only. Other expected outcomes
(e.g. presence/absence of adverse events,
serious adverse events have not been re-
ported)
Other bias Unclear risk Source of funding has not been reported.
Chien 1973
Methods Allocation: randomised.
Blindness: single.
Duration: 30 days.
Design: parallel group.
Country: USA.
Participants Diagnosis: psychosis.
N = 31.
Age: 17-62 years, mean ~ 37 years.
Sex: 24M, 22F.
History: acutely psychotic, recently admitted.
Setting: hospital.
Interventions 1. Fluphenazine enanthate: dose 12.5 -75 mg/IM, mean 28.5 mg/IM every 12 days. N
= 16.
2. Chlorpromazine: dose mean 388 mg/day. N = 15.
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: TESF.
Unable to use -
Behaviour: NOSIE (no data).
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Chien 1973 (Continued)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants and personnel not
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “each patient was rated after 10 days of
treatment on a seven-point scale of global
improvement by an independent research
psychiatrist who had no knowledge of the
patient’s medication”. Blinding methods of
nurses rating NOISE not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported.
Selective reporting (reporting bias) Unclear risk Data for NOSIE not reported.
Other bias Low risk “supported in part by Public Health Ser-
vice research grant MH-16128 from the
National Institute of Mental Health.”
Chouinard 1978
Methods Allocation: randomised.
Blindness: double.
Duration: 9 months.
Design: parallel group.
Country: Canada.
Participants Diagnosis: schizophrenia.
N = 32.
Age: 20-60 years.
Sex: 16M, 16F.
History: informed consent given.
Setting: community.
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Chouinard 1978 (Continued)
Interventions 1. Fluphenazine enanthate: dose 6.25-100 mg/IM biweekly. N = 16.
2. Pipothiazine palmitate: dose 25-100 mg/IM monthly. N = 16
Dose adjusted to therapeutic response.
Outcomes Global state: CGI, need for additional medication.
Mental state: BPRS.
Behaviour: leaving the study early.
Adverse effects: HRSD, EPS, TESF.
Unable to use -
Adverse effects: various effects (no SD).
Physiological: various measures (non-clinical outcomes, data unusable)
Notes Analysis: last observation carried forward.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random allocation. Methods of randomi-
sation not reported.
Allocation concealment (selection bias) Unclear risk Allocation concealment details not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Except for the nurse responsible for giving
the injections, the procedure was double
blind.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 patients did not complete the study. Rea-
sons for dropping out have been described.
Number of drop-outs was balanced be-
tween the groups. “Psychiatric evaluations
of these four patientsweremade on the days
they left the study and were used ...for the
statistical analysis of the rating scale data.”
Selective reporting (reporting bias) High risk Not all outcomes fully reported. The study
reports most but not all expected out-
comes (e.g.presence/absence serious ad-
verse events)
Other bias Unclear risk Source of funding has not been reported.
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Chouinard 1982
Methods Allocation: randomised.
Blindness: double.
Duration: 7 months, preceded by 1 month stabilisation period.
Design: parallel group.
Country: Canada.
Participants Diagnosis: schizophrenia (DSM II).
N = 50*
Age: 24-65 years, median ~ 41 years.
Sex: 27M, 21F.
History: on FE for 1 month, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 2.5-250 mg/IM, mean 27 mg/IM monthly. N = 24.
2. Fluphenazine enanthate: dose 2.5-325 mg/IM, mean ~ 35 mg/IM biweekly. N = 24
Dose adjusted to therapeutic response.
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Additional medication.
Unable to use -
Mental state: BPRS (no SD).
Adverse effects: TESF (no data); ESRS (authors own scale**).
Notes Authors contacted.
Results for FE & FD pooled.
* 2 dropped out after randomisation/ moved & suicide.
** see Marshall et al 1998
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind”. “Both preparations were
administered as identical suspensions in
oil”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessment of psychiatric symptoms was
based on clinical interviews conducted by
the psychiatrist...under blind conditions”
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Chouinard 1982 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two patients did not complete the 28
week trial...One of these left the coun-
try after 12 weeks of treatment with
fluphenazine decanoate; the other commit-
ted suicide after 22 weeks of treatment with
fluphenazine enanthate”
Selective reporting (reporting bias) High risk Results reported incompletely for BPRS
scores. Adverse events,other than EPS and
TD not reported
Other bias Unclear risk Source of funding not reported.
Chouinard 1984
Methods Allocation: randomised, stratified by sex & past frequency of depot administration.
Blindness: double.
Duration: 8 months.
Design: parallel group.
Country: Canada.
Participants Diagnosis: schizophrenia (DSM III).
N = 72.
Age: 18-66 years, mean ~ 44 years.
Sex: 36M, 36F.
History: on depot >3 months; duration illness 3-38 years, mean 16 years, able to give
informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 2.5-300 mg/IM, mean 75 mg/IM every 2-4 weeks. N
= 36.
2. Haloperidol decanoate: dose 15-900 mg/IM, mean 225 mg/IM every 2-4 weeks. N
= 36
Outcomes Global state: CGI, need for additional medication.
Mental state: BPRS.
Behaviour: leaving the study early.
Unable to use -
Adverse effects: ESRS (authors own scale*), TESF (no data).
Physiological: various measures (non clinical outcomes, data unusable)
Notes Statistics: last observation brought forward.
*see Marshall et al 1998.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Chouinard 1984 (Continued)
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double -blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up have not been reported.
Selective reporting (reporting bias) High risk Most of the outcomes have been reported
only as P .05.
Other bias Unclear risk Source of funding has not been reported.
Cookson 1986
Methods Allocation: randomised, separate randomisation sequences for males and females.
Blindness: double.
Duration: 8 months.
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia implied.
N = 19.
Age: 26-60 years.
Sex: 9M, 10F.
History: 1 yr treatment with fluphenazine decanoate, overweight BMI 25+, physically
fit, stable during previous year
Setting: community.
Interventions Fluphenazine decanoate: dose 26.4 mg/IM, every 2-6 weeks, average 3.6 months. N =
9.
2. Haloperidol decanoate: dose 22.2 mg/IM every 2-5 weeks, average 3.6 months. N =
10
Outcomes Behaviour: leaving the study early.
Unable to use -
Mental state: CPRS, KGS (no data).
Adverse effects: SAS, AIMS (no data).
Physiological: various measures (non clinical outcomes, data unusable)
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Cookson 1986 (Continued)
Notes Analysis: last observation carried forward.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomly assigned...Separate randomi-
sation sequences were used for male and fe-
male patients.” Method not reported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up are imbalanced. “Two
patients- both on the haloperidol de-
canoate-dropped out”. Also, prolactin lev-
els not measured for all subjects i.e. “avail-
able for six patients on fluphenazine de-
canoate ...and eight on haloperidol de-
canoate.”
Selective reporting (reporting bias) High risk Body weight and prolactin levels have been
reported.However, results of clinical assess-
ments not fully reported
Other bias Unclear risk Source of funding not reported.
Crawford 1974
Methods Allocation: randomised.
Blindness: double.
Duration: 40 weeks.
Design: parallel group.
Country: United Kingdom (Scotland).
Participants Diagnosis: schizophrenia (Forest & Hay 1971/72 criteria).
N = 31.
Age: 20-65 years.
Sex: 9M, 22F.
History: mean duration illness 1-27 years, mean ~ 14 years.
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Crawford 1974 (Continued)
Setting: community.
Interventions 1. Fluphenazine decanoate: (dosage not stated). N = 14.
2. Trifluoperazine hydrochloride (oral): (dosage not stated). N = 17
Outcomes Behaviour: leaving the study early.
Unable to use -
Mental state: BPRS (no data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind”. “The preparations em-
ployed had identical appearances”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 participants, both from the trifluoper-
azine hydrochloride group, dropped out
“within four weeks” of the study and
were not included in the analysis. With-
drawal rate was 6/15 in the trifluoper-
azine hydrochloride group and 2/12 in the
fluphenazine group
Selective reporting (reporting bias) High risk Not all outcome data was fully reported.
Other bias Unclear risk Source of funding not reported.
64Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Curry 1972
Methods Allocation: randomised.
Blindness: double.
Duration: 28 days.
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia.
N = 37.
Age: not stated.
Sex: male and female.
History: chronically ill.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: (dosage not stated). N = 19.
2. Chlorpromazine (oral): (dosage not stated). N = 18.
Outcomes Behaviour: WWBRS.
Leaving the study early.
Unable to use -
Mental state: BPRS (no SD).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported.
Selective reporting (reporting bias) High risk Incomplete study results. Results not re-
ported as mean (SD).
Other bias Unclear risk Source of funding not reported.
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Dencker 1973
Methods Allocations: randomised.
Blindness: double.
Duration: 3 years.
Design: 3 months adjustment, 1-3 months maintenance, 2-6 months maintenance, 2-
year follow-up.
Country: Sweden.
Participants Diagnosis: schizophrenia.
N = 67.
Age: 18-65 years, mean ~ 41 years.
Sex: 51M, 14F.
History: duration illness > 5 years.
Setting: 1 year in hospital, 2 years in community.
Interventions 1.Fluphenazine decanoate: dose 3.1-50mg/IM, mean 6.25 mg/IM monthly (mean
monthly dose for 2-year continuation phase 27.8 mg/IM). N = 35.
2. Pipothiazine palmitate: dose 25-400 mg/IM, mean 50 mg/IM monthly (mean
monthly dose for 2-year continuation phase 152.3 mg/IM). N = 32
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: EPS, HRSD.
Unable to use -
Mental state: BPRS, S-Scale, HRSD (no SD).
Cognitive: Handwriting test (non-clinical outcomes, data not usable).
Social ability: ADL, work performance, SRE (non-clinical outcomes, data not usable).
Adverse effects: EPS (no data).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind”. “ the injections were given
by a nurse, who was the only person who
knew the code”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “double blind”. “ the injections were given
by a nurse, who was the only person who
knew the code.” “most of rating were made
by one psychologist, and the rest by one of
the psychiatrists”
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Dencker 1973 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up balanced in numbers
across intervention groups 9% vs 17%
Selective reporting (reporting bias) High risk Although all outcomes have been reported,
data for most of the outcomes (BPRS,
Hamilton depression scale, side effects rat-
ing scale, rating scale for extra-pyramidal
side effect) cannot be used i.e. only mean
reported (SD not reported)
Other bias Unclear risk Source of funding not reported
Donlon 1976
Methods Allocation: randomised.
Blindness: double.
Duration: 2 months.
Design: parallel group.
Country: USA.
Participants Diagnosis: schizophrenia.
N = 40/41*.
Age: 18-57 years, mean ~ 29 years.
Sex: 12M, 18F.
History: able to give informed consent.
Setting: hospital & community.
Interventions 1. Fluphenazine decanoate: dose 75-500mg/IM, mean 296.4 mg/IM 2-3x week. N =
14.
2. Fluphenazine enanthate: dose 50-550 mg/IM, mean 387.5 mg/IM 2-3x week. N =
16
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: EPS Rating Scale.
Unable to use -
Global state: CGI (no data).
Mental state: BPRS (no data).
Notes Data put in depot vs depot category in both FE & FD treatment groups
*2 different N values in the paper.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Donlon 1976 (Continued)
Random sequence generation (selection
bias)
Unclear risk “assigned...on a randombasis”.Methodnot
reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double blind”, “FE and FD were supplied
in identical bottles”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding of outcome asses-
sors not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported. 41 par-
ticipants randomised, but number in each
group not reported. Allocation per group
reported for 30 patients: “Eleven patients
either voluntarily dropped out or were lost
to follow-up prior to the end of 1 month.
..3 patients on FE terminated during the
second month”, other reasons for leaving
early not reported
Selective reporting (reporting bias) High risk CGI and BPRS results incompletely re-
ported (only P values).
Other bias Unclear risk Source of funding not reported.
Dotti 1979
Methods Allocation: randomised.
Blindness: double.
Duration: 9 months.
Design: parallel group.
Country: Italy.
Participants Diagnosis: schizophrenia.
N = 20.
Age: 19-32 years.
Sex: all male.
History: previous episodes of psychosis.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25-50 mg (frequency not stated). N = 10.
2. Placebo: (frequency not stated). N = 10.
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Dotti 1979 (Continued)
Outcomes Behaviour: leaving the study early.
Mental state: BPRS.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, no further details reported.
Allocation concealment (selection bias) Unclear risk Medication was prepared in a pharmacy,
but no details of allocation concealment re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double blind”, no details reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double blind”, no details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Four participants left the study early, one
from the fluphenazine group and three
from the placebo group, reasons not re-
ported
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Source of funding not reported.
Falloon 1978
Methods Allocation: randomised.
Blindness: double.
Duration: 20 months.
Design: 2 trials - I & II.
Country: United Kingdom.
Participants Diagnosis: schizophrenia (Schneider).
N = 44.
Age: 17-60 years, mean ~ 39 years.
Sex: 20M, 24F.
History: stabilised prior to study entry.
Setting: community.
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Falloon 1978 (Continued)
Interventions 1. Fluphenazine decanoate: dose mean 25 mg/IM weekly, maximum 50 mg/ biweekly.
N = 20.
2. Pimozide: dose mean 8 mg/day, maximum 16 mg/day. N = 24.
Flexible dosage.
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: checklist for SE’s.
Unable to use -
Mental state: PSE (no data).
Social ability: SPS (non-clinical outcome, data unusable).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double- blind control conditions...active
pimozide tablets +inert fluphenazine in-
jections, or...active fluphenazine injections
+inert pimozide tablets.” Blinding of per-
sonnel unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double- blind”. Blinding of outcome as-
sessor unclear.
Incomplete outcome data (attrition bias)
All outcomes
High risk Three patients (all from one group) were
withdrawn, losses to follow-up are unbal-
anced
Selective reporting (reporting bias) High risk Incomplete reporting of data.
Other bias Unclear risk Sources of funding not reported.
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Feng 1990
Methods Allocation: randomised.
Blindness: double.
Duration: 12 weeks.
Design: parallel group.
Country: China.
Participants Diagnosis: schizophrenia (Huangshan council schizophrenia standard 1984).
N = 30.
Age: 27-54 years, mean ~ 41 years.
Sex: 24M, 64F.
History: all chronically ill > 5 years.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose 25 mg/mL fortnightly injections. N = 15.
2. Haloperidol decanoate: dose 25 mg/mL monthly injections. N = 15
Outcomes Behaviour: leaving the study early.
Adverse effects.
Unable to use -
Mental state: MIE (data unusable).
Adverse effects: SAS (data unusable).
Global state: CGI (not reported).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind...patients and doctors did
not know what kind of medicine to be ap-
plied till end of treatment”. Blinding de-
tails not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blind...patients and doctors did
not know what kind of medicine to be ap-
plied till end of treatment”. Blinding de-
tails not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up unbalanced between
groups: 3 (20%) in the haloperidol group
and 1 (7%) in the fluphenazine group
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Feng 1990 (Continued)
Selective reporting (reporting bias) High risk CGI outcome data not reported, no usable
data for MIE and SAS
Other bias Unclear risk Source of funding not reported.
Frangos 1978
Methods Allocation: randomised (randomisation code).
Blindness: double.
Duration: 16 weeks.
Design: parallel group.
Country: Greece.
Participants Diagnosis: schizophrenia.
N = 50.
Age: 21-62 years, mean ~ 44 years.
Sex: 25 M, 25 F.
History: hospitalised for at least 2 years.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose 25-150 mg/IM, mean 76 mg/IM biweekly. N = 25.
2. Fluspirilene decanoate: dose 4-20 mg/IM, mean 12 mg/IM weekly. N = 25
Outcomes Adverse effects: SE Rating Scale.
Unable to use -
Global state: CGI (no data).
Mental state: BPRS (no SD).
Behaviour: NOSIE (no SD).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”, “according to a ran-
domisation code”.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “all patients were treated with weekly injec-
tions; fluspirilene administered every week
and fluphenazine decanoate every 2 weeks
with placebo...in the between periods”.
Blinding details of personnel administering
the injections not reported
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Frangos 1978 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “randomisation code unknown to the in-
vestigators involved with the patient evalu-
ation”. “investigators concerned with drug
administration were not involved in the pa-
tient evaluations”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details reported, losses to follow-up not
reported.
Selective reporting (reporting bias) High risk Data reported incompletely: only P values
for BPRS, NOISE-30, and extrapyramidal
symptoms. Adverse events reported, pres-
ence/absence of serious adverse events not
reported
Other bias Unclear risk Source of funding has not been reported.
Goldstein 1978
Methods Allocation: randomised.
Blindness: single.
Duration: 6 weeks.
Design: 6 month follow-up (not controlled).
Country: United States.
Participants Diagnosis: schizophrenia.
N = 104.
Age: mean ~ 23 years.
Sex: 45M, 37F.
History: acutely ill, 1st or 2nd admission, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine enanthate: dose (high) 1 mL/IM biweekly. N = 53.
2. Fluphenazine enanthate: dose (low) 0.25 mL/IM biweekly. N = 51
Outcomes Behaviour: leaving the study early.
Unable to use -
Mental state: BPRS (no data).
Family therapy: non-clinical outcome (data unusable).
Notes Analysis: last observation carried forward.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Goldstein 1978 (Continued)
Random sequence generation (selection
bias)
Unclear risk “...patient was... assigned by a random
method”. Details of method not reported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “ single blind...the patient was blind to the
dose level but the treating psychiatrist was
not”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...all ratings of clinical behavior were car-
ried out by raters blind to drug and family
therapy status.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “...eight withdrew after release from the
hospital... treatment refusers came from
three groups; high dose therapy (two), low
dose therapy (three), low dose no ther-
apy (three).” None of the participants from
high dose no therapy dropped out
Selective reporting (reporting bias) High risk Relapse reported. Data for BPRS not re-
ported as mean SD, data for family therapy
not reported
Other bias Low risk Supported by grants from National Insti-
tute for Mental Health
Hirsch 1975
Methods Allocation: randomised.
Blindness: double.
Duration: 7 months.
Design: parallel group.
Country: Norway.
Participants Diagnosis: schizophrenia.
N = 81.
Age: under 67 years.
Sex: male & female.
History: chronically ill.
Seting: community.
Interventions 1. Fluphenazine decanoate: dose monthly average 25 mg/IM. N = 40.
2. Placebo. N = 41.
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Hirsch 1975 (Continued)
Outcomes Global state: relapse.
Behaviour: leaving the study early.
Unable to use -
Mental state: PSE (data unusable).
Behaviour: SPS (data unusable).
Notes Unable to complete risk of bias table - PDF missing.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated by a research assis-
tant”, no further details reported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, “A number of checks by
questionnaires filled out by the doctors,
nurses, and the patient’s general practi-
tioner confirmed that the double-blind
procedure had been successful”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”, details of blinding of out-
come assessors not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk “One patient had [drugs from other
sources], and he was excluded from the
analysis”
Selective reporting (reporting bias) High risk Some outcomes were not fully reported: no
data for PSE and SPS
Other bias Unclear risk Source of funding not reported.
Hogarty 1979
Methods Allocation: randomised.
Blindness: double.
Duration: 2 years.
Design: parallel study.
Country: United States.
Participants Diagnosis: schizophrenia.
N = 105.
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Hogarty 1979 (Continued)
Age: 18-55 years, mean ~ 34 years.
Sex: 46M, 54F.
History: received no other psychotropic medication, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 12.5-125 mg/IM, mean 25 mg/IM biweekly. N = 27.
2. Fluphenazine hydrochloride (oral): dose 2.5-40 mg/IM, mean 2.5 mg/IM daily. N =
25
Outcomes Behaviour: leaving the study early.
Unable to use -
Mental state: BPRS (no SD).
Behaviour: KAS (no data).
Adverse effects: SSI, SEC, HSC, TESS (no data).
Notes Last observation carried forward
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Subjects blinded; “...pro-
viding each patient with an injection and
tablets i.e. active injections of fluphenazine
decanoate with inactive placebo tablets
or placebo injections...with active...tablets.
The active and placebo forms of the
medication were identical in appearance.
” Blinding of details of personnel not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information: number of sub-
jects allocated per group unclear; “...the
analyses included only patients known to
be receiving their injection... and who
appeared for their prescribed oral medi-
cation, independent whether they... took
their tablets or not.”
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Hogarty 1979 (Continued)
Selective reporting (reporting bias) High risk Outcomes not reported (SSI, HCI, KAS)
or incompletely reported (BPRS)
Other bias Low risk “...supported by Psychopharmacology Re-
search Branch, National Institute of Men-
tal Health”
Hogarty 1988
Methods Allocation: randomised, stratification by dose & household EE.
Blindness: double.
Duration: 2 years.
Design: dosage study.
Country: United States.
Participants Diagnosis: schizophrenia, schizoaffective (RDC).
N = 70.
Age: mean 28 yrs, range 17-55 yrs.
Sex: 40 M, 30 F.
History: living at home, mean duration illness ~ 7 years, stabilised 6 months after dis-
charge, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: standard dose mean 25 mg/IM biweekly. N = 33.
2. Fluphenazine decanoate: minimal dose mean 3.8 mg/IM biweekly. N = 37
Prescribed dose - no upper or lower limit.
Outcomes Behaviour: leaving the study early.
Unable to use -
Mental state: BPRS, SCL-90 (no data).
Adverse effects: MRQ (no data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “random”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. “...injections were pro-
vided by two non blinded nurses who
scrupulously concealed the information on
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Hogarty 1988 (Continued)
dose assignment from patients and the
treating clinical research team. Blinding de-
tails not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”double-blind“. ”...injections were pro-
vided by two non blinded nurses who
scrupulously concealed the information on
dose assignment from patients and the
treating clinical research team. Blinding de-
tails not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-outs have been reported per group of
intervention. Overall losses to follow-up
data balanced across intervention groups:
14 (42%) drop-outs at standard dose and
16 (43%) drop-outs at minimal dose, with
similar reasons for missing data. Dropouts
for clinical reasons (relapse) also balanced
Selective reporting (reporting bias) High risk Outcome data (BPRS, MRQ, SCL-90, so-
cial performance) incompletely reported
Other bias Low risk Funded by a grant from the Schizophre-
nia Research Branch, National Institute of
Mental Health
Hranov 1998
Methods Allocation: randomised.
Blindness: not described.
Duration: 6 months.
Design: parallel group.
Country: not reported.
Participants Diagnosis: schizophrenia (ICD-10).
N = 41.
Age: 21-55. mean ~ 41 years.
Sex: 17M, 24F.
History: not stated.
Setting: not stated.
Interventions 1 Fluphenazine decanoate: dose 99.3 mg/IM/month. N = 21.
2. Haloperidol decanoate: dose 47.3 mg/month. N = 20.
Outcomes Behaviour: leaving the study early.
Unable to use -
Global state: CGI (data unusable).
Mental state: PANSS (data unusable).
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Hranov 1998 (Continued)
Adverse effects: UKU (data unusable).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “ randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 (30%) participants in the fluphenazine
group and 4 (19%) in the haloperidol
group left the study early. Reasons for leav-
ing early not reported
Selective reporting (reporting bias) High risk Outcome results reported incompletely.
Other bias Unclear risk Source of funding not reported.
Jain 1975
Methods Allocation: randomised.
Blindness: double.
Duration: 20 weeks, preceded by 2-week washout.
Design: parallel group.
Country: Canada.
Participants Diagnosis: schizophrenia.
N = 30.
Age: 24-61 years, mean ~ 49 years.
Sex: 14F, 16M.
History: hospitalised for under 1 year.
Setting: hospital.
Interventions 1. Fluphenazine enanthate: dose 125 mg/IM biweekly. N = 15.
2. Pipothiazine palmitate: dose 250 mg/IM biweekly. N = 15.
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Jain 1975 (Continued)
Outcomes Global state: CGI.
Behaviour: leaving the study early.
Adverse effects: TESS.
Unable to use -
Mental state: BPRS (no data).
Notes 73% drop-out rate in the PP group, data not usable.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up unbalanced between
groups: 4 (27%) participants left the study
early in the pipothiazine group and 1 (5%)
in the fluphenazine group
Selective reporting (reporting bias) High risk Outcome data incompletely reported for
BPRS.
Other bias Low risk Partially supported by Public Health Ser-
viceGrant from theDepartment ofHealth,
Education and Welfare, Washington D.C
Javed 1991
Methods Allocation: randomised.
Blindness: double.
Duration: 12 weeks.
Design: parallel group.
Country: Pakistan.
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Javed 1991 (Continued)
Participants Diagnosis: schizophrenia (DSM III).
N = 45.
Age: mean ~ 50 years.
Sex: 33M, 5F.
History: stabilised for 6 months on neuroleptics, involved in rehabilitation, duration
illness 13 years.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose 25 mg/IM biweekly. N = 20.
2. Flupenthixol decanoate: dose 40 mg/IM biweekly. N = 18.
Outcomes :Behaviour: leaving the study early.
Mental state: HRSD.
Adverse effects: EPSE, SE checklist.
Unable to use -
Global state: CGI (no SD).
Mental state: BPRS (no SD).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7/45 patients dropped out of the study. 1/7
died and 6/7 “dropped out for reasons not
related to the treatment...did not keep up
their appointments.” The number of drop-
outs not reported across the intervention
group
Selective reporting (reporting bias) High risk All outcomes reported as mean scores
(without SD): CGI, BPRS, Hamilton,
SAS, Side effects checklist (side effects not
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Javed 1991 (Continued)
described). Serious adverse events not re-
ported
Other bias Unclear risk Source of funding not reported.
Jolley 1990
Methods Allocation: randomised.
Blindness: double.
Duration: 2 years.
Design: 2 year follow-up.
Country: United KIngdom.
Participants Diagnosis: schizophrenia (DSM III).
N = 54.
Age: not stated.
Sex: not stated.
History: stable patients in remission, who has been free of florid symptoms (delusions,
hallucinations, bizarre behaviour and thought disorders) for at least 6 months.
Setting: community.
Interventions 1. Fluphenazine decanoate: (dosage not reported). N = 27.
2. Placebo. (dosage not reported). N = 27.
Outcomes Death.
Behaviour: leaving the study early.
Adverse effects: AIMS.
Unable to use -
Adverse effects: SAS (data unusable).
Social ability: SAS (non clinical outcomes, data unusable).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
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Jolley 1990 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow up balanced across the
groups: 5 (19%) in the placebo group and
6 (22%) in the treatment group
Selective reporting (reporting bias) High risk Not all outcomes have been fully reported.
Other bias Low risk Supported by grants fromTheDepartment
for Health and Social Security, NorthWest
Thames Regional Research Fund and the
Priory hospital
Ju 2000
Methods Allocation: Randomly assigned.
Blindness: not mentioned.
Duration: 12 weeks.
Design: parallel.
Country: China.
Participants Diagnosis: schizophrenia (CCMD-2-R).
N = 152.
Age: mean ~ 31 years, range 18-45.
Sex: 93M, 59F
History: course of disease 2-6 years.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: start from 25 mg, controlled dose at range of 25-125 mg,
given once for every 2 weeks. N = 49.
2. Pipothiazine palmitate: start from 25 mg, controlled dose at range of 25-125 mg,
given once for every 4 weeks. N = 103
Outcomes Global state: clinically important global change.
Behaviour: leaving the study early.
Mental state: BPRS, SANS, SAPS.
Adverse effects: TESS, RSESE.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Ju 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the patients complete the 12-week treat-
ment.
Selective reporting (reporting bias) Low risk All the outcomes were reported.
Other bias Low risk No other sources of bias.
Kane 1978
Methods Allocation: randomised.
Blindness: unclear.
Duration: 2 weeks.
Design: parallel.
Country: United States.
Participants Diagnosis: schizophrenia (criteria not reported).
N = 49.
Age: 13-37 years.
Sex: 29M, 20F.
History: Recently discharged schizophrenic patients stabilized onoral antipsychoticmed-
ication and procyclidine.
Setting: community.
Interventions 1. Fluphenazine enanthate, 12.5mg and 2 mcg benztropine mesylate; IM. N = 12
2. Fluphenazine decanoate, 12.5 mg and 2 mcg benztropine mesylate; IM. N = 13
3. Fluphenazine enanthate, 18.75 mg IM. N = 14
4. Fluphenazine decanoate, 18.75 mg.; IM. N = 10
Outcomes Adverse effects: SAS
Notes 11/23 patients receiving fluphenazine decanoate and 13/26 patients receiving
fluphenazine enanthate also took oral antipsychotics. 3 patients in the fluphenazine enan-
thate and 2 in the fluphenazine decanoate group received imipramine and 1 patient in
each group received lithium
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Kane 1978 (Continued)
The two fluphenazine decanoate and two fluphenazine enanthate groups were combined
in the analysis as the doses are standard doses in each group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding details of personnel and patients
not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An examination of extrapyramidal side ef-
fects was carried out ...by a physician blind
to the type of injection received”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up or missing data bal-
anced across intervention groups, with sim-
ilar reasons for missing data. “The data
was incomplete in 11 patients (22%) due
to noncompliance. 10 of these 11 patients
missed the 2-week examination. There was
no significant difference in compliance
between the fluphenazine enanthate and
fluphenazine decanoate groups”
Selective reporting (reporting bias) High risk The study reports only the primary out-
come i.e. extrapyramidal symptoms. Other
expected outcomes (e.g. relapse, hospital
admission, non-EPS adverse events) have
not been reported
Other bias Unclear risk Source of funding not reported.
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Kane 1983
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: dosage study.
Country: United States.
Participants Diagnosis: schizophrenia (RDC).
N = 126.
Age: 17-60 years, mean ~ 29 years.
Sex: 63M, 37F.
History: in state of remission, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate (low dose): dose 1.25-5.0 mg/IM biweekly. N = 62.
2. Fluphenazine decanoate (standard dose): dose 12.5-50 mg/IM biweekly. N = 64
Outcomes Behaviour: leaving the study early.
Adverse effects: SDS, SAS.
Unable to use -
Global State: CGI (no data).
Mental State: BPRS (no data).
Behaviour: SAS-R (data unusable).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported.
Selective reporting (reporting bias) High risk Outcome data for BPRS and CGI not re-
ported.
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Kane 1983 (Continued)
Other bias Low risk “...supported, in part, by grants...from the
National Institute of Mental Health”
Kaneno 1991
Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: parallel group.
County: Japan.
Participants Diagnosis: schizophrenia.
N = 259.
Age: 20 - 65 years.
Sex: 168M, 91F.
History: not stated.
Setting: hospital and community.
Interventions 1. Fluphenazine decanoate: dose 12-50 mg/ml/IM administered 6 times at 4-week in-
tervals. N = 127.
2. Haloperidol: dose 3.0-12.1mg administered 6 times. N = 132
Outcomes Suicide.
Behaviour: leaving the study early.
Unable to use -
Mental state: BPRS, KORS (no SD).
Adverse effects: OSR (no SD).
Notes Article mostly written in Japanese, risk of bias assessed from the English section only
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation details not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
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Kaneno 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants (completed and termi-
nated) were entered to the analysis. No
missing data
Selective reporting (reporting bias) High risk Data not reported fully formental state and
adverse effects
Other bias Unclear risk The paper is in Japanese.
Kelly 1977
Methods Allocation: randomised.
Blindness: single.
Duration: 9 months.
Design: parallel group.
Country: UK.
Participants Diagnosis: schizophrenia (Schneider 1st Rank).
N = 60.
Age: 18 - 65 years, mean ~ 42 years.
Sex: 18M, 35F.
History: not stated.
Setting: community.
Excluded: epilepsy, ECT, brain damage, pregnancy, marked metal retardation or parkin-
sonism
Interventions 1. Fluphenazine decanoate: dose 1ml/IM every 3 weeks. N = 30.
2. Flupenthixol decanoate: dose 1ml/IM every 3 weeks. N = 30
Medication adjusted weeks 1-9, stable thereafter.
Outcomes Leaving the study early.
Global state: relapse.
Unable to use -
Mental state: BPRS (no SD).
Adverse effects: EPS (no data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Low risk “the key to the allocation [was] known only
to the hospital pharmacist and to the nurse
administering the injections”
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Kelly 1977 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information: patientsmay have
blinded, nurses were unblinded. “...the key
to the allocation [was] known only to the
nurse administering the injections.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number and reasons for missing data bal-
anced. 60 randomised, 53 completed pa-
tients. 6 patients relapsed (3 in each group
and 1 became pregnant
Selective reporting (reporting bias) High risk No data reported for EPS, data not fully
reported for BPRS.
Other bias Unclear risk Source of funding not reported.
Keskiner 1971
Methods Allocation: randomised.
Blindness: double.
Duration: 8 weeks (4 weeks before cross-over).
Design: cross-over.
Country: United States.
Participants Diagnosis: schizophrenia.
N = 12.
Age: 25 - 51 years, mean ~ 38 years.
Sex: 3M, 9F.
History: duration of illness 5-25 years (mean 14 years).
Setting: hospital.
Interventions 1. Fluphenazine enanthate: dose 1 mg/kg body weight/IM single dose. N = 6.
2. Fluphenazine decanoate: dose 1 mg/kg body weight IM single dose. N = 6
Outcomes Behaviour: leaving the study early.
Unable to use -
Global state: GES (data unusable).
Mental state: BPRS (data unusable).
Adverse effects: TESS (data unusable).
Notes
Risk of bias Risk of bias
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Keskiner 1971 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly separated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Selective reporting (reporting bias) High risk Reports reported incompletely.
Other bias Low risk “Supported, in part, by Psychiatric Re-
search Foundation of Missouri and The
Squibb Institute forMedical Research, new
brunswick, NJ”
Khazaie 2005
Methods Allocation: randomised.
Blindness: double blind.
Duration: 54 weeks.
Design: parallel.
Country: Iran.
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM IV).
N = 50.
Age: mean ~ 34 years.
Sex: 36M, 14F.
History: duration of illness mean 12.0 years (SD = 6.6).
Setting: community.
Interventions 1. Fluphenazine decanoate: 25 mg every 2 weeks. N = 25.
2. Fluphenazine decanoate: 25 mg every 6 weeks. N = 25.
All patients, in both groups, received injections every two weeks; group 1 received
fluphenazine at each time i.e. every two weeks and group 2 received placebo injections
between each fluphenazine injection
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Khazaie 2005 (Continued)
Outcomes Mental state: BPRS.
Clinical impression: CGI.
Quality of life: Quality of life Scale.
Extrapyramidal adverse effects: Maryland Psychiatric Research Center Involuntary
Movement Scale
Not used in review -
General functioning: Level of Functioning Scale.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up balanced in numbers
across allocation groups: 7 participants
from the 2-week group and 6 from the 6-
week group. Reasons for drop-outs not re-
ported per allocation group
Selective reporting (reporting bias) Low risk All outcome results have been reported.
Other bias Unclear risk Source of funding not reported.
Kissling 1985
Methods Allocation: randomised (coin throwing).
Blindness: double.
Duration: 6 months.
Design: parallel group.
Country: Germany.
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Kissling 1985 (Continued)
Participants Diagnosis: schizophrenia, schizoaffective psychosis (DSM III).
N = 54.
Age: FD - mean age 28 years, HD - mean age 35 years.
Sex: 24M, 7F.
History: on oral medication, required depot treatment for >6 months, able to give
informed consent.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose mean 25 mg/IM biweekly. N = 22.
2. Haloperidol decanoate: dose mean 50 mg/IM monthly. N = 32
Outcomes Behaviour: leaving the study early.
Unable to use -
Global state: need for additional anticholinergic medication (data unusable).
Mental state: BPRS (data unusable).
Adverse effects: EPMS, DOTES, STESS (data unusable).
Physiological: serum levels (non clinical outcomes).
Notes The drop-out rate after 6 months was FD-60%, HD- 30%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random allocation (coin throwing)”.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up/missing data imbal-
anced in numbers or reasons across inter-
vention groups. 10 (30%) of participants
in the haloperidol group left the study early
and 13 (60%) in the fluphenazine group
Selective reporting (reporting bias) High risk All outcomes have been reported, however
data presented is not usable
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Kissling 1985 (Continued)
Other bias Unclear risk Source of funding not reported.
Kreisman 1988
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: dosage study.
Country: United States.
Participants Diagnosis: schizophrenia (Research Diagnostic Criteria - Spitzer 1977).
N = 132.
Age: 17- 60 years.
Sex: 91 M, 41 F.
History: ’were in remission, at a stable clinical plateau’.
Setting: community.
Excluded: presumptive tardive dyskinesia, neurological disorders, serious substance
abuse, mental retardation, physical illnesses, or requiring adjunctive medication except
for antiparkinsonian agents and minor tranquillisers
Interventions 1. Fluphenazine decanoate (low dose): dose 1.25-5 mg/cc biweekly. N = 66.
2. Fluphenazine decanoate (high dose): dose 12.5-50 mg/cc biweekly. N = 66
Outcomes Global state: relapse.
Unable to use -
Global state: GAS (data unusable).
Mental state: BPRS (no SD).
Behaviour: SAS II, PRS (no usable data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
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Kreisman 1988 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 132 participants entered the study, the final
sample was 51. Reasons for losses to follow-
up not reported
Selective reporting (reporting bias) High risk Outcomes reported as P values.
Other bias Unclear risk Source of funding not reported
Kurland 1966
Methods Allocation: randomised.
Blindness: double.
Duration: 24 weeks (first arm 12 weeks).
Design: cross-over.
Country: United States.
Participants Diagnosis: schizophrenia.
N = 19.
Age: 23 - 53 years.
Sex: all male.
History: chronically ill.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose mean 25 mg/IM monthly. N = 9.
2. Fluphenazine enanthate: dose mean 22.8 mg/IM monthly. N = 10
Outcomes Adverse effects.
Unable to use -
Physiological: weight measures, BP (non-clinical outcomes).
Notes No continuous outcomes measured.
Data put in depot vs depot category in both FE & FD treatment groups
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Low risk “Medication was administered under a
code number known only to the pharma-
cist.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
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Kurland 1966 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients completed the study.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk “grant-in aid from the Squibb Institute for
Medical Research”
Lehmann 1980
Methods Allocation: randomised.
Blindness: double.
Duration: 24 weeks.
Desgin: dosage study.
Country: Germany.
Participants Diagnosis: schizophrenia (ICD 2951).
N = 40.
Age: 35 -38 years.
Sex: 27M,13F.
History: all patients chronically ill and resistant to standard doses of neuroleptics.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose 225 mg/day. N = 20.
2. Fluphenazine decanoate: dose 25 mg/day. N = 20.
Outcomes Global state: GRS.
Behaviour: leaving the study early.
Unable to use -
Mental state: EWL-K (no usable data).
Notes Article in German.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, details not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
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Lehmann 1980 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk To assure the double-blindness, the pa-
tients whose doses were reduced were given
placebo injections
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Forty patients were randomised and 39 pa-
tients were analysed after 24 weeks. There
was one drop-out from the high-dosage
group
Selective reporting (reporting bias) Unclear risk Unable to use data for EWL-K, other out-
comes reported.
Other bias Unclear risk Source of funding not reported.
Leong 1989
Methods Allocation: randomised.
Blindness: partial.
Duration: 28 weeks.
Design: parallel group.
Country: Singapore.
Participants Diagnosis: schizophrenia (ICD-295).
N = 60.
Age: 18 - 65 years, mean ~ 38 years.
Sex: 27M, 33F.
History: able to give informed consent, patients in remission.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 12.5-50 mg/IM monthly. N = 30.
2. Pipothiazine palmitate: dose 25-50 mg/IM monthly. N = 30.
Flexible dose.
Outcomes Global state: CGI, need for additional medication.
Mental state: BPRS.
Behaviour: leaving the study early.
Adverse effects: various measures, EPS.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Leong 1989 (Continued)
Random sequence generation (selection
bias)
High risk “randomised”, “On admission, the patients
were assigned the next available study num-
ber in numerical sequence and allocated
to receive either pipothiazine palmitate or
fluphenazine decanoate”
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The administration of the study medica-
tions was open to the person giving the in-
jections...”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...the patients’ symptoms and side effects.
..were assessed by one of the investigators
who had no knowledge of which study
medication had been prescribed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the trial.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Source of funding not reported.
Levenson 1976
Methods Allocation: randomised.
Blindness: double.
Duration: 21 days.
Design: 3 treatment groups.
Country: United States.
Participants Diagnosis: schizophrenia (Spitzerian criteria).
N = 12.
Age: 18 - 53 years, mean ~ 30 years.
Sex: 4M, 8F.
History: able to give informed consent.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose 2.5-7.5 mg/day. N 5.
2. Thiothixine: dose 5 -15 mg/day. N = 3.
3. Haloperidol: dose 2.5 -7.5mg/day. N = 4.
Outcomes Behaviour: leaving the study early.
Adverse effects.
Unable to use -
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Levenson 1976 (Continued)
Mental state: BPRS (no usable data).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Five patients received an administrative
discharge from the study prior ton remis-
sion for reasons unrelated to their illness,
to the medication they were receiving, or
to any other pertinent study variable”
Selective reporting (reporting bias) High risk Clinical outcome (BPRS) reported incom-
pletely.
Other bias Unclear risk Source of funding not reported.
Lundin 1990
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year (preceded by 6 month ’run-in’ period).
Design: parallel group.
Country: Norway.
Participants Diagnosis: schizophrenia (NIMH Collaborative Study/ DSM III).
N = 58.
Age: 18 -65 years.
Sex: 46M, 12F.
History: > 3 months satisfactory response on depot, duration illness 6 -< 24 months,
able to give informed consent.
Setting: community.
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Lundin 1990 (Continued)
Interventions 1. Fluphenazine decanoate: dose mean 34.8 mg/IM monthly. N = 30.
2. Flupenthixol decanoate: dose mean 54.7 mg/IM monthly. N = 28
Outcomes Behaviour: leaving the study early.
Unable to use -
Global state: TES (no data).
Mental state: BPRS, CPRS (no data).
Adverse effects: EPS, HRSD, CSE (no data).
Social ability: KAS (non clinical outcome, data unusable).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up / missing data bal-
anced across intervention groups, with sim-
ilar reasons for missing data
Selective reporting (reporting bias) High risk Results reported incompletely: BPRS,
CPRS, CSE, SAS, HRSD, KAS
Other bias Unclear risk Source of funding not reported.
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MacCrimmon 1978
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: parallel group.
Country: Canada.
Participants Diagnosis: schizophrenia.
N = 49.
Age: 28-54 years, mean ~ 40 years.
Sex: 16M, 23F.
History: duration illness 1-21 years, mean ~ 12 years.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25-37.5/IM every 28 days. N = 24.
2. Fluphenazine enanthate: dose 25-37.5 mg/IM every 25 days. N = 25
Outcomes Global state: need for additional medication.
Mental state: BPRS.
Behaviour: leaving the study early.
Side effects: Bordeleau Scale.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up/missing data imbal-
anced in numbers and reasons across in-
tervention groups. Fluphenazine enanthate
3 (12%) and fluphenazine decaonate 7
(29%)
Selective reporting (reporting bias) Low risk Outcomes have been reported: BPRS,
extrapyramidal symptoms, other adverse
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MacCrimmon 1978 (Continued)
events and serious adverse events
Other bias Unclear risk Source of funding not reported.
Magnus 1979
Methods Allocation: randomised, prearranged prescribing list.
Blindness: open.
Duration: 6 months.
Design: parallel group.
Country: UK.
Participants Diagnosis: schizophrenia.
N = 50.
Age: ’approximately equal in both groups’.
Sex: male and female ’approximately equal in both groups’
History: newly admitted to hospital (either first episode or relapse).
Setting: community and hospital.
Interventions 1. Fluphenazine decanoate: every 2-3 weeks, dose range 50-100 mg/IM. N = 26.
2. Fluspirilene: weekly, dose range 6-12 mg/IM. N = 24.
Indiviually adjusted doses.
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects.
Unable to use -
Mental state: BPRS (no SD) self and nurse’s assessment (no data).
Social ability: WWBRS (non-clinical outcomes, data unusable)
Notes Authors contacted.
Unable to complete risk of bias table - PDF missing.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were allocated...according to a
pre-arranged randomised prescribing list”
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial.
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Magnus 1979 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All but two (one in each group) completed
six months treatment”
Selective reporting (reporting bias) High risk Not all outcomes reported: no SD reported
for BPRS and no data for nurse’s assessment
Other bias Unclear risk Smith Kline & French Laboratories pro-
vided statistical help.
Malm 1974
Methods Allocation: randomised.
Blindness: double.
Duration: 8 weeks.
Design: parallel group.
Country: Sweden.
Participants Diagnosis: schizophrenia.
N = 62.
Age: 18-65 years.
Sex: 21M, 36F.
History: duration illness 2-39 years, mean ~15 years.
Setting: hospital.
Interventions 1. Fluphenazine enanthate: dose 7.5-50 mg/IM, mean 28.5 mg/IM biweekly. N = 26.
2. Fluspirilene: dose 1-14 mg/IM, mean 5.7 mg/IMweekly. N = 31
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Unable to use -
Mental state: S-Scale (no data).
Behaviour: ADL (no data).
Adverse effects: SE scale (no SD).
Physiological: various measures (non-clinical outcomes, data unusable)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “allocated randomly”. Method not re-
ported.
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Malm 1974 (Continued)
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Patients blinded. Nurses
administering the injections: not blinded
to the study medications
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 62 participants were enrolled but number
randomised to each group not reported.
5 participants were withdrawn during the
first two months, intervention groups not
reported
Selective reporting (reporting bias) High risk Outcomes incompletely reported: S-Scale,
Side effects, Nurses’ ratings (ADL)
Other bias Low risk “Supported, in part, by a grant from LEO
Research Foundation, Helsingborg.”
Marder 1987
Methods Allocation: randomised.
Blindness: double.
Duration: 2 years.
Design: dosage study.
Country: United States.
Participants Diagnosis: schizophrenia (DSM III).
N = 66.
Age: mean ~ 35 years.
Sex: all male.
History: drug free for a month, duration illness mean 24 months (5 mg), 170 months
(25 mg).
Setting: community and hospital.
Interventions 1. Fluphenazine decanoate (low dose): dose mean 5 mg/IM biweekly. N = 35.
2. Fluphenzazine decanoate (standard): dose mean 25 mg/IM biweekly. N = 31
Outcomes Global state: relapse.
Behaviour: leaving the study early.
Adverse effects: need for additional medication.
Unable to use -
Mental state: BPRS (no data).
Adverse effects: Hopkins SCL-90R, side-effects scale (no data)
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Marder 1987 (Continued)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”randomised“. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/35 and 6/31 participants left the study
early during the first six months”, reasons
not reported
Selective reporting (reporting bias) Unclear risk Outcomes incompletely reported: SCL-90,
SE Scale, IMEPS, Subjective EPS Rating
Scale. P values for most outcomes and data
at 1 month (SCL-90) and three months
(side effects)
Other bias Low risk “...supported by Veterans Administration
Medical Research and the UCLA Mental
Mental Health Clinical Research Center
for the Study of schizophrenia; and the na-
tional Institute of mental Health grant...E.
R. Squibb and Sons...provided the lowdose
formulation of fluphenazine decanoate.”
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McClelland 1976
Methods Allocation: randomised.
Blindness: double.
Duration: 6 months (preceded by pretrial of 6 weeks).
Design: dosage study.
Country: UK.
Participants Diagnosis: schizophrenia (Kraepelinian).
N = 50.
Age: 18-60 years.
Sex: 22M, 28F.
History: disabled, able to give informed consent, minimum hospital stay > 12 months.
Setting: hospital.
Interventions 1. Fluphenazine decanoate (VHD): dose mean 250 mg/IM weekly. N = 25.
2. Fluphenazine decanoate (standard): dose mean 12.5 mg/IM weekly. N = 25
Outcomes Global state: need for additional medication.
Mental state: BPRS.
Behaviour: leaving the study early.
Adverse effects: EPS Scale.
Unable to use -
Behaviour: WWBRS (no data).
Physiological measures: weight (non-clinical outcomes, data unusable)
Notes Unable to complete risk of bias table - PDF missing.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Random allocation”, no further details re-
ported.
Allocation concealment (selection bias) Low risk “Allocation to the experimental or control
group was carried out by the hospital phar-
macist”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind design and entailed the
’double-dummy’ technique.” “The man-
ufacturer prepared 10-ml ampules of
fluphenazine decanoate, 25mg/ml and in-
active preparation containing only sesame
oil, as well as 0.5 ml ampules with 25 mg/
ml of the drug and a sesame oil placebo”.
“All hospital personnel were ’blind”’.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”, blinding of outcome as-
sessors not reported.
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McClelland 1976 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Twoparticipants in the VHDgroup left the
study early and three in the standard dose
group
Selective reporting (reporting bias) High risk No data were reported for the WWBRS.
Other bias Unclear risk Source of funding not reported.
McCreadie 1980
Methods Allocation: randomised.
Blindness: double.
Duration: 9 months.
Design: parallel group.
Country: United Kingdom (Scotland).
Participants Diagnosis: schizophrenia (Feighner’s Criteria).
N = 35.
Age: 19-70 years, mean 47-55 years.
Sex: all male.
History: on antipsychotics for mean 4 years, duration illness 18-26 years, able to give
informed consent.
Setting: hospital and community.
Interventions 1. Fluphenazine decanoate: dose mean 12.5 mg/IM, maximum 50 mg/IM weekly. N =
18.
2. Pimozide: dose mean 8mg, maximum 32 mg every 4 days/week. N = 16
Outcomes Global state: relapse, need for additional medication.
Adverse effects: Kraweicka scale.
Unable to use -
Mental state: Hamilton-Lorr scale (no data).
Behaviour: Wing Ward Behaviour Scale (no data).
Notes N differs in the paper and abstract.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
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McCreadie 1980 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. “To ensure
double-blind conditions patients received
active fluphenazine injections and placebo
pimozide tablets, or placebo injections and
active tablets.” Participants blinded. Blind-
ing details of personnel unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details of out-
come assessors unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up and missing data bal-
anced across intervention groups (4/16 vs
3/18), with similar reasons for missing
data (relapse: 3/16 vs 3/18; 1 participant
dropped out due to non-compliance with
medication)
Selective reporting (reporting bias) High risk Hamiiton-Lorr, Wing and Griffiths scales’
results not reported
Other bias Unclear risk Funding source not reported. Medication
supplied by Janssen Pharmaceutical and
Squibb
McCreadie 1982
Methods Allocation: randomised.
Blindness: double.
Duration: 9 months.
Design: parallel group.
Country: United Kingdom (Scotland).
Participants Diagnosis: schizophrenia (Feighner’s criteria).
N = 28.
Age: 27-70 years, mean ~ 55 years.
Sex: all male.
History: duration illness >27 yrs.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose range 2-25 mg/IM, mean 14 mg/IM biweekly. N = 15.
2. Pimozide: dose range 10-60 mg, mean 40 mg, weekly. N = 13
Outcomes Mental state: Krawiecka sub-scales.
Behaviour: leaving the study early.
Adverse effects: parkinsonism, tardive dyskinesia.
Unable to use -
Mental state: HLS (no data).
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McCreadie 1982 (Continued)
Behaviour: WWBRS (no data).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. “To ensure double blind
conditions, patients received either active
pimozide tablets and dummy fluphenazine
injections or dummy tablets and active in-
jections.” Blinding details of personnel, un-
clear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details of out-
come assessors, unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up balanced across inter-
vention groups (38% vs 40%), with sim-
ilar reasons (exacerbation, adverse events)
for missing data
Selective reporting (reporting bias) High risk Hamilton-Lorr scale, Wing Ward Be-
haviour Scale results not reported
Other bias Low risk “...supported by a research grant from
Dumfries and Galloway Health Board”.
Medication and other materials provided
by Janssen Pharmaceutical and Squibb
Limited
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McKane 1987
Methods Allocation: randomised.
Blindness: double.
Duration: 48 weeks. (preceded by 12 weeks ’run in’ period where additional medication
allowed).
Design: parallel group.
Country: United Kingdom (Scotland).
Participants Diagnosis: schizophrenia (Feighner (1972).
N = 38.
Age: 31-71 years, mean ~ 56 years.
Sex: 22M, 16F.
History: previously on antipsychotics, consent given by next of kin.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose mean 106 mg/IM/week, week 12 dose mean 105/IM
monthly. N = 19.
2. Haloperidol decanoate: dose mean 127 mg/IM, week 12 dose mean 120 mg/IM
monthly. N = 19
Outcomes Global state: Global 5-point scale, need for additional medication.
Behaviour: leaving the study early.
Adverse effects: AIMS, SAS, Parkinsonism.
Notes 5 people unaccounted for in th FD group.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Five patients left the study during the run-
in period and 17 patients on haloperidol
and 16 on fluphenazine entered the study
proper. Losses to follow-up/missing data
balanced in numbers 6/17 vs 4/16 but
imbalanced in reasons (relapse 6/17 vs 1/
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McKane 1987 (Continued)
16; non-compliance: 0/17 vs 2/16; adverse
events: 0/17 vs 1/16) across intervention
groups
Selective reporting (reporting bias) Low risk Outcome results reported: Krawieka,
Wing, SAS, AIMS.
Other bias High risk “Janssen Pharmaceutical...financial and
other assistance”.
McLaren 1992
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia (ICD-9).
N = 47.
Age: 20-65 yrs.
Sex: 27M, 20F.
History: good physical health, received antipsychotics for at least 1 year previously,
duration illness 18 years, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 16-300 mg/IM/month, mean 103 mg/IM/month. N
= 24.
2. Bromperidol decanoate: dose 67-400 mg/IM/month, mean 242 mg/IM/month. N =
23
Outcomes Global state: relapse, need for additional medication.
Behaviour: leaving the study early.
Symptoms: NSRS.
Unable to use -
Mental state: KWS, MARDRS (no data).
Social ability: MRSS (non clinical outcome, data unusable).
Adverse effects: AIMS (data unusable), SAS (no data).
Physiological measures: weight, blood samples (non-clinical outcomes, data unusable)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
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McLaren 1992 (Continued)
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “double-blind” “identical ampoules”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details of out-
come assessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Two patients, both on fluphenazine de-
canoate withdrew consent”. “Five patients,
all in the bromperidol decanoate group
were withdrawn from the study...following
relapse”, “One other patient, on bromperi-
dol decanoate, was lost to follow-up during
the sixth week of the study having deterio-
rated before contact was lost”
Selective reporting (reporting bias) High risk Data not reported or incomplete for
the NSRS, Krawiecka-Goldberg scale,
MARDRS, MRSS, SAS, AIMS
Other bias High risk financial support: Jannsen Pharmaceutical.
Odejide 1982
Methods Allocation: randomised.
Blindness: double.
Duration: 12 months.
Design: parallel group.
Country: Nigeria.
Participants Diagnosis: schizophrenia (ICD-9).
N = 70.
Age: not stated.
Sex: not stated.
History: treated with FD < 2 years, < 2 acute periods, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25 mg/IM every 4-8 weeks. N = 35.
2. Placebo. N = 35.
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: AIMS.
Unable to use -
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Odejide 1982 (Continued)
Mental state: BPRS, PSE (no data).
Notes 2 drop-outs unaccounted for in th FD group.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. “patients were unaware of
the contents of their injections”. Blinding
details of other personnel (e.g. nurses who
administered the injections), not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The psychiatrist who evaluated follow-up
status, was blind to treatment status...”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 53/70 participants completed the study.
Losses to follow-up or missing data bal-
anced across intervention groups
Selective reporting (reporting bias) High risk Outcomes not reported (PSE) or incom-
pletely reported (BPRS).
Other bias Unclear risk Source of funding not reported.
Pinto 1979
Methods Allocation: randomised.
Blindness: double.
Duration: 18 months (preceded by 3 months ’run-in’ period - medication unchanged).
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia.
N = 64.
Age: not stated.
Sex: not stated.
History: receiving depot for at least 6 months, stable - no hospital admission for at least
3 months prior to trial.
Setting: community.
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Pinto 1979 (Continued)
Interventions 1. Fluphenazine decanoate: dose mean 25 mg/IM every 3 weeks (initial dose 12.5 mg).
N = 33.
2 Flupenthixol decanoate: dose mean 36.6 mg/IM every 3 weeks (initial dose 20 mg).
N = 31
Outcomes Global state: need for additional medication.
Adverse effects: EPSE.
Leaving the study early.
Unable to use -
Mental state: BPRS (no SD).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”randomly allocated“. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk ”double-blind“. Patients blinded, nurses
unblinded. ”injections were prepared and
administered by nursing staff...neither the
clinician nor the patients were aware of the
treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “...rating clinicians in ignorance of the al-
location of patients to treatment groups”
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up/missing data imbal-
anced in numbers across intervention
groups. “a total of eight patients all in the
fluphenazine group, dropped-out of the
trial...”
Selective reporting (reporting bias) High risk Outcome data incompletely reported
(BPRS).
Other bias Unclear risk Source of funding not reported.
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Quitkin 1978
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year (six weeks prior to study entry, participants were stabilised on
fluphenazine decanoate 0.5-2 mL/ 2 weeks.
Design: parallel group.
Country: United States.
Participants Diagnosis: schizophrenia (RDC).
N = 60.
Age: 17-49 years.
Sex: 41M,19F.
History: < 2 psychotic episodes, able to give informed consent.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 0.5-4 IM/mL biweekly. N = 29.
2. Penfluridol (oral): dose 20-160 mg, weekly. N = 27.
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Unable to use -
Global state: CGI (no data).
Mental state: BPRS (no data).
Adverse effects: KAS (no data).
Social ability: SAS (non clinical outcome, data unusable).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “random”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk “After 56 patients completed the study, the
Food and Drug Administration suspended
the use penfluridol”, “these four patients
whose failure to complete the study is un-
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Quitkin 1978 (Continued)
related to the clinical efficacy...will not be
considered in further analysis”
35/56 participants completed the study;
4 from the penfluridol and 8 from the
fluphenazine group left the study early
Selective reporting (reporting bias) High risk Outcome data not reported: BPRS, CGI,
KASP, KASR.
Other bias Unclear risk Source of funding not reported.
Rifkin 1977
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year (psychotherapy given every 2 weeks for first 6 months, monthly there-
after).
Design: 3 treatment groups.
Country: United States.
Participants Diagnosis: schizophrenia (Kraepelinian).
N = 73.
Age: 17-38 years, mean
Sex: 50M, 23F.
History: 16 participants acutely ill, stable while receiving FD/F HCL for 4 weeks, able
to give informed consent.
Setting: community.
Interventions 1.Fluphenazine decanoate: dose range 0.5-2.0 IM/mL, mean 0.5 mL/IM biweekly. N =
23.
2. Fluphenazine hydrochloride (oral): dose range 5-20 mg, mean 5 mg/daily. N = 28.
3. Placebo. N = 22.
Outcomes Behaviour: leaving the study early.
Mental state: relapse.
Adverse effects: toxicity.
Unable to use -
Global State: CGI (no data).
Mental state: BPRS (patient evaluation, no data).
Adverse effects: KAS (no data).
Notes N differs in paper I for chronic patients compared to paper II.
Continuous data reported in paper II but not usable- not separated into separate groups
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Rifkin 1977 (Continued)
Random sequence generation (selection
bias)
Unclear risk “random”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Patients blinded: “All pa-
tients received biweekly injections and
daily pills-some being placebo.” Blinding
details of personnel not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of drop-outs are balanced across
the intervention groups but reasons have
not been reported
Selective reporting (reporting bias) Unclear risk Outcomes not fully reported.
Other bias Low risk “...supported by national Institute of Men-
tal Health grant...”
Rossi 1990
Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: parallel group.
Country:
Participants Diagnosis: schizophrenia (DSM III-R).
N = 30.
Age: 19-42 years, mean ~ 29 years.
Sex: 18M, 13F.
History: duration of illness (< 1 year n = 6), (1-6 years n = 20), (> 6 years n = 4).
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25-50 mg/IM, mean 30 mg/IM monthly. N = 15.
2. Bromperidol decanoate: dose 50-100 mg/IM, mean 85 mg/IM monthly. N = 15
Outcomes Behaviour: leaving the study early.
Unable to use -
Global state: CGI (no SD).
Mental state: BPRS (no SD).
Behaviour: CBS (no SD).
Side effects: DOTES, TESS, EPSE (data unusable).
116Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rossi 1990 (Continued)
Notes Unable to complete ’Risk of bias’ table - article in Italian
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Russell 1982
Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia (ICD-9).
N = 33.
Age: mean ~ 36 years.
Sex: 12M, 16F.
History: duration illness 9 years, able to give informed consent.
Setting: unclear.
Interventions 1. Fluphenazine decanoate: dose mean 12.5 mg/IM, maximum dose 25.5 mg/IM every
2-3 weeks. N = 13.
2. Fluspiriline decanoate: dose mean 3 mg/IM, maximum dose 10.94 mg/IM weekly. N
= 20
Outcomes Global state: need for additional medication.
Behaviour: leaving the study early.
Adverse effects: EPRS.
Unable to use -
Global state: CGI (no SD).
Mental state: BPRS (no SD).
Adverse effects: SAS (no data).
Behaviour: MACC-BAS (no data).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomallocation”.Methodnot reported.
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Russell 1982 (Continued)
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Subjects
blinded “...placebo injections being given.
..in the intervening weeks...”. Blinding de-
tails of personnel not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “double-blind”. “...a second psychiatrist
rated each patient blind...”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Twofluspirilene and three fluphenazine pa-
tients dropped out after one week“, reasons
not reported
Selective reporting (reporting bias) High risk BPRS and CGI incompletely reported (P
values). SAS and MACC Behavior Adjust-
ment Scale results not reported
Other bias Unclear risk ”...supported by McNeil (Canada) labora-
tories.
Schlosberg 1978
Methods Allocation: randomised.
Blindness: double.
Duration: 9 months (depot), 3 months (placebo)*.
Design: parallel group.
Country: Israel.
Participants Diagnosis: schizophrenia.
N = 75 (12 in placebo trial).
Age: mean 42 years.
Sex: not stated.
History: duration illness mean ~ 17 years.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose 6.25-50 mg/IM monthly. N = 30.
2. Pipothiazine palmitate: dose 6.25-50 mg/IM monthly. N = 30
Outcomes Leaving the study.
Global Impression.
Side effects.
Unable to use -
Mental state: BPRS (no SD).
Behaviour: NOSIE (no SD).
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Schlosberg 1978 (Continued)
Notes * Wash-out period 14 days.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Patients blinded: “The
drugs injected were pipotiazine palmitate,
fluphenazine decanoate, and placebo...”.
Blinding details of personnel not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not reported.
Selective reporting (reporting bias) High risk BPSD and NOISE results incompletely re-
ported.
Other bias Unclear risk Source of funding not reported.
Schneider 1981
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year (preceded by 2 weeks washout).
Design: parallel group.
Country: United States.
Participants Diagnosis: schizophrenia (DSM II).
N = 59.
Age: 21-65 years, mean ~ 45 years.
Sex: 51M, 8F.
History: duration illness mean ~ 21 years, able to give informed consent.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose 12.5-400 mg/IM every 2-5 weeks. N = 27.
2. Pipothiazine palmitate: dose 50-400 mg/IM every 2-5 weeks. N = 32
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Schneider 1981 (Continued)
Outcomes Leaving the study early.
Unable to use -
Global state: CGI (no data).
Physiological measures: blood samples (non-clinical outcome, data unusable)
Notes 67% attrition rate in the treatment group, therefore the data are not usable
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of drop-outs not reported per allo-
cation group. 59 patients were randomised,
“a total of 34 patients remained in the study
long enough to have at least 10 blood anal-
yses”
Selective reporting (reporting bias) High risk Data not reported for CGI.
Other bias Unclear risk Source of funding not reported.
Schooler 1976
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: parallel group.
Country: United States.
Participants Diagnosis: schizophrenia (Schneiderian 1st rank).
N = 197.
Age: 18-55 years, mean ~ 30 years.
Sex: 58M, 42F.
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Schooler 1976 (Continued)
History: newly admitted from the community.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 12.5-100 mg/IM, mean 34.7 mg/IM every 3 weeks. N
= 102.
2. Fluphenazine (orally): dose max 60 mg, mean 25.2 mg/IM daily. N = 95
Outcomes Leaving the study early.
Additional medication.
Side effects: TESS.
Notes No continuous outcomes measured.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients blinded; blinding details of per-
sonnel not reported.“...an injection of de-
pot fluphenazine plus oral placebo or depot
placebo plus oral fluphenazine. Both injec-
tions and pills...administered under dou-
ble-blind conditions.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information. Losses to follow-
up not reported.
Selective reporting (reporting bias) High risk Incomplete data. “Treatment emergent
symptoms were evaluated... by both a
physician and a nurse...The data in this pa-
per are the nurse’s ratings”
Other bias Low risk “...supported by the National Institute of
Mental Health grants...”
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Schooler 1979
Methods Allocation: randomised.
Blindness: double.
Duration: 1 year.
Design: parallel group.
Country: USA.
Participants Diagnosis: schizophrenia.
N = 214*.
Age: mean ~ 29 years.
Sex: not stated.
History: not stated.
Setting: community.
Interventions 1. Fluphenazine decanoate: (dose and frequency not stated). N = 107.
2. Fluphenazine hydrochloride: (dose and frequency not stated). N = 107
Outcomes Relapse.
Unable to use -
Mental state: BPRS (no SD).
Side effects: SCL-9 (no SD).
Notes *Maintenance phase
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information. Losses to follow-
up not reported.
Selective reporting (reporting bias) High risk BPRS and SCL-90 results incompletely re-
ported.
Other bias Unclear risk Source of funding not reported.
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Schooler 1980
Methods Allocation: randomised, stratified by sex.
Blindness: double.
Duration: 1 year.
Design: parallel group.
Country: United States.
Participants Diagnosis: schizophrenia.
N = 290*.
Age: 18-55 years, mean ~ 29 years.
Sex: 170M, 120F.
History: able to give informed consent.
Setting: initially in hospital for 7-9 weeks intensive treatment, followed by community
Interventions 1. Fluphenazine decanoate: dose 12.5-100 mg/IM, mean 34.2 mg/IM every 3 weeks. N
= 143.
2. Fluphenazine hydrochloride (oral): dose 2.5-60 mg, mean 24.8mg daily. N = 147
Outcomes Leaving the study early.
Side effects: DOTES, SCL-90.
Unable to use -
Global state: CGI, Community Nursing Assessment (no data).
Mental state: BPRS, HRSD (no data).
Social ability: SAS (non clinical outcomes, data unusable).
Notes Results for both FD & FHCL groups together.
Authors contacted
* 214 entered maintenance phase.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “stratified by sex, randomly assigned”.
Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. “...either fluphenazine de-
canoate and oral placebo or fluphenazine
hydrochloride and placebo injection.” Pa-
tients blinded. Blinding details of person-
nel not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blind”. Blinding details not re-
ported.
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Schooler 1980 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 290 participants were randomised to the
“intensive phase” of the study lasting 7 to 9
weeks. “76 participants were removed from
treatment during the intensive treatment
phase. Therewere no significant differences
between the two treatments in reasons for
or number of these terminations”
“214 (107 from each of the two treat-
ment regimes) entered the one-year ”main-
tenance phase“ of the study”.
“Patients continued to receive study treat-
ment for a maximum of one year or un-
til termination for either treatment-related
or administrative reasons”. Survival analy-
sis was performed in the study
Selective reporting (reporting bias) High risk Incomplete report of outcome data (BPRS,
Hopkins Symptom Checklist-90, CGI),
no data Hamilton Depression Scale. Full
BPRS data (mean SD) not reported per al-
location group
Other bias Low risk “...supported by the Nations Institute of
Mental Health grants...”
Schooler 1997
Methods Allocation: randomised.
Blindness: double.
Duration: 16-24 weeks.
Design: dosage study.
Country: United States.
Participants Diagnosis: schizophrenia (DSM III).
N = 313.
Age: mean 29.6 years.
Sex: 207M 106F.
History: acutely ill.
Setting: community and /or hospital.
Interventions 1. Fluphenazine decanoate (low dose): dose 2.5-10 mg biweekly. N = 106.
2. Fluphenazine decanoate (standard): dose 12.5-50 mg biweekly. N = 107
Outcomes Rehospitalised.
Unable to use -
Global impression: CGI (no data).
Mental state: BPRS, SANS (no data).
Side effects: AIMS, EPS, Early Signs Questionnaire (no data).
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Schooler 1997 (Continued)
Family therapy strategies: (non-clinical outcomes, data unusable)
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information on losses to follow-up not re-
ported.
Selective reporting (reporting bias) High risk Outcomes not reported: BPRS, SANS,
CGI,Neurological Rating Scale (extrapyra-
midal symptoms), Early Signs Question-
naire. Family treatment strategies outcomes
incompletely reported
Other bias Unclear risk Source of funding unclear. “All dou-
ble-blind medication supplies as well as
open label fluphenazine decanoate and
fluphenazine hydrochloride were provided
courtesy of Bristol-Myers Squibb Com-
pany...”. “multicentre clinical trial...in col-
laboration with the Division of Treatment
and Clinical Research of the national Insti-
tute of Mental Health”
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Sharma 1991
Methods Allocation: randomised.
Blindness: double.
Duration: 48 weeks.
Design: parallel group.
Country: UK.
Participants Diagnosis: schizophrenia (DSM III).
N = 59.
Age: 30-81 years, mean ~ 52 years.
Sex: 34M, 25F.
History: duration illness 22 years, able to give informed consent.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose 100 mg/IM/monthly. N = 29.
2. Haloperidol decanoate: dose 100 mg/IM/monthly. N = 30.
Outcomes Leaving the study early.
Additional medication.
Side effects: EPS Rating Scale, AIMS.
Unable to use -
Mental state: CPRS (data unusable).
Physiological measures: weight (non-clinical outcomes, data unusable)
Notes N and drop-out numbers for each group changes.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up unbalanced in num-
bers (6/30 fluphenazine vs 10/29 haloperi-
dol) and reasons (treatment failure “pri-
mary reason for withdrawal in one patient
onfluphenazine and5patients on haloperi-
dol”)
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Sharma 1991 (Continued)
Selective reporting (reporting bias) High risk CPRS results reported incompletely.
Other bias Unclear risk Source of funding not reported.
Shenoy 1981
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Design: parallel group.
Country: USA.
Participants Diagnosis: schizophrenia (DSM III criteria).
N = 31.
Age: mean 37.4 (11.33) years, range 23-59.
Sex: not reported.
History: chronic ambulatory schizophrenia patients treated with fluphenazine decanoate
for two years.
Setting: outpatients.
Interventions 1. Placebo, every 3 weeks. N = 17
2. Fluphenazine decanoate (dose not reported), every 3 weeks. N = 14
Outcomes Global state: relapse, GAS.
Mental State: SADS.
Unable to use -
Adverse effects: AIMS (data not reported per treatment group)
Notes Participants in group 1 were given placebo injections as a “drug holiday”. At the end of
the 6-week study they were returned to their routine active medication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “patients were randomly assigned”.
Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
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Shenoy 1981 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk None of the patients relapsed. 3 partici-
pants did not complete the trial: 2 in the
active and 1 in the placebo group. All drop-
out were due to “failure to meet appoint-
ments”
Selective reporting (reporting bias) Low risk All outcomes have been reported.
Other bias Unclear risk Source of funding has not been reported.
Shu 1983
Methods Allocation: randomised.
Blindness: double.
Duration: 6 weeks.
Design: parallel group.
Country: China.
Participants Diagnosis: schizophrenia.
N = 34.
Age: 15-48 years.
Sex: all male.
History: not stated.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: (dose and frequency not stated). N = 16.
2. Penflurdidol + placebo: (dose and frequency not stated). N = 18
Outcomes Global state: CGI.
Leaving the study early.
Side effects: SAS.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
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Shu 1983 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up balanced across in-
tervention groups: 3 (18%) lost in the
fluphenazine group and 2 (11%) in the
penflurdidol group, with similar reasons for
missing data (exacerbation)
Selective reporting (reporting bias) Low risk Outcome data have been reported: CGI, A
standardized psychiatric Assessment Scale
for Chronic psychiatric Patients, rating
Scale for Extramidal Side Effects (Simpson
G M)
Other bias Unclear risk Source of funding not reported.
Simon 1978
Methods Allocation: randomised.
Blindness: open.
Duration: 18 months.
Design: 3 treatment groups.
Country: France.
Participants Diagnosis: schizophrenia (French classification of mental illness).
N = 181.
Age: 21-45 years.
Sex: 117M, 64F.
History: duration illness 3-10 years.
Setting: community and/or hospital.
Interventions 1. Fluphenazine decanoate: dose mean 88 mg/IM every 22 days. N = 57.
2. Pipothiazine decanoate: dose mean 90 mg/IM every 25 days. N = 61.
3. Standard oral neuroleptics: no further details. N = 63.
Outcomes Leaving the study early.
Global state: CGI.
Mental state: BPRS, NOSIE.
Additional medication.
Side effects.
Notes
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Simon 1978 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “balanced randomization”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “open study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “open study”
Incomplete outcome data (attrition bias)
All outcomes
High risk 39 participants left the study early, 14 in the
fluphenazine group, 15 in the pipothiazine
group and 10 in the standard neuroleptics
group. Reasons were similar across groups.
“The 18 dropouts due to independent
causes and those lost to follow up were not
considered in the analysis”
Selective reporting (reporting bias) Low risk All outcome data has been reported.
Other bias Unclear risk “...supported by a grant from the Fonda-
tion de L’Industrie pharmaceutique pour la
recherche...”
Singh 1979
Methods Allocation: randomised.
Blindness: double.
Duration: 44 weeks.
Design: parallel group.
Country: Canada.
Participants Diagnosis: schizophrenia (DSM-II).
N = 30.
Age: 29-59 years, mean ~ 44 years.
Sex: 24M, 6F.
History: duration illness 3-32 years.
Setting: community.
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Singh 1979 (Continued)
Interventions 1. Fluphenazine enanthate: dose 25-75 mg/IM, mean 44.2 mg/IM/monthly. N = 15.
2. Pipothiazine palmitate: dose 100-150 mg/IM, mean 125 mg/IM/monthly. N = 15
Outcomes Mental state: BPRS.
Side effects.
Unable to use -
Physicological measures: (non-clinical outcomes, data unusable)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind”. Patients blinded; “ ...test
medications were administered blind...on
alternate two weeks, patients in the pipoti-
azine group received an injection of sesame
oil...”. Blinding details of personnel not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients completed the study.
Selective reporting (reporting bias) Low risk Outcome data reported for BPRS and side
effects.
Other bias Unclear risk Source of funding not reported.
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Song 1993
Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: 3 treatment groups.
Country: not reported.
Participants Diagnosis: schizophrenia.
N = 154.
Age: not stated.
Sex: not stated.
History: chronic.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: (dose and frequency not stated). N = 50.
2. Pipothiazine palmitate (oral): (dose and frequency not stated). N = 52.
3. Pipothiazine palmate (oral, non-blinded): (dose and frequency not stated). N = 52
Outcomes Leaving the study early.
Mental state: BPRS*.
Unable to use -
Side effects: TESS (data unusable).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blindness in pipotiazine palmitate
group and Fluphenazine Decanoate group,
and one non-blindness pipotiazine palmi-
tate group”. Details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blindness in pipotiazine palmitate
group and Fluphenazine Decanoate group,
and one non-blindness pipotiazine palmi-
tate group”. Details not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported.
Selective reporting (reporting bias) High risk Outcome data for TESS not reported fully.
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Song 1993 (Continued)
Other bias Unclear risk Source of funding not reported.
Van Praag 1970
Methods Allocation: randomised.
Blindness: double.
Duration: 8 weeks, follow-up 4 weeks.
Design: parallel group.
Country: The Netherlands.
Participants Diagnosis: psychotic*.
N = 25.
Age: not stated.
Sex: not stated
History: chronic and acute.
Setting: hospital.
Interventions 1. Fluphenazine enanthate: dose mean 25 mg/IM + oral placebo every 3 weeks. N = 13.
2. Fluphenazine oral + depot placebo: dose and frequency not reported. N = 12
All received concomitant orphenadrine (Disipal) 50 mg tds.
Outcomes Additional medication.
Unable to use -
Side effects: EPS checklist (no data).
Behaviour: Wing Scale - Scale A (no data), Scale B: (authors own scale **).
Physiological measures: (non-clinical outcomes, data unusable)
Notes * Group 1 were acutely ill.
Group 2. were chronically ill.
**Marshall 1998.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “divided at random”.Methodnot reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “One category received active fluphenazine
orally and placebo injections; the other
received oral placebos and injections of
fluphenazine enanthate...The test drug
and placebo were contained in identi-
cal capsules...Active fluid and placebo
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Van Praag 1970 (Continued)
fluid were indistinguishable...Strict dou-
ble-blind conditions prevailed throughout
the experiment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Strict double-blind conditions prevailed
throughout the experiment.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data imbalanced across interven-
tion groups 8% (oral group) versus 25%
(depot group): 2 participants in the depo
category left the study early due to deteri-
oration of symptoms, a further patient in
the depot category left due to encephalitis.
1 participant in the oral category due to se-
vere oligophrenia
Selective reporting (reporting bias) High risk Outcome data not fully reported.
Other bias Unclear risk Source of funding not reported.
Van Praag 1973
Methods Allocation: randomised.
Blindness: double.
Duration: 4 weeks.
Design: parallel group.
Country: The Netherlands.
Participants Diagnosis: acutely psychotic.
N = 33.
Age: 19-70 years, mean ~ 42 years.
Sex: 19F, 11M.
History: not stated.
Setting: hospital.
Interventions 1. Fluphenazine decanoate: dose 25 mg/IM every 3 weeks. N = 15.
2. Fluphenazine enanthate: dose 25 mg/IM every 3 weeks. N = 18
Outcomes Leaving the study early.
Additional medication.
Unable to use -
Behaviour: Wing Scale - A & B (no data).
Notes Data put in depot vs depot category in both FE & FD treatment groups
Risk of bias Risk of bias
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Van Praag 1973 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly divided”. Method not reported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The conditions of a double-blind test were
ensured”. Blinding details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The evaluators- physicians and nurses-
were blind to the distribution of enanthate
and decanoate...”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across intervention
groups: 2 (14%) participants from the
enanthate group and 1 (6%) from the de-
canoate group, with similar reasons for
missing data
Selective reporting (reporting bias) High risk Outcome data not reported (Wing Scale A
and Scale B)
Other bias Unclear risk Source of funding not reported
Walker 1983
Methods Allocation: randomised.
Blindness: double.
Duration: 24 weeks (preceded by 12 week open trial).
Design: parallel group.
Country: United Kingdom.
Participants Diagnosis: schizophrenia.
N = 39.
Age: 23-67 years, mean ~ 45 years.
Sex: male and female.
History: currently maintained on depot neuroleptics, at least one hospitalisation, dura-
tion illness 1-20 years.
Setting: community.
Interventions 1.Fluphenazine decanoate: dose 12.5mg/weeks-37.5 mg/4 weeks, mean 24.8 mg/IM
every 3-4 weeks. N = 20.
2. Clopenthixol decanoate: dose 200mg/4 weeks - 600 mg/2 weeks, mean 220 mg/IM
every 3-4 weeks. N = 19
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Walker 1983 (Continued)
Outcomes Side effects: Side Effects Inventory.
Unable to use -
Global state: CGI, Krawiecka, Goldberg & Vaughan Rating Scale (no SD).
Mental state: BPRS (no SD).
Physiological measures: blood/liver tests, weight, BP ( non-clinical outcomes, data un-
usable)
Notes Authors contacted.
Analysis: last observation carried forward.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missed data per allocation group unclear.
“Forty five patients entered the trial. Six pa-
tients failed to return following the first in-
terview and so were discounted. One pa-
tient returned to her home country, and so
failed to attend for the final assessment”
Selective reporting (reporting bias) High risk Outcome data incompletely reported (SD
not reported): CGI, BPRS, Krawiecka,
Goldberg & Vaughan Rating Scale
Other bias Unclear risk Source of funding not reported.
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Wistedt 1983
Methods Allocation: randomised.
Blindness: double.
Duration: 2 years.
Design: parallel group.
Country: Sweden.
Participants Diagnosis: schizophrenia (Bleuler’s criteria).
N = 32.
Age: 26-67 years, mean ~ 41years.
Sex: 15M, 17F.
History: stabilised on depots, relapse in connection with withdrawal; duration illness
mean ~ 14 years.
Setting: not stated.
Interventions 1. Fluphenazine decanoate: dose mean 27mg/IM every 3 weeks. N = 15.
2. Flupenthixol decanoate: dose mean 31mg/IM every 3 weeks. N = 17
Outcomes Leaving the study early.
Side effects: SRSE, AIMS.
Unable to use -
Global state: CGI (no data).
Mental state: CPRS (no data).
Notes Authors contacted.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “allocated randomly”. Method not re-
ported.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double-blind”. Blinding details not re-
ported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The injections were given by a nurse who
did not participate in the assessment.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data balanced across intervention
groups (27% fluphenazine group vs 40%
flupenthixol group). Reasons for losses to
follow-up not reported
Selective reporting (reporting bias) High risk Incomplete outcome data: CGI, CPRS.
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Other bias Unclear risk Source of funding not reported.
Wistedt 1984
Methods Allocation: randomised.
Blindness: double.
Duration: 20 weeks.
Design: parallel group.
Country: Sweden.
Participants Diagnosis: schizophrenia (RDC).
N = 51.
Age range: 21-63 years.
Sex: 33M, 18F.
History: 6 months treatment forseen, duration illness < 12 years, able to give informed
consent.
Setting: 4 weeks in hospital, thereafter in the community.
Interventions 1. Fluphenazine decanoate: dose mean 84 mg/IM/monthly. N = 26.
2. Haloperidol decanoate: dose mean 122 mg/IM/monthly. N = 25
Depot (FD/HD) dose range: 25-100 mg/injection, initially adjusted at 2nd injection
(max. 300 mg)
Outcomes Global State: CGI.
Mental state: CPRS.
Leaving the study early.
Additional medication.
Side effects: EPS, AIMS.
Unable to use -
Physiological measures: drug plasma levels, weight changes (non clinical outcomes, data
unusable)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “allocated to the two groups according to a
randomisation list...Patients were balanced
in groups of six” Details not reported
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Injections were give double-blind”. Blind-
ing details not reported
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Wistedt 1984 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across interven-
tion groups (15% fluphenazine vs 15%
haloperidol), with similar reasons for miss-
ing data
Selective reporting (reporting bias) Low risk All primary outcomes reported: CPRS,
CGI, EPS.
Other bias Unclear risk Source of funding not reported.
Woggon 1977
Methods Allocation: randomised.
Blindness: double.
Duration: 6 months.
Design: parallel group.
Country: Germany.
Participants Diagnosis: schizophrenia (ICD Nr).
N = 61.
Age: 21-79 years.
Sex: 36M, 25F.
History: 6 months treatment.
Setting: community.
Interventions 1. Fluphenazine decanoate: dose 25-37.5 mg/IM every 3 weeks. N = 30.
2. Pipothiazine palmitate: dose 100 mg/IM every 4 weeks. N = 31
Outcomes Leaving the study early.
Unable to use -
Side effects: (data unusable).
Notes Article in German.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, no further details reported.
Allocation concealment (selection bias) Unclear risk Not reported.
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Woggon 1977 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The tests were performed double-blind.
The dosage of both drugs and the addi-
tional medications were prescribed by an
investigator who himself did not take part
in the ratings
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, details not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up.
Selective reporting (reporting bias) Unclear risk Data for side effects not usable, other out-
comes reported.
Other bias Unclear risk Source of funding not reported.
Diagnostic tools:
CCMD-2-R: Chinese Classification of Mental Disorders, Second Edition, Revised
DSM III - Diagnostic Statistical Manual, version 3
ICD-9 - International Classification of Diseases, version 9
RDC - Research Diagnostic Criteria
Rating scales
Global state:
CGI - Clinical Global Impression
GAS - Global Assessment Scale
GRS - Global Rating Scale
GES - Global Evaluation Scale
KWS - Krawiecka-Goldberg Scale
PRS - Patient Rejection Scale
TES - Therapeutic Effects Scale
Mental state:
BPRS - Brief Psychiatric Rating Scale
CPRS - Comprehensive Psychopathological Rating Scale
EWL-K - List of Attributes self rating scale.
HLS - Hamilton-Lorr Scale
HRSD - Hamilton Psychiatric Rating Scale for Depression
KGS -
KORS - Keio University’s Simplified Rating Scale for Psychiatric Symptoms
KWS -
MIE - Mental Illness Evaluation
PANSS - Positive and Negative Syndrome Scale
PSE - Wing Ward Present State Examination
SANS - Scale for Assessment of Negative Symptoms
SAPS - Scale for Assessment of Positive Symptoms
S-Scale - The Symptom Scale
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Behaviour:
CBS - Current Behaviour Schedule
MACC-BAS - MACC Behaviour Adjustment Scale
PRS -
WWBRS - Wing Ward Behaviour Rating Scale
Symptom scales:
HSC - Hopkins Symptom Checklist
MRSS - Morningside Rehabilitation Rating Scale
NSRS - Negative Symptom Rating Scale
SSI - Springfield Symptom Index
SCL-90 - Symptom Checklist -90
Social behaviour:
ADL - Activities of Daily Living
KAS - Katz Adjustment Scale
SAS - Social Adjustment Scale
SRE - Schedule of Recent Events
SBAS - Social Behaviour Assement Schedule
SPS - Social Performance Schedule
Side effects
AIMS - Abnormal Involuntary Movement Side effects
Bordeleau Scale
CSE - Clinical Side Effects Scale
DOTES - Dosage Record & Treatment Emergent Symptom Scale
EPMS - Extrapyramidal Motor Side-effects
EPSS - Extrapyramidal Side-effects Symptoms
EPS -Extrapyramidal symptom scale
IMEPS - Involuntary Movement and EPS Scale
MARDRS- Montgomery-Asberg Depression Rating Scale
MRQ - Medication Response Questionnaire
NOSIE - Nurses Observation Scale for Inpatient Evaluation
OSR - Overall Safety Rating
RSESE - Rating Scale for Extrapyramidal Side Effects
SAS - Simpson and Angus Scale
SDS - Simpson Dyskinesia Scale
SRSE - Simpson Rating Scale for EPS
SEC -Side Effects Checklist
SCL-9 Side effects Check List 9
STESS - Total Score of Side Effects Self Rating
TESF - Treatment Emergent Symptom Form
TESS - Treatment Emergent Symptoms Scale
UKU - Side Effects Rating Scale
Miscellaneous:
bid - twice daily
BMI - body mass index
BP - Blood Pressure
EE - Expressed Emotion
IM - intramuscular
NIMH - National Institute of Mental Health
SD - standard deviation
tds - three times daily
VHD - Very High Dose
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abuzzahab 1976a Allocation: not randomised.
Abuzzahab 1976b Allocation: double blind.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus pimozide.
Abuzzahab 1977 Allocation: not randomised.
Abuzzahab 1980 Allocation: double blind.
Participants: people with psychopathology.
Interventions: fluphenazine HCl versus pimozide.
Ahlfors 1971 Allocation: randomly selected.
Participants: people with schizophrenia.
Interventions: fluphenazine enanthate versus pipotiazine undecylenic ester.
Outcomes: no data presented.
Ahlfors 1973 Allocation: randomised.
Particpants: people with schizophrenia.
Interventions: fluphenazine enanthate versus pipotiazine undecylenate.
Outcomes: no usable data, authors contacted.
Altamura 1987 Allocation: not randomised.
Angst 1975 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluspirilen versus penfluridol versus perphenazino enanthate
versus pipothiazine palmitate.
Outcomes: no usable data.
Arato 1979 Allocation: not randomised (retrospective study).
Astrup 1974 Allocation: not randomised.
Balon 1982 Allocation: double blind - cross-over study.
Participants: people with schizophrenia.
Interventions: depot fluphenazine decanoate versus hydroxyprotepine decanoate.
Outcomes: no usable data.
Bankier 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: trifluoperazine versus placebo.
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Bao 1991 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: flupenthixol decanoate versus chlorpromazine.
Barnes 2010 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: first generation antipsychotics versus second generation (non-clozapine) antipsychotics
Barsa 1965 Allocation: double blind.
Participants: not specified.
Bastie 1974 Allocation: not randomised.
Benassi 1968 Allocation: not randomised.
Berliner 1974 Allocation: not randomised.
Bilone 1988 Allocation: not randomised.
Bloch 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: lidocaine-prilocaine cream versus placebo to reduce pain injection site pain of depot antipsy-
chotics
Boyer 1987 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: amisulpride versus fluphenazine.
Outcomes: no usable data (no SDs).
Brankovic 1998 Allocation: not randomised.
Breier 1987 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine - withdrawal study.
Caranza 1973 Allocation: not randomised.
Carpenter 1992 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine versus placebo versus diazepam.
Outcomes: withdrawal study.
Carpenter 1993 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: Fluphenazine decanoate 1 cc, every 2 weeks versus fluphenazine decanoate 1 cc, every 6 weeks.
Outcome data: no usable data reported (conference proceeding)
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Carpenter 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate injection 2/52 versus 6/52 with oral fluphenazine prescribed as re-
quired
Casacchia 1989 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: bromperidol decanoate versus fluphenazine decanoate.
Outcomes: no usable data.
Castellini Allocation: open - cross-over study.
Chacon 1972 Allocation: double blind - cross-over study.
Chacon 1973 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus chloropromazine.
Outcomes: no usable data, authors contacted.
Charalampous 1977 Allocation: random double-blind fashion.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus pentofluridol.
Chien 1974 Allocation: randomised.
Participants: people with psychotic illnesses including schizophrenia.
Interventions: fluphenazine enanthate versus different dosages of antiparkinson drugs (not antipsychotics)
Childers 1964 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: electro convulsive therapy (ECT) versus oral fluphenazine versus chlorpromazine versus chlor-
promazine with ECT
Chouinard 1970 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus pimozide.
Chowdhury 1980 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus flupenthixol decanoate.
Outcomes: no usable data, authors contacted.
Clark 1971 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus chlorpromazine versus thioridazine versus placebo
Cohen 1985 Allocation: not randomised.
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Cole 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus chlorpromazine versus acetophenazine
Cookson 1991 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: haloperidol decanoate versus fluphenazine decanoate.
Outcomes: no usable data.
Coufal 1981 Allocation: not randomised.
Curry 1979 Allocation: double blind - cross-over study.
Curson 1985 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate and flupenthixol decanoate versus placebo, the data for the two
antipsychotics (depot and oral) were analysed as one group
Curson 1986 Allocation: not randomised.
De Alarcon 1969 Allocation: not randomised - case reports.
De Buck 1973 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine (dosage study).
Del Giudice 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine enanthate versus fluphenazine hydrochloride (orally).
Outcomes: no usable data, no continuous outcomes measured.
Dencker 1978 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: high - low doses of fluphenazine enanthate.
Outcomes: no usable data.
Dencker 1981 Allocation: not randomised.
Dengler 1969 Allocation: not randomised.
DeWolfe 1971 Allocation: randomised
Participants: people with schizophrenia.
Interventions: fluphenazine enanthate versus thorazine-stelazine (orally).
Outcomes: data not usable, drop-out rate 60% in 6-week trial
Donlon 1976 1 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluphenazine enanthate.
Outcomes: no usable data.
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Donlon 1977 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus pimozide.
Donlon 1978 Allocation: quasi-randomised.
Doongaji 1988 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus penfluridol.
Outcomes: no usable data, authors contacted.
Dossenbach 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus olanzapine.
Downing 1963 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus fluphenazine versus thioridazine versus placebo.
Outcomes: no usable data.
Emsley 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: quetiapine versus haloperidol with fluphenazine prescribed (4-week run-in phase)
Engelhardt 1973 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus haloperidol versus placebo
Engstrand 1969 Allocation: not randomised.
Faltus 1974 Allocation: not randomised.
Faretra 1970 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus haloperidol.
Ferenc 2000 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus olanzapine.
Filip 1985 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus oxyprothepin decanoate with cross over at 6 months.
Outcomes: no usable data - results provided at 12 months without separating the treatments
Floru 1974 Allocation: not randomised.
Floru 1975 Allocation: not randomised.
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Giannelli 1990 Allocation: not randomised.
Gillis 1981 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: no usable data.
Gitlin 1988 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data (plasma study).
Gitlin 2001 Allocation: randomised cross-over trial.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data, no results reported for first phase of the study
Goff 2005 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: d-cycloserine as add-on to conventional antipsychotics versus placebo add-on
Goldberg 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus fluphenazine versus thioridazine.
Outcomes: no usable data.
Goldberg 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: placebo versus thioridazine versus chlorpromazine versus fluphenazine.
Outcomes: no usable data.
Goldberg 1970 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: prolixin enanthate versus oral phenothiazines
Goldberg 1981 Allocation: randomised - withdrawal study.
Gopalakrishnan 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: sildenafil versus placebo.
Grosser 1970 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluphenazine enanthate.
Outcomes: no usable data.
Haider 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine enanthate versus fluphenazine (oral).
Outcomes: no usable data.
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Hall 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus haloperidol.
Hamilton 1979 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus flupenthixol decanoate.
Outcomes: no usable data, no outcomes measured.
Hanlon 1965 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus chlorpromazine, thioridazine, trifluoperazine, prochlorpromazine,
perphenazine, thiopropazate and trifluperazine
Harper 1976 Allocation: double blind - cross-over study.
Participants: people with schizophrenia.
Interventions: chlorpromazine depot preparations versus fluphenazine.
Outcomes: no usable data.
Haslam 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus flupenthixol decanoate.
Outcomes: no usable data, data difficult to interpret.
Held 1970 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: phenothiazines and placebo.
Outcomes: no usable data.
Hirsch 1973 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate and placebo, withdrawal study
Hirsch 1978 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine versus flupenthixol.
Outcomes: no usable data.
Hirsch 1989 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus active injections with haloperidol prescribed as required
Hogarty 1995 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate - low dose versus standard dose.
Outcomes: fluphenazine decanoate measured against anxiolytics or antidepressants not antipsychotics
Holden 1970 Allocation: double blind - cross-over study.
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Holt 1984 Allocation: not randomised.
Hsu 1967 Allocation: randomised.
Participants: people suffering from psychotic disorders, including schizophrenia.
Interventions: fluphenazine enanthate versus placebo.
Outcomes: no usable data.
Inderbitzen 1994 Allocation: not randomised.
Inderbitzin 1993 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: reduced fluphenazine decanoate dose by 50% (10% per month for 5 months) versus at least
20 mg fluphenazine decanoate every four weeks.
Outcome data: no usable data reported (conference proceeding)
Ionescu 1983 Allocation: not randomised.
Iqbal 1978 Allocation: not randomised.
Irwin 1986 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: 5-HT versus placebo.
Itil 1970a Allocation: not randomised.
Itil 1970b Allocation: double blind - cross-over study.
Itil 1971 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine hydrochloride.
Outcomes: no usable data.
Itil 1978 Allocation: not randomised.
Jakovljevic 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus olanzapine.
James 1977 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus penfluridol.
Outcomes: no usable data (no SD).
Johnson 1975 Allocation: not randomised.
Jones 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: first generation antipsychotics versus second generation antipsychotics
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Kabes 1980a Allocation: “divided randomly into 2 groups” - cross-over study.
Participants: people with schizophrenia.
Interventions: depot preparations plus fluphenazine, oxyprothepine/oxyprotepin.
Outcomes: no usable data.
Kabes 1980b Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oxyprothepin decanoate versus fluphenazine decanoate - medication crossed over at 6 months.
Outcomes: no usable data - results presented at 12 months without differentiating each treatment arm
Kabes 1981 Allocation: double blind - cross-over study.
Participants: people with schizophrenia.
Interventions: oxyprothepin decanoate versus fluphenazine decanoate.
Outcomes: no usable data.
Kane 1979 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate and placebo.
Outcomes: withdrawal study.
Kane 1982 Allocation: randomised.
Participants: people with acute first episode schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data, authors contacted.
Kane 1983 b Allocation: not randomised - review article.
Keith 2002 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: Continuous low dose (2.5-10 mg) fluphenazine decanoate versus standard dose (12.5-50 mg)
versus targeted dose (vehicle), delivered by injection every two weeks for two years.
Outcome data: no usable data reported (conference proceeding)
Kelly 1999 Allocation: not randomised.
Kenway 1971 Allocation: randomised - cross-over study.
Keskiner 1968a Allocation: not randomised.
Keskiner 1968b Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: withdrawal study.
King 1979 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: family therapy in conjunction with high- and low-dose phenothiazines
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Kinon 1993 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine high dose versus fluphenazine low dose versus haloperidol.
Outcomes: no usable data.
Kinross-Wright 1963 Allocation: not randomised.
Knights 1979 Allocation: not randomised.
Kong 1989 Allocation: not randomised.
Landmark 1994 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluphenazine hydrochloride (oral).
Outcomes: no usable data, no clinical outcomes reported.
Lapierre 1975 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine versus pimozide.
Outcomes: no usable data.
Lapierre 1976 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine versus pimozide + half of each group received psychotherapy.
Outcomes: no usable data.
Lapierre 1978 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus penfluridol.
Lapierre 1983 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: pipothiazine palmitate versus fluphenazine decanoate.
Outcomes: no usable data.
Lasky 1962 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: chlorpromazine versus thioridazine versus chlorprothixene versus triflupromazine.
Outcomes: no usable data - drop outs > 50%.
Leff 1971 Allocation: randomised.
Particpants: people with schizophrenia.
Interventions: trifluperazine versus chlorpromazine.
Leff 1973 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: maintenance therapy and life events.
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Levinson 1990 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine 10, 20 mg/day for 24 days and fluphenazine 10, 20 and 30 mg/day
for 28 days.
Outcomes: no usable data.
Lewis 2003 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: first generation antipsychotics versus second generation antipsychotics
Litman 1994 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine versus benztropine (1st phase) and fluphenazine versus clozapine 92nd phase).
Outcomes: no usable data.
Ljubin 2000 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus olanzapine.
Mahmoud 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: risperidone versus conventional antipsychotics
Marder 1986 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate (dosage study).
Outcomes: no usable data.
Marder 1989 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluphenazine (oral).
Outcomes: no usable data, drug metabolism study - no clinical outcomes measured
Marder 1990a Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate (dosage study).
Outcomes: no usable data, authors contacted.
Marder 1991a Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate (dosage study).
Outcomes: no usable data, pharmacological study - no clinical outcomes reported
Marder 1991b Allocattion: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data, trial of different measuring procedures
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Marder 1996 Allocation: randomised.
Particpants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data.
Marder 2002 Allocation: randomised.
Particpants: people with schizophrenia.
Interventions: low-dose fluphenazine decanoate versus medium dose fluphenazine decanoate versus high-
dose fluphenazine decanoate.
Outcomes: no usable data.
Martenyi 2000 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: olanzapine versus fluphenazine.
Outcomes: no usable data.
Martin 1972 Allocation: not randomised.
Mattes 1984 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: lithium versus fluphenazine (oral and decanoate) versus placebo.
Outcomes: no usable data.
McCreadie 1983 Allocation: not randomised.
McCreadie 1986 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: haloperidol versus fluphenazine.
Outcomes: no usable data.
Meco 1987 Allocation: not randomised but double blinded.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus haloperidol decanoate.
Outcomes: no usable data, authors contacted.
Mimica 1998 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus olanzapine.
Montejo 2010 Allocation: not randomised.
Morris 1970 Allocation: randomised - cross-over study.
National 1964 Allocation: “randomly assigned”.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus chlorpromazine versus thioridazine versus placebo
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Nestoros 1978 Allocation: “randomly assigned”
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus butaclamol.
Owen 1993 Allocation: admitted sequentially - cross-over study.
Palma 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: flupenthixol decanoate versus other neuroleptics including fluphenazine decanoate.
Outcomes: fluphenazine decanoate results not presented separately from the other neuroleptics
Pichot 1988 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus amisulpride.
Pickar 1987 Allocation: review of studies.
Pickar 1992 Allocation: double blind - cross-over study.
Pickar 1994 Allocation: double blind - cross-over study.
Pollack 1964 Allocation: randomised.
Partcipants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data.
Preussler 1995 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: clozapine versus fluphenazine.
Outcomes: no usable data.
Preussler 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: clozapine versus fluphenazine.
Outcomes: no usable data.
Quitkin 1975 Allocation: “randomly assigned”.
Participants: people with schizophrenia.
Interventions: oral fluphenazine (dosage study).
Quitkin 1977 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus penfluridol.
Outcomes: no usable data, preliminary report.
Ravaris 1965 Allocation: not randomised.
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Ravaris 1967 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine enanthate versus fluphenazine (oral).
Outcomes: no usable data.
Rifkin 1976 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluphenazine (oral) versus placebo.
Outcomes: no usable data.
Roose 1982 Allocation: not randomised.
Rossger 1997 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: clozapine versus fluphenazine.
Outcomes: no usable data.
Saxena 1996 Allocation: non-specific - authors contacted (conference abstract)
Schausberger 1999 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus olanzapine.
Schipper 1971 Allocation: not randomised.
Schooler 1971 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: acetophenazine maleate versus chlorpromazine versus fluphenazine hydrochloride.
Outcomes: no usable data.
Schooler 1977 Allocation: not randomised - double blinded.
Schubert 1988 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine versus haloperidol.
Outcomes: no usable data.
Shafti 2009 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine versus placebo as add-on to olanzapine
Simpson 1970 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine.
Outcomes: no usable data.
Siris 1990 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: imipramine versus placebo as add-on to fluphenazine decanoate and benztropine
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Siris 1991 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: imipramine versus placebo as add-on to fluphenazine decanoate and benztropine
Steingard 1994 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine versus placebo.
Outcomes: no usable data.
Stevens 1973 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus placebo.
Outcomes: no usable data.
Tegeler 1985 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus clopenthixol decanoate.
Outcomes: no usable data, authors contacted.
Tetreault 1969 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine enanthate versus oral fluphenazine bichloralhydrate
Tran 1998 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: olanzapine versus fluphenazine.
Outcomes: no usable data.
Tsai 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: sarcosine versus placebo as add-on to antipsychotics
Tsai 2006 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: D-alanine versus placebo as add-on to antipsychotics as add-on to antipsychotics
Turner 1966 Allocation: randomised.
Participants: not described.
Turner 2004 Allocation: not randomised.
Ushakov 1990 Allocation: not randomised, case series.
van Putten 1986 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: 1st report - haloperidol (dosage study), 2nd report - fluphenazine (dosage study).
Outcomes: no usable data.
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van Putten 1991 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine (dosage study).
Outcomes: no usable data.
Verster 1998 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus generic substitute
Vestre 1962 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: oral fluphenazine versus triflupromazine versus phenobarbital
Viala 1988 Allocation: not randomised.
Villeneuve 1970 Allocation: not randomised.
Vinar 1970 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: fluphenazine versus fluphenazine long-acting form.
Outcomes: no usable data.
Weiden 1993 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate (dosage study).
Outcomes: no usable data, prescribing patterns study.
Wiles 1990 Allocation: double blind.
Participants: people with schizophrenia.
Interventions: haloperidol decanoate versus fluphenazine decanoate.
Outcomes: no usable data, authors contacted.
Winter 1973 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate versus fluspirilene decanoate.
Outcomes: no usable data.
Wistedt 1981 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate and flupenthixol decanoate versus placebo.
Outcomes: no usable data, the two drug treatments are grouped as one group
Wistedt 1983a Allocation: randomised.
Participants: people with schizophrenia.
Interventions: fluphenazine decanoate and flupenthixol decanoate versus placebo.
Outcomes: no usable data - both drugs placed in one group.
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Wistedt 1983b Allocation: randomised.
Participants: people with schizophrenia.
Interventions: discontinuation study.
Zapletalek 1981 Allocation: not randomised.
Characteristics of studies awaiting assessment [ordered by study ID]
Angst 1973
Methods
Participants
Interventions
Outcomes
Notes Article in German
del Giudice 1970
Methods
Participants
Interventions
Outcomes
Notes Missing PDF
Jue 1996
Methods
Participants
Interventions
Outcomes
Notes Missing PDF
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Kabes 1984
Methods
Participants
Interventions
Outcomes
Notes Missing PDF
Ravanic 1996
Methods
Participants
Interventions
Outcomes
Notes Missing PDF
Ushakov 1990a
Methods Unclear
Participants People with schizophrenia
Interventions 1. Fluphenazine decanoate (moditen-depot)
2. haloperidol decanoate
Outcomes Efficacy
Notes Article in Russian
159Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. FLUPHENAZINE DECANOATE vs PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 54 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.25, 99.51]
2 Global state: 1. Relapse 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 short term (6 weeks to 5
months)
1 31 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 medium term (6 months
to 1 year)
3 196 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.24, 1.60]
2.3 longer term (more than 1
year)
1 54 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.19, 0.64]
3 Global state: 2. GAS (short term
- 6 weeks to 5 months) (high
score = worse)
1 28 Mean Difference (IV, Fixed, 95% CI) 3.61 [-4.41, 11.63]
4 Leaving the study early 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 short term (6 weeks to 5
months)
1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [0.24, 24.07]
4.2 medium term (6 months
to 1 year)
4 216 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.77, 2.19]
4.3 longer term (more than 1
year)
1 54 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.23, 0.96]
5 Mental state: 1. BPRS (endpoint
scores - high score = worse)
1 16 Mean Difference (IV, Fixed, 95% CI) -2.03 [-4.51, 0.45]
6 Mental state: 2. Depression
(medium term - 6 months to 1
year)
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.45, 2.22]
7 Adverse effects: 1. Movement
disorders - tardive dyskinesia
(longer term - more than 1
year)
1 54 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.11]
8 Adverse effects: 2. Toxicity 1 45 Risk Ratio (M-H, Fixed, 95% CI) 7.65 [1.04, 56.26]
Comparison 2. FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. No clinically
important global change
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 immediate (0 to 5 weeks) 2 74 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.46, 0.81]
1.2 medium term (6 months
to 1 year)
1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.56, 1.27]
2 Global state: 2. Relapse 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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2.1 medium term (6 months
to 1 year)
6 419 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.75, 2.83]
2.2 longer term (more than 1
year)
3 216 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.81, 1.95]
3 Global state: 3. Clinical Global
Impression (short term - 6
weeks to 5 months) (high score
= worse)
1 34 Mean Difference (IV, Fixed, 95% CI) -0.10 [-2.79, 2.59]
4 Leaving the study early 13 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 immediate (0-5 weeks) 1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.30]
4.2 short term (6 weeks to 5
months)
1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.32, 8.85]
4.3 medium term (6 months
to 1 year)
9 887 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.73, 1.25]
4.4 longer term (more than 1
year)
2 164 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.61, 2.36]
5 Behaviour: 1. NOSIE-30 -
endpoint scores (high score =
poor)
1 120 Mean Difference (IV, Fixed, 95% CI) -0.56 [-6.92, 5.80]
6 Behaviour: 2. skewed data
(endpoint scores)
Other data No numeric data
7 Mental state: 1. BPRS - endpoint
scores (longer term - more than
1 year) (high score = poor)
1 120 Mean Difference (IV, Fixed, 95% CI) -0.75 [-5.75, 4.25]
8 Mental state: 2. Depression 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 medium term (6 months
to 1 year)
1 214 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.60, 1.32]
8.2 longer term (more than 1
year)
1 44 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.91, 2.57]
9 Adverse effects: 1a. Movement
disorders - general
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 medium term (6 months
to 1 year)
3 259 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.24, 0.91]
9.2 longer term (more than 1
year)
1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.12, 1.28]
10 Adverse effects: 1b. Movement
disorders - akathisia
1 51 Risk Ratio (M-H, Fixed, 95% CI) 20.54 [1.25, 337.94]
11 Adverse effects: 1c.
Movement disorders - needing
anticholinergic drugs
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 immediate (0 to 5 weeks) 1 37 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 medium term (6 months
to 1 year)
2 231 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.21, 3.45]
11.3 longer term (more than
1 year)
1 120 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.25]
12 Adverse effects: 1d. Movement
disorders - tardive dyskinesia
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 medium term (6 months
to 1 year)
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.41, 0.93]
12.2 longer term (more than
1 year)
1 120 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 2.99]
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13 Adverse effects: 1e. Movement
disorders - tremor (longer term
- more than 1 year)
1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.26, 2.45]
14 Adverse effects: 1f. Movement
disorders - average score
(Simpson & Angus, 0 to 5
weeks, high = poor)
1 32 Mean Difference (IV, Fixed, 95% CI) 1.3 [0.01, 2.59]
15 Adverse effects: 2. Blurred
vision - medium term (6
months to 1 year)
1 197 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.75, 2.38]
16 Adverse effects: 3. Toxicity -
medium term (6 months to 1
year)
1 51 Risk Ratio (M-H, Fixed, 95% CI) 4.87 [1.14, 20.72]
17 Adverse effects: 4. General
adverse effects
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 immediate (0 to 5 weeks) 1 37 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [0.24, 92.65]
17.2 medium term (6 months
to 1 year)
2 242 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.70, 1.37]
18 SENSITIVITY ANALYSIS
Global state: 2. Relapse
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 3. FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 38 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.31]
2 Global state: 1. No clinically
important global change
4 339 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.97, 1.18]
2.1 short term (6 weeks to 5
months)
1 152 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.89, 1.51]
2.2 medium term (6 months
to 1 year)
3 187 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.96, 1.12]
3 Global state: 2. Relapse 16 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 short term (6 weeks to 5
months)
1 51 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.27, 3.43]
3.2 medium term (6 months
to 1 year)
11 581 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.56, 1.18]
3.3 longer term (more than 1
year)
4 252 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.77, 1.92]
4 Global state: 3. Severly ill
(medium term 6 months to 1
year)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.94, 1.23]
5 Global state: 4. Needing
additional antipsychotic
treatment (6 months to 1 year)
2 91 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.14, 1.96]
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6 Global state: 5. Clinical Global
Impression. (short term - 6
weeks to 5 months) (skewed
data)
Other data No numeric data
7 Global state: 6. Clinical Global
Impression. (medium term - 6
months to 1 year)
2 90 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.41, 0.21]
8 Global state: 7. Clinical Global
Impression - not improved
(high score = poor)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 short term (6 weeks to 5
months)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 2.5 [0.53, 11.70]
8.2 medium term (6 months
to 1 year)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.18, 3.07]
9 Leaving the study early 23 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 immediate (0 to 5 weeks) 1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 short term (6 weeks to 5
months)
3 233 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.32, 1.84]
9.3 medium term (6 months
to 1 year)
15 775 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.89, 1.44]
9.4 By more than 1 year 5 319 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.64, 1.23]
10 Behaviour: 1. NOSIE-30 -
endpoint scores (high score =
poor)
1 118 Mean Difference (IV, Fixed, 95% CI) -5.21 [-10.85, 0.43]
11 Mental state: 1. BPRS
(endpoint scores - high score =
poor)
7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 short term (6 weeks to 5
months)
2 203 Mean Difference (IV, Fixed, 95% CI) 1.11 [0.86, 1.36]
11.2 medium term (6 months
to 1 year)
3 162 Mean Difference (IV, Fixed, 95% CI) 1.20 [1.10, 1.30]
11.3 longer term (more than
one year)
2 141 Mean Difference (IV, Fixed, 95% CI) 0.85 [-2.32, 4.03]
12 Mental state: 2. BPRS
(endpoint scores 6 months to 1
year - dichotomous data)
1 67 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.59, 1.43]
13 Mental state: 3. Depression (6
months to 1 year)
1 67 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.81, 1.28]
14 Mental state: 4. SAPS and
SANS (endpoint scores - high
score = poor) (skewed data)
Other data No numeric data
14.1 SAPS Other data No numeric data
14.2 SANS Other data No numeric data
15 Adverse effects: 1a. Movement
disorders - general
7 308 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.91, 1.35]
15.1 immediate term (0 to 5
weeks)
1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.24, 3.68]
15.2 short term (6 weeks to 5
months)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.43, 9.32]
15.3 medium term (6 months
to 1 year)
4 234 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.86, 1.34]
163Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15.4 longer term (more than
1 year)
1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.76, 1.69]
16 Adverse effects: 1b.
Movement disorders - needing
anticholinergic drugs
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 short term (6 weeks to 5
months)
1 51 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.96, 2.28]
16.2 medium term (6 months
to 1 year)
8 448 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.93, 1.64]
16.3 longer term (more than
1 year)
3 220 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.86, 1.83]
17 Adverse effects: 1c. Movement
disorders - parkinsonism
3 190 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.47, 2.69]
17.1 immediate (0 to 5 weeks) 1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.24, 3.68]
17.2 medium term (6 months
to 1 year)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.37, 4.21]
17.3 longer term (more than
1 year)
1 118 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 16.71]
18 Adverse effects: 1d. Movement
disorders - tardive dyskinesia:
longer term (more than 1 year)
2 150 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.32, 1.23]
19 Adverse effects: 1e. Movement
disorders - tremor
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 short term (6 weeks to 5
months)
2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.76, 2.46]
19.2 medium term (6 months
to 1 year)
3 152 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.73, 1.78]
20 Adverse effects: 1f. Movement
disorders - endpoint scores
(short term - 6 weeks to 5
months)
Other data No numeric data
20.1 TESS (high = poor) Other data No numeric data
20.2 RSESE (high = poor) Other data No numeric data
21 Adverse effects: 2. Blurred
vision
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 medium term (6 months
to 1 year)
1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.78]
21.2 longer term (more than
1 year)
1 64 Risk Ratio (M-H, Fixed, 95% CI) 17.88 [1.08, 294.82]
22 Adverse effects: 3. Dry mouth:
longer term (more than 1 year)
1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.38, 1.37]
23 Adverse effects: 4. General
adverse effects
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 short term (6 weeks to 5
months)
2 88 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.07, 1.74]
23.2 medium term (6 months
to 1 year)
5 249 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.83, 1.32]
24 SENSITIVITY ANALYSIS
Global state: 2. Relapse
11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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24.1 medium term (6 months
to 1 year)
11 581 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.56, 1.18]
Comparison 4. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Relapse (medium
term - 6 months to 1 year)
2 182 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.30, 14.91]
2 Global state: 2. Needing
additional antispsychotic
treatment (medium term - 6
months to 1 year)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.45, 6.24]
3 Global state: 3. Not improved
(medium term - 6 months to 1
year)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 nurse rated 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [1.09, 2.30]
3.2 psychiatrist rated 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.77, 1.74]
4 Leaving the study early (medium
term - 6 months to 1 year)
2 90 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.15, 2.36]
5 Mental state: BPRS endpoint
scores (medium term - 6
months to 1 year, high score =
poor)
1 50 Mean Difference (IV, Fixed, 95% CI) -0.03 [-5.79, 5.73]
6 Adverse effects: Movement
disorders - needing
anticholinergic drugs (medium
term - 6 months to 1 year)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.45, 6.24]
Comparison 5. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: Relapse 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 medium term (6 months
to 1 year)
3 471 Risk Ratio (M-H, Random, 95% CI) 3.33 [0.77, 14.51]
1.2 longer term (more than 1
year)
3 172 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.38, 1.89]
2 Leaving the study early 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 longer term (more than 1
year)
3 172 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.33, 1.36]
3 Adverse effects: 1. Movement
disorders (medium term - 6
months to 1 year)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Tardive dyskinesia 1 126 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.10, 2.72]
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3.2 Needing anticholinergic
drugs
1 50 Risk Ratio (M-H, Fixed, 95% CI) 2.55 [0.72, 9.05]
4 Adverse effects: 2. Continuous
data - skewed data (endpoint
scores, high = poor)
Other data No numeric data
Comparison 6. FLUPHENAZINE ENANTHATE vs PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adverse effects: Movement
disorders - general
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Needing anticholinergic
drugs (short term - 6 weeks to
5 months)
1 25 Risk Ratio (M-H, Fixed, 95% CI) 9.69 [0.58, 163.02]
Comparison 7. FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: No clinically
important global change
(immediate - 0 to 5 weeks)
1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.27, 1.66]
2 Adverse effects: Movement
disorders - general
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 movement disorders:
immediate (0 to 5 weeks)
1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.34 [0.53, 10.30]
2.2 side effects: immediate (0
to 5 weeks)
1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.94, 8.45]
2.3 parkinsonism: immediate
(0 to 5 weeks)
1 31 Risk Ratio (M-H, Fixed, 95% CI) 6.56 [0.91, 47.21]
Comparison 8. FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Needing
additional antipsychotic
treatment (6 months to 1 year)
2 65 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.24, 1.05]
2 Global state: 2. Relapse 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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2.1 short term (6 weeks to 5
months)
1 57 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [0.66, 8.61]
2.2 medium term (6 months
to 1 year)
1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.87]
3 Leaving the study early 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 immediate (0 to 5 weeks) 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.62]
3.2 short term (6 weeks to 5
months)
1 57 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [0.66, 8.61]
3.3 medium term (6 months
to 1 year)
1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.87]
4 Mental state: 1. BPRS - endpoint
scores (medium term - 6
months to 1 year) (high score =
poor)
1 30 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.34, 0.46]
5 Mental state: 2. Depression
(medium term - 6 months to 1
year)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.39, 124.83]
6 Adverse effects: 1a. Movement
disorders - general (medium
term - 6 months to 1 year)
2 63 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.75, 3.07]
7 Adverse effects: 1b. Movement
disorders - needing additional
anticholinergic drugs
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 short term (6 weeks to 5
months)
1 57 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [1.16, 7.06]
7.2 medium term (6 months
to 1 year)
2 65 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.76, 1.35]
8 Adverse effects: 1c. Movement
disorders - tardive dyskinesia:
medium term (6 months to 1
year)
1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.46, 1.71]
9 Adverse effects: 1d. Movement
disorders - tremor (medium
term - 6 months to 1 year)
3 95 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.82, 1.87]
10 Adverse effects: 2. Blurred
vision (medium term - 6
months to 1 year)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 68.26]
11 Adverse effects: 3. Dry mouth
(medium term - 6 months to 1
year)
2 62 Risk Ratio (M-H, Fixed, 95% CI) 0.8 [0.36, 1.76]
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Comparison 9. FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDI-
ATE/HIGH DOSE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: Relapse (short term
- 6 weeks to 5 months)
1 104 Risk Ratio (M-H, Fixed, 95% CI) 9.35 [2.28, 38.29]
2 Leaving the study early (short
term - 6 weeks to 5 months)
1 104 Risk Ratio (M-H, Fixed, 95% CI) 3.12 [0.66, 14.74]
Comparison 10. FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Needing
additional antipsychotic
treatment
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 immediate (0 to 5 weeks) 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.18, 0.86]
1.2 mediium term (6 months
to 1 year)
1 48 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.15, 6.53]
2 Global state: 2. Relapse 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 immediate (0 to 5 weeks) 2 44 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.18, 2.43]
2.2 short term (6 weeks to 5
months)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [0.70, 7.48]
2.3 medium term (6 months
to 1 year)
1 49 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [0.71, 8.32]
3 Behavioiur: Leaving the study
early
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 immediate (0 to 5 weeks) 2 44 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.18, 2.43]
3.2 short term (6 weeks to 5
months)
2 42 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [0.70, 7.48]
3.3 medium term (6 months
to 1 year)
1 49 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [0.71, 8.32]
4 Mental State: BPRS medium
term (6 months to 1 year - high
score = poor)
1 39 Mean Difference (IV, Fixed, 95% CI) 0.0 [-3.93, 3.93]
5 Adverse effects: 1a. Movement
disorders - general
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Immediate (0 to 5 weeks) 1 49 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [0.82, 8.64]
5.2 short term (6 weeks to 5
months)
2 49 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.79, 1.64]
6 Adverse effects: 1b. Movement
disorders - needing
anticholinergic drugs
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 immediate (0 to 5 weeks) 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.12, 0.70]
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6.2 short term (6 weeks to 5
months)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.82, 1.20]
6.3 medium term (6 months
to 1 year)
2 97 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.57, 1.07]
7 Adverse effects: 1c. Movement
disorders - parkinsonism (short
term - 6 weeks to 5 months)
1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.01]
8 Adverse effects: 1d. Movement
disorders - akathisia (Immediate
- 0 to 5 weeks)
1 49 Risk Ratio (M-H, Fixed, 95% CI) 6.19 [0.82, 46.62]
9 Adverse effects: 2. General
adverse effects (immediate - 0
to 5 weeks)
1 11 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 1.14]
Comparison 11. FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6 WEEKS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Relapse (1 year) 1 37 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.55, 1.44]
2 Leaving the study early (1 year) 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.46, 2.98]
3 Mental state: 1. BPRS - endpoint
scores (1 year) (high score =
poor)
1 Mean Difference (Fixed, 95% CI) Subtotals only
3.1 Total 1 37 Mean Difference (Fixed, 95% CI) 2.72 [-1.16, 6.60]
3.2 Thought disorder 1 37 Mean Difference (Fixed, 95% CI) -0.39 [-1.51, 0.73]
4 Adverse effects: 1. Movement
disorders - MPRC (1 year, high
= poor)
1 Mean Difference (Fixed, 95% CI) Subtotals only
4.1 Parkinsonian symptoms 1 37 Mean Difference (Fixed, 95% CI) 1.3 [-0.03, 2.63]
4.2 Dyskinesia 1 37 Mean Difference (Fixed, 95% CI) 2.4 [-1.77, 6.57]
5 Quality of life: Quality of life
scale (1 year) (high score =
good)
1 37 Mean Difference (Fixed, 95% CI) 1.42 [-9.68, 12.52]
169Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 1 Death.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 1 Death
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jolley 1990 2/27 0/27 100.0 % 5.00 [ 0.25, 99.51 ]
Total (95% CI) 27 27 100.0 % 5.00 [ 0.25, 99.51 ]
Total events: 2 (FLUPHENAZINE DECANOATE), 0 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours fluphz decan Favours placebo
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Analysis 1.2. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 2 Global state: 1.
Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 2 Global state: 1. Relapse
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (6 weeks to 5 months)
Shenoy 1981 0/14 0/17 Not estimable
Subtotal (95% CI) 14 17 Not estimable
Total events: 0 (FLUPHENAZINE DECANOATE), 0 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 medium term (6 months to 1 year)
Hirsch 1975 7/40 28/41 30.6 % 0.26 [ 0.13, 0.52 ]
Odejide 1982 15/35 23/35 34.0 % 0.65 [ 0.42, 1.02 ]
Rifkin 1977 20/23 15/22 35.3 % 1.28 [ 0.92, 1.77 ]
Subtotal (95% CI) 98 98 100.0 % 0.62 [ 0.24, 1.60 ]
Total events: 42 (FLUPHENAZINE DECANOATE), 66 (PLACEBO)
Heterogeneity: Tau2 = 0.63; Chi2 = 24.16, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.99 (P = 0.32)
3 longer term (more than 1 year)
Jolley 1990 8/27 23/27 100.0 % 0.35 [ 0.19, 0.64 ]
Subtotal (95% CI) 27 27 100.0 % 0.35 [ 0.19, 0.64 ]
Total events: 8 (FLUPHENAZINE DECANOATE), 23 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00059)
0.1 0.2 0.5 1 2 5 10
Favours fluphz decan Favours placebo
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Analysis 1.3. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 3 Global state: 2.
GAS (short term - 6 weeks to 5 months) (high score = worse).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 3 Global state: 2. GAS (short term - 6 weeks to 5 months) (high score = worse)
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shenoy 1981 12 67.17 (10.7041) 16 63.56 (10.72) 100.0 % 3.61 [ -4.41, 11.63 ]
Total (95% CI) 12 16 100.0 % 3.61 [ -4.41, 11.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 4 Leaving the study
early.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 4 Leaving the study early
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Shenoy 1981 2/14 1/17 100.0 % 2.43 [ 0.24, 24.07 ]
Subtotal (95% CI) 14 17 100.0 % 2.43 [ 0.24, 24.07 ]
Total events: 2 (FLUPHENAZINE DECANOATE), 1 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 medium term (6 months to 1 year)
Dotti 1979 1/10 3/10 15.0 % 0.33 [ 0.04, 2.69 ]
Hirsch 1975 8/40 6/41 29.6 % 1.37 [ 0.52, 3.59 ]
Odejide 1982 9/35 8/35 40.0 % 1.13 [ 0.49, 2.58 ]
Rifkin 1977 8/23 3/22 15.3 % 2.55 [ 0.78, 8.39 ]
Subtotal (95% CI) 108 108 100.0 % 1.30 [ 0.77, 2.19 ]
Total events: 26 (FLUPHENAZINE DECANOATE), 20 (PLACEBO)
Heterogeneity: Chi2 = 2.99, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
3 longer term (more than 1 year)
Jolley 1990 7/27 15/27 100.0 % 0.47 [ 0.23, 0.96 ]
Subtotal (95% CI) 27 27 100.0 % 0.47 [ 0.23, 0.96 ]
Total events: 7 (FLUPHENAZINE DECANOATE), 15 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
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Analysis 1.5. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 5 Mental state: 1.
BPRS (endpoint scores - high score = worse).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 5 Mental state: 1. BPRS (endpoint scores - high score = worse)
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dotti 1979 9 21.11 (2.56) 7 23.14 (2.47) 100.0 % -2.03 [ -4.51, 0.45 ]
Total (95% CI) 9 7 100.0 % -2.03 [ -4.51, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 6 Mental state: 2.
Depression (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 6 Mental state: 2. Depression (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odejide 1982 9/35 9/35 100.0 % 1.00 [ 0.45, 2.22 ]
Total (95% CI) 35 35 100.0 % 1.00 [ 0.45, 2.22 ]
Total events: 9 (FLUPHENAZINE DECANOATE), 9 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 7 Adverse effects: 1.
Movement disorders - tardive dyskinesia (longer term - more than 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 7 Adverse effects: 1. Movement disorders - tardive dyskinesia (longer term - more than 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jolley 1990 19/27 23/27 100.0 % 0.83 [ 0.62, 1.11 ]
Total (95% CI) 27 27 100.0 % 0.83 [ 0.62, 1.11 ]
Total events: 19 (FLUPHENAZINE DECANOATE), 23 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 8 Adverse effects: 2.
Toxicity.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 1 FLUPHENAZINE DECANOATE vs PLACEBO
Outcome: 8 Adverse effects: 2. Toxicity
Study or subgroup
FLUPHENAZINE
DECANOATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rifkin 1977 8/23 1/22 100.0 % 7.65 [ 1.04, 56.26 ]
Total (95% CI) 23 22 100.0 % 7.65 [ 1.04, 56.26 ]
Total events: 8 (FLUPHENAZINE DECANOATE), 1 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 1
Global state: 1. No clinically important global change.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 1 Global state: 1. No clinically important global change
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Adamson 1973 11/19 17/18 50.0 % 0.61 [ 0.41, 0.91 ]
Curry 1972 11/19 17/18 50.0 % 0.61 [ 0.41, 0.91 ]
Subtotal (95% CI) 38 36 100.0 % 0.61 [ 0.46, 0.81 ]
Total events: 22 (FLUPHENAZINE DECANOATE), 34 (ORAL NEUROLEPTICS)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00069)
2 medium term (6 months to 1 year)
Song 1993 22/50 27/52 100.0 % 0.85 [ 0.56, 1.27 ]
Subtotal (95% CI) 50 52 100.0 % 0.85 [ 0.56, 1.27 ]
Total events: 22 (FLUPHENAZINE DECANOATE), 27 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
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Analysis 2.2. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 2
Global state: 2. Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 2 Global state: 2. Relapse
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 medium term (6 months to 1 year)
Barnes 1983 8/19 8/17 19.2 % 0.89 [ 0.43, 1.86 ]
McCreadie 1980 3/18 3/16 11.3 % 0.89 [ 0.21, 3.80 ]
McCreadie 1982 6/15 5/13 16.8 % 1.04 [ 0.41, 2.62 ]
Quitkin 1978 8/29 3/27 13.5 % 2.48 [ 0.73, 8.40 ]
Rifkin 1977 20/23 3/28 15.0 % 8.12 [ 2.75, 23.92 ]
Schooler 1980 58/107 66/107 24.2 % 0.88 [ 0.70, 1.11 ]
Subtotal (95% CI) 211 208 100.0 % 1.46 [ 0.75, 2.83 ]
Total events: 103 (FLUPHENAZINE DECANOATE), 88 (ORAL NEUROLEPTICS)
Heterogeneity: Tau2 = 0.46; Chi2 = 20.42, df = 5 (P = 0.001); I2 =76%
Test for overall effect: Z = 1.12 (P = 0.26)
2 longer term (more than 1 year)
Falloon 1978 8/20 5/24 19.6 % 1.92 [ 0.74, 4.95 ]
Hogarty 1979 13/27 13/25 49.4 % 0.93 [ 0.54, 1.59 ]
Simon 1978 14/57 10/63 31.0 % 1.55 [ 0.75, 3.20 ]
Subtotal (95% CI) 104 112 100.0 % 1.25 [ 0.81, 1.95 ]
Total events: 35 (FLUPHENAZINE DECANOATE), 28 (ORAL NEUROLEPTICS)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.38, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 2.3. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 3
Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score = worse).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 3 Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score = worse)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shu 1983 16 5 (3.6) 18 5.1 (4.4) 100.0 % -0.10 [ -2.79, 2.59 ]
Total (95% CI) 16 18 100.0 % -0.10 [ -2.79, 2.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 4
Leaving the study early.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 4 Leaving the study early
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0-5 weeks)
Curry 1972 0/19 1/18 100.0 % 0.32 [ 0.01, 7.30 ]
Subtotal (95% CI) 19 18 100.0 % 0.32 [ 0.01, 7.30 ]
Total events: 0 (FLUPHENAZINE DECANOATE), 1 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 short term (6 weeks to 5 months)
Shu 1983 3/16 2/18 100.0 % 1.69 [ 0.32, 8.85 ]
Subtotal (95% CI) 16 18 100.0 % 1.69 [ 0.32, 8.85 ]
Total events: 3 (FLUPHENAZINE DECANOATE), 2 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
3 medium term (6 months to 1 year)
Barnes 1983 1/19 1/17 1.2 % 0.89 [ 0.06, 13.23 ]
Rifkin 1977 8/23 2/28 2.1 % 4.87 [ 1.14, 20.72 ]
Quitkin 1978 8/29 3/27 3.7 % 2.48 [ 0.73, 8.40 ]
McCreadie 1980 3/18 3/16 3.8 % 0.89 [ 0.21, 3.80 ]
McCreadie 1982 6/15 5/13 6.3 % 1.04 [ 0.41, 2.62 ]
Song 1993 3/50 6/52 7.0 % 0.52 [ 0.14, 1.97 ]
Crawford 1974 2/14 10/17 10.7 % 0.24 [ 0.06, 0.93 ]
Kaneno 1991 13/127 16/132 18.6 % 0.84 [ 0.42, 1.68 ]
Schooler 1980 36/143 40/147 46.7 % 0.93 [ 0.63, 1.36 ]
Subtotal (95% CI) 438 449 100.0 % 0.96 [ 0.73, 1.25 ]
Total events: 80 (FLUPHENAZINE DECANOATE), 86 (ORAL NEUROLEPTICS)
Heterogeneity: Chi2 = 12.21, df = 8 (P = 0.14); I2 =34%
Test for overall effect: Z = 0.32 (P = 0.75)
4 longer term (more than 1 year)
Falloon 1978 0/20 3/24 25.2 % 0.17 [ 0.01, 3.11 ]
Simon 1978 14/57 10/63 74.8 % 1.55 [ 0.75, 3.20 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 77 87 100.0 % 1.20 [ 0.61, 2.36 ]
Total events: 14 (FLUPHENAZINE DECANOATE), 13 (ORAL NEUROLEPTICS)
Heterogeneity: Chi2 = 2.20, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 2.5. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 5
Behaviour: 1. NOSIE-30 - endpoint scores (high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 5 Behaviour: 1. NOSIE-30 - endpoint scores (high score = poor)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simon 1978 57 152.25 (16.97) 63 152.81 (18.55) 100.0 % -0.56 [ -6.92, 5.80 ]
Total (95% CI) 57 63 100.0 % -0.56 [ -6.92, 5.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 6
Behaviour: 2. skewed data (endpoint scores).
Behaviour: 2. skewed data (endpoint scores)
Study Intervention mean SD N
Barnes 1983 Fluphenazine decanoate 5.7 4.1 19
Barnes 1983 Pimozide 4.2 5.5 17
Analysis 2.7. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 7
Mental state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 7 Mental state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score = poor)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simon 1978 57 60.33 (14.8) 63 61.08 (12.98) 100.0 % -0.75 [ -5.75, 4.25 ]
Total (95% CI) 57 63 100.0 % -0.75 [ -5.75, 4.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 8
Mental state: 2. Depression.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 8 Mental state: 2. Depression
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 medium term (6 months to 1 year)
Schooler 1979 32/107 36/107 100.0 % 0.89 [ 0.60, 1.32 ]
Subtotal (95% CI) 107 107 100.0 % 0.89 [ 0.60, 1.32 ]
Total events: 32 (FLUPHENAZINE DECANOATE), 36 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 longer term (more than 1 year)
Falloon 1978 14/20 11/24 100.0 % 1.53 [ 0.91, 2.57 ]
Subtotal (95% CI) 20 24 100.0 % 1.53 [ 0.91, 2.57 ]
Total events: 14 (FLUPHENAZINE DECANOATE), 11 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
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Analysis 2.9. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 9
Adverse effects: 1a. Movement disorders - general.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 9 Adverse effects: 1a. Movement disorders - general
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 medium term (6 months to 1 year)
McCreadie 1980 5/18 8/16 46.9 % 0.56 [ 0.23, 1.36 ]
McCreadie 1982 3/15 8/13 47.4 % 0.33 [ 0.11, 0.98 ]
Schooler 1979 1/102 1/95 5.7 % 0.93 [ 0.06, 14.68 ]
Subtotal (95% CI) 135 124 100.0 % 0.47 [ 0.24, 0.91 ]
Total events: 9 (FLUPHENAZINE DECANOATE), 17 (ORAL NEUROLEPTICS)
Heterogeneity: Chi2 = 0.80, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
2 longer term (more than 1 year)
Falloon 1978 3/20 9/24 100.0 % 0.40 [ 0.12, 1.28 ]
Subtotal (95% CI) 20 24 100.0 % 0.40 [ 0.12, 1.28 ]
Total events: 3 (FLUPHENAZINE DECANOATE), 9 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
0.1 0.2 0.5 1 2 5 10
Favours fluphz decan Favours oral neuroleptics
183Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.10. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 10
Adverse effects: 1b. Movement disorders - akathisia.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 10 Adverse effects: 1b. Movement disorders - akathisia
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rifkin 1977 8/23 0/28 100.0 % 20.54 [ 1.25, 337.94 ]
Total (95% CI) 23 28 100.0 % 20.54 [ 1.25, 337.94 ]
Total events: 8 (FLUPHENAZINE DECANOATE), 0 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 11
Adverse effects: 1c. Movement disorders - needing anticholinergic drugs.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 11 Adverse effects: 1c. Movement disorders - needing anticholinergic drugs
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 immediate (0 to 5 weeks)
Adamson 1973 0/19 0/18 Not estimable
Subtotal (95% CI) 19 18 Not estimable
Total events: 0 (FLUPHENAZINE DECANOATE), 0 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 medium term (6 months to 1 year)
McCreadie 1980 8/18 4/16 48.3 % 1.78 [ 0.66, 4.80 ]
Schooler 1980 7/102 15/95 51.7 % 0.43 [ 0.19, 1.02 ]
Subtotal (95% CI) 120 111 100.0 % 0.86 [ 0.21, 3.45 ]
Total events: 15 (FLUPHENAZINE DECANOATE), 19 (ORAL NEUROLEPTICS)
Heterogeneity: Tau2 = 0.79; Chi2 = 4.52, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.22 (P = 0.83)
3 longer term (more than 1 year)
Simon 1978 46/57 49/63 100.0 % 1.04 [ 0.86, 1.25 ]
Subtotal (95% CI) 57 63 100.0 % 1.04 [ 0.86, 1.25 ]
Total events: 46 (FLUPHENAZINE DECANOATE), 49 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
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Analysis 2.12. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 12
Adverse effects: 1d. Movement disorders - tardive dyskinesia.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 12 Adverse effects: 1d. Movement disorders - tardive dyskinesia
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 medium term (6 months to 1 year)
McCreadie 1982 9/15 13/13 100.0 % 0.62 [ 0.41, 0.93 ]
Subtotal (95% CI) 15 13 100.0 % 0.62 [ 0.41, 0.93 ]
Total events: 9 (FLUPHENAZINE DECANOATE), 13 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
2 longer term (more than 1 year)
Simon 1978 0/57 3/63 100.0 % 0.16 [ 0.01, 2.99 ]
Subtotal (95% CI) 57 63 100.0 % 0.16 [ 0.01, 2.99 ]
Total events: 0 (FLUPHENAZINE DECANOATE), 3 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
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Analysis 2.13. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 13
Adverse effects: 1e. Movement disorders - tremor (longer term - more than 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 13 Adverse effects: 1e. Movement disorders - tremor (longer term - more than 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Falloon 1978 4/20 6/24 100.0 % 0.80 [ 0.26, 2.45 ]
Total (95% CI) 20 24 100.0 % 0.80 [ 0.26, 2.45 ]
Total events: 4 (FLUPHENAZINE DECANOATE), 6 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 14
Adverse effects: 1f. Movement disorders - average score (Simpson & Angus, 0 to 5 weeks, high = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 14 Adverse effects: 1f. Movement disorders - average score (Simpson % Angus, 0 to 5 weeks, high = poor)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shu 1983 16 2.6 (2) 16 1.3 (1.7) 100.0 % 1.30 [ 0.01, 2.59 ]
Total (95% CI) 16 16 100.0 % 1.30 [ 0.01, 2.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 15
Adverse effects: 2. Blurred vision - medium term (6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 15 Adverse effects: 2. Blurred vision - medium term (6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schooler 1980 23/102 16/95 100.0 % 1.34 [ 0.75, 2.38 ]
Total (95% CI) 102 95 100.0 % 1.34 [ 0.75, 2.38 ]
Total events: 23 (FLUPHENAZINE DECANOATE), 16 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 16
Adverse effects: 3. Toxicity - medium term (6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 16 Adverse effects: 3. Toxicity - medium term (6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rifkin 1977 8/23 2/28 100.0 % 4.87 [ 1.14, 20.72 ]
Total (95% CI) 23 28 100.0 % 4.87 [ 1.14, 20.72 ]
Total events: 8 (FLUPHENAZINE DECANOATE), 2 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 17
Adverse effects: 4. General adverse effects.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 17 Adverse effects: 4. General adverse effects
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Adamson 1973 2/19 0/18 100.0 % 4.75 [ 0.24, 92.65 ]
Subtotal (95% CI) 19 18 100.0 % 4.75 [ 0.24, 92.65 ]
Total events: 2 (FLUPHENAZINE DECANOATE), 0 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 medium term (6 months to 1 year)
McCreadie 1982 6/15 8/13 19.7 % 0.65 [ 0.31, 1.38 ]
Schooler 1980 37/107 35/107 80.3 % 1.06 [ 0.73, 1.54 ]
Subtotal (95% CI) 122 120 100.0 % 0.98 [ 0.70, 1.37 ]
Total events: 43 (FLUPHENAZINE DECANOATE), 43 (ORAL NEUROLEPTICS)
Heterogeneity: Chi2 = 1.29, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 2.18. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 18
SENSITIVITY ANALYSIS Global state: 2. Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Outcome: 18 SENSITIVITY ANALYSIS Global state: 2. Relapse
Study or subgroup
FLUPHENAZINE
DECANOATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Barnes 1983 8/19 8/17 0.89 [ 0.43, 1.86 ]
McCreadie 1980 3/18 3/16 0.89 [ 0.21, 3.80 ]
McCreadie 1982 6/15 5/13 1.04 [ 0.41, 2.62 ]
Quitkin 1978 8/29 3/27 2.48 [ 0.73, 8.40 ]
Rifkin 1977 20/23 3/28 8.12 [ 2.75, 23.92 ]
Schooler 1980 58/107 66/107 0.88 [ 0.70, 1.11 ]
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Analysis 3.1. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 1 Death.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 1 Death
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McKane 1987 1/19 0/19 100.0 % 3.00 [ 0.13, 69.31 ]
Total (95% CI) 19 19 100.0 % 3.00 [ 0.13, 69.31 ]
Total events: 1 (FLUPHENAZINE DECANOATE), 0 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 2 Global state: 1. No clinically important global change.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 2 Global state: 1. No clinically important global change
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Ju 2000 32/49 58/103 30.1 % 1.16 [ 0.89, 1.51 ]
Subtotal (95% CI) 49 103 30.1 % 1.16 [ 0.89, 1.51 ]
Total events: 32 (FLUPHENAZINE DECANOATE), 58 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
2 medium term (6 months to 1 year)
Dencker 1973 32/35 29/32 24.4 % 1.01 [ 0.87, 1.17 ]
Leong 1989 29/30 27/30 21.7 % 1.07 [ 0.94, 1.23 ]
Schlosberg 1978 30/30 29/30 23.8 % 1.03 [ 0.94, 1.13 ]
Subtotal (95% CI) 95 92 69.9 % 1.04 [ 0.96, 1.12 ]
Total events: 91 (FLUPHENAZINE DECANOATE), 85 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 144 195 100.0 % 1.07 [ 0.97, 1.18 ]
Total events: 123 (FLUPHENAZINE DECANOATE), 143 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Chi2 = 0.62, df = 1 (P = 0.43), I2 =0.0%
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Analysis 3.3. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 3 Global state: 2. Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 3 Global state: 2. Relapse
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Wistedt 1984 4/26 4/25 100.0 % 0.96 [ 0.27, 3.43 ]
Subtotal (95% CI) 26 25 100.0 % 0.96 [ 0.27, 3.43 ]
Total events: 4 (FLUPHENAZINE DECANOATE), 4 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 medium term (6 months to 1 year)
Chouinard 1984 1/36 0/36 1.0 % 3.00 [ 0.13, 71.28 ]
Cookson 1986 0/9 2/10 4.9 % 0.22 [ 0.01, 4.05 ]
Dencker 1973 6/35 3/32 6.4 % 1.83 [ 0.50, 6.71 ]
Kelly 1977 3/28 3/26 6.3 % 0.93 [ 0.21, 4.20 ]
Leong 1989 0/30 1/30 3.1 % 0.33 [ 0.01, 7.87 ]
Lundin 1990 9/30 11/28 23.2 % 0.76 [ 0.37, 1.56 ]
Magnus 1979 1/26 1/26 2.0 % 1.00 [ 0.07, 15.15 ]
McLaren 1992 0/24 6/23 13.5 % 0.07 [ 0.00, 1.24 ]
Russell 1982 3/13 2/20 3.2 % 2.31 [ 0.44, 11.98 ]
Schlosberg 1978 9/30 8/30 16.3 % 1.13 [ 0.50, 2.52 ]
Sharma 1991 6/29 10/30 20.0 % 0.62 [ 0.26, 1.49 ]
Subtotal (95% CI) 290 291 100.0 % 0.82 [ 0.56, 1.18 ]
Total events: 38 (FLUPHENAZINE DECANOATE), 47 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 8.59, df = 10 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
3 longer term (more than 1 year)
McKane 1987 2/19 3/19 11.8 % 0.67 [ 0.13, 3.55 ]
Pinto 1979 8/33 0/31 2.0 % 16.00 [ 0.96, 266.03 ]
Simon 1978 14/57 15/61 56.8 % 1.00 [ 0.53, 1.88 ]
Wistedt 1983 6/15 8/17 29.4 % 0.85 [ 0.38, 1.89 ]
Subtotal (95% CI) 124 128 100.0 % 1.22 [ 0.77, 1.92 ]
Total events: 30 (FLUPHENAZINE DECANOATE), 26 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 4.89, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 0.85 (P = 0.39)
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Analysis 3.4. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 4 Global state: 3. Severly ill (medium term 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 4 Global state: 3. Severly ill (medium term 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leong 1989 29/30 27/30 100.0 % 1.07 [ 0.94, 1.23 ]
Total (95% CI) 30 30 100.0 % 1.07 [ 0.94, 1.23 ]
Total events: 29 (FLUPHENAZINE DECANOATE), 27 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 5 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 5 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chouinard 1984 2/36 2/36 34.5 % 1.00 [ 0.15, 6.72 ]
Cookson 1986 1/9 4/10 65.5 % 0.28 [ 0.04, 2.05 ]
Total (95% CI) 45 46 100.0 % 0.53 [ 0.14, 1.96 ]
Total events: 3 (FLUPHENAZINE DECANOATE), 6 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 6 Global state: 5. Clinical Global Impression. (short term - 6 weeks to 5 months) (skewed data).
Global state: 5. Clinical Global Impression. (short term - 6 weeks to 5 months) (skewed data)
Study Intervention mean SD N
Wistedt 1984 Fluphenazine decanoate 2.9 2 26
Wistedt 1984 Pipothiazine 2.9 1.5 25
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Analysis 3.7. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 7 Global state: 6. Clinical Global Impression. (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 7 Global state: 6. Clinical Global Impression. (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chouinard 1984 36 2.8 (0.8) 36 2.9 (0.7) 79.7 % -0.10 [ -0.45, 0.25 ]
Schlosberg 1978 9 2 (0.71) 9 2.11 (0.78) 20.3 % -0.11 [ -0.80, 0.58 ]
Total (95% CI) 45 45 100.0 % -0.10 [ -0.41, 0.21 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 8 Global state: 7. Clinical Global Impression - not improved (high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 8 Global state: 7. Clinical Global Impression - not improved (high score = poor)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Frangos 1978 5/25 2/25 100.0 % 2.50 [ 0.53, 11.70 ]
Subtotal (95% CI) 25 25 100.0 % 2.50 [ 0.53, 11.70 ]
Total events: 5 (FLUPHENAZINE DECANOATE), 2 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
2 medium term (6 months to 1 year)
Leong 1989 3/30 4/30 100.0 % 0.75 [ 0.18, 3.07 ]
Subtotal (95% CI) 30 30 100.0 % 0.75 [ 0.18, 3.07 ]
Total events: 3 (FLUPHENAZINE DECANOATE), 4 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 3.9. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 9 Leaving the study early.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 9 Leaving the study early
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Levenson 1976 0/5 0/7 Not estimable
Subtotal (95% CI) 5 7 Not estimable
Total events: 0 (FLUPHENAZINE DECANOATE), 0 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 short term (6 weeks to 5 months)
Feng 1990 3/15 5/15 55.1 % 0.60 [ 0.17, 2.07 ]
Ju 2000 0/49 0/103 Not estimable
Wistedt 1984 4/26 4/25 44.9 % 0.96 [ 0.27, 3.43 ]
Subtotal (95% CI) 90 143 100.0 % 0.76 [ 0.32, 1.84 ]
Total events: 7 (FLUPHENAZINE DECANOATE), 9 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
3 medium term (6 months to 1 year)
Chouinard 1984 1/32 0/32 0.6 % 3.00 [ 0.13, 71.00 ]
Cookson 1986 0/9 2/10 2.9 % 0.22 [ 0.01, 4.05 ]
Dencker 1973 6/35 3/32 3.9 % 1.83 [ 0.50, 6.71 ]
Hranov 1998 6/21 4/20 5.1 % 1.43 [ 0.47, 4.32 ]
Kelly 1977 3/30 3/30 3.7 % 1.00 [ 0.22, 4.56 ]
Kissling 1985 13/22 10/32 10.0 % 1.89 [ 1.02, 3.52 ]
Leong 1989 0/30 1/30 1.8 % 0.33 [ 0.01, 7.87 ]
Lundin 1990 9/30 11/28 14.0 % 0.76 [ 0.37, 1.56 ]
Magnus 1979 1/26 1/24 1.3 % 0.92 [ 0.06, 13.95 ]
Rossi 1990 2/15 3/15 3.7 % 0.67 [ 0.13, 3.44 ]
Russell 1982 3/13 2/20 1.9 % 2.31 [ 0.44, 11.98 ]
Schlosberg 1978 9/30 8/30 9.9 % 1.13 [ 0.50, 2.52 ]
Schneider 1981 18/27 16/32 18.1 % 1.33 [ 0.86, 2.06 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sharma 1991 6/29 10/30 12.1 % 0.62 [ 0.26, 1.49 ]
Woggon 1977 9/30 9/31 10.9 % 1.03 [ 0.48, 2.24 ]
Subtotal (95% CI) 379 396 100.0 % 1.13 [ 0.89, 1.44 ]
Total events: 86 (FLUPHENAZINE DECANOATE), 83 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 10.22, df = 14 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
4 By more than 1 year
Dencker 1973 10/34 21/33 41.1 % 0.46 [ 0.26, 0.83 ]
McKane 1987 7/19 8/19 15.4 % 0.88 [ 0.40, 1.93 ]
Pinto 1979 8/33 0/31 1.0 % 16.00 [ 0.96, 266.03 ]
Simon 1978 14/57 15/61 28.0 % 1.00 [ 0.53, 1.88 ]
Wistedt 1983 6/15 8/17 14.5 % 0.85 [ 0.38, 1.89 ]
Subtotal (95% CI) 158 161 100.0 % 0.89 [ 0.64, 1.23 ]
Total events: 45 (FLUPHENAZINE DECANOATE), 52 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 9.04, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 3.10. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 10 Behaviour: 1. NOSIE-30 - endpoint scores (high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 10 Behaviour: 1. NOSIE-30 - endpoint scores (high score = poor)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simon 1978 57 152.25 (16.97) 61 157.46 (14.04) 100.0 % -5.21 [ -10.85, 0.43 ]
Total (95% CI) 57 61 100.0 % -5.21 [ -10.85, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 11 Mental state: 1. BPRS (endpoint scores - high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 11 Mental state: 1. BPRS (endpoint scores - high score = poor)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 short term (6 weeks to 5 months)
Ju 2000 49 28 (7) 103 26 (9) 0.9 % 2.00 [ -0.62, 4.62 ]
Wistedt 1984 26 4.1 (0.4) 25 3 (0.5) 99.1 % 1.10 [ 0.85, 1.35 ]
Subtotal (95% CI) 75 128 100.0 % 1.11 [ 0.86, 1.36 ]
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 8.76 (P < 0.00001)
2 medium term (6 months to 1 year)
Chouinard 1984 36 24.5 (7.2) 36 25 (5.7) 0.1 % -0.50 [ -3.50, 2.50 ]
Leong 1989 30 2.8 (0.2) 30 1.6 (0.2) 99.9 % 1.20 [ 1.10, 1.30 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rossi 1990 15 38.4 (13.9) 15 37.6 (2.8) 0.0 % 0.80 [ -6.38, 7.98 ]
Subtotal (95% CI) 81 81 100.0 % 1.20 [ 1.10, 1.30 ]
Heterogeneity: Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 23.21 (P < 0.00001)
3 longer term (more than one year)
McKane 1987 12 8.2 (5.4) 11 8.5 (5) 55.8 % -0.30 [ -4.55, 3.95 ]
Simon 1978 57 60.33 (14.8) 61 58.02 (11.32) 44.2 % 2.31 [ -2.47, 7.09 ]
Subtotal (95% CI) 69 72 100.0 % 0.85 [ -2.32, 4.03 ]
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Chi2 = 0.48, df = 2 (P = 0.79), I2 =0.0%
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Analysis 3.12. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dencker 1973 18/35 18/32 100.0 % 0.91 [ 0.59, 1.43 ]
Total (95% CI) 35 32 100.0 % 0.91 [ 0.59, 1.43 ]
Total events: 18 (FLUPHENAZINE DECANOATE), 18 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 13 Mental state: 3. Depression (6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 13 Mental state: 3. Depression (6 months to 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dencker 1973 29/35 26/32 100.0 % 1.02 [ 0.81, 1.28 ]
Total (95% CI) 35 32 100.0 % 1.02 [ 0.81, 1.28 ]
Total events: 29 (FLUPHENAZINE DECANOATE), 26 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 14 Mental state: 4. SAPS and SANS (endpoint scores - high score = poor) (skewed data).
Mental state: 4. SAPS and SANS (endpoint scores - high score = poor) (skewed data)
Study Intervention mean SD N
SAPS SAPS
Ju 2000 Fluphenazine decanoate 31.4 21.1 49
Ju 2000 Pipothiazine palmitate 20.1 23.1 103
SANS SANS
Ju 2000 Fluphenazine decanoate 14.6 11.4 49
Ju 2000 Pipothiazine palmitate 9.4 14.7 103
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Analysis 3.15. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 15 Adverse effects: 1a. Movement disorders - general.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 15 Adverse effects: 1a. Movement disorders - general
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate term (0 to 5 weeks)
Levenson 1976 2/5 3/7 3.8 % 0.93 [ 0.24, 3.68 ]
Subtotal (95% CI) 5 7 3.8 % 0.93 [ 0.24, 3.68 ]
Total events: 2 (FLUPHENAZINE DECANOATE), 3 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 short term (6 weeks to 5 months)
Feng 1990 4/15 2/15 3.0 % 2.00 [ 0.43, 9.32 ]
Subtotal (95% CI) 15 15 3.0 % 2.00 [ 0.43, 9.32 ]
Total events: 4 (FLUPHENAZINE DECANOATE), 2 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
3 medium term (6 months to 1 year)
Dencker 1973 33/35 28/32 44.2 % 1.08 [ 0.92, 1.26 ]
Leong 1989 3/30 2/30 3.0 % 1.50 [ 0.27, 8.34 ]
McLaren 1992 9/24 9/23 13.9 % 0.96 [ 0.46, 1.98 ]
Schlosberg 1978 11/30 10/30 15.1 % 1.10 [ 0.55, 2.19 ]
Subtotal (95% CI) 119 115 76.2 % 1.08 [ 0.86, 1.34 ]
Total events: 56 (FLUPHENAZINE DECANOATE), 49 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.25, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
4 longer term (more than 1 year)
Wistedt 1983 12/15 12/17 17.0 % 1.13 [ 0.76, 1.69 ]
Subtotal (95% CI) 15 17 17.0 % 1.13 [ 0.76, 1.69 ]
Total events: 12 (FLUPHENAZINE DECANOATE), 12 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Total (95% CI) 154 154 100.0 % 1.11 [ 0.91, 1.35 ]
Total events: 74 (FLUPHENAZINE DECANOATE), 66 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 1.05, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.69, df = 3 (P = 0.88), I2 =0.0%
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Analysis 3.16. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 16 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 16 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (6 weeks to 5 months)
Wistedt 1984 20/26 13/25 100.0 % 1.48 [ 0.96, 2.28 ]
Subtotal (95% CI) 26 25 100.0 % 1.48 [ 0.96, 2.28 ]
Total events: 20 (FLUPHENAZINE DECANOATE), 13 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
2 medium term (6 months to 1 year)
Chouinard 1984 33/36 32/36 31.6 % 1.03 [ 0.89, 1.20 ]
Dencker 1973 26/35 24/32 26.0 % 0.99 [ 0.75, 1.31 ]
Leong 1989 0/30 2/30 0.9 % 0.20 [ 0.01, 4.00 ]
Magnus 1979 12/26 4/24 6.7 % 2.77 [ 1.03, 7.42 ]
McLaren 1992 6/24 3/23 4.4 % 1.92 [ 0.54, 6.77 ]
Russell 1982 6/13 3/20 4.8 % 3.08 [ 0.93, 10.19 ]
Schlosberg 1978 13/30 11/30 12.9 % 1.18 [ 0.63, 2.20 ]
Sharma 1991 14/29 10/30 12.7 % 1.45 [ 0.77, 2.72 ]
Subtotal (95% CI) 223 225 100.0 % 1.24 [ 0.93, 1.64 ]
Total events: 110 (FLUPHENAZINE DECANOATE), 89 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Tau2 = 0.06; Chi2 = 14.24, df = 7 (P = 0.05); I2 =51%
Test for overall effect: Z = 1.47 (P = 0.14)
3 longer term (more than 1 year)
McKane 1987 16/19 17/19 35.7 % 0.94 [ 0.73, 1.21 ]
Pinto 1979 28/33 13/31 26.9 % 2.02 [ 1.30, 3.14 ]
Simon 1978 46/57 42/61 37.3 % 1.17 [ 0.95, 1.45 ]
Subtotal (95% CI) 109 111 100.0 % 1.26 [ 0.86, 1.83 ]
Total events: 90 (FLUPHENAZINE DECANOATE), 72 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Tau2 = 0.09; Chi2 = 10.67, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 1.18 (P = 0.24)
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Analysis 3.17. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 17 Adverse effects: 1c. Movement disorders - parkinsonism.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 17 Adverse effects: 1c. Movement disorders - parkinsonism
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Levenson 1976 2/5 3/7 33.5 % 0.93 [ 0.24, 3.68 ]
Subtotal (95% CI) 5 7 33.5 % 0.93 [ 0.24, 3.68 ]
Total events: 2 (FLUPHENAZINE DECANOATE), 3 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 medium term (6 months to 1 year)
Leong 1989 5/30 4/30 53.6 % 1.25 [ 0.37, 4.21 ]
Subtotal (95% CI) 30 30 53.6 % 1.25 [ 0.37, 4.21 ]
Total events: 5 (FLUPHENAZINE DECANOATE), 4 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
3 longer term (more than 1 year)
Simon 1978 1/57 1/61 12.9 % 1.07 [ 0.07, 16.71 ]
Subtotal (95% CI) 57 61 12.9 % 1.07 [ 0.07, 16.71 ]
Total events: 1 (FLUPHENAZINE DECANOATE), 1 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 92 98 100.0 % 1.12 [ 0.47, 2.69 ]
Total events: 8 (FLUPHENAZINE DECANOATE), 8 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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Analysis 3.18. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 18 Adverse effects: 1d. Movement disorders - tardive dyskinesia: longer term (more than 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 18 Adverse effects: 1d. Movement disorders - tardive dyskinesia: longer term (more than 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Simon 1978 0/57 3/61 26.5 % 0.15 [ 0.01, 2.89 ]
Wistedt 1983 7/15 10/17 73.5 % 0.79 [ 0.41, 1.55 ]
Total (95% CI) 72 78 100.0 % 0.62 [ 0.32, 1.23 ]
Total events: 7 (FLUPHENAZINE DECANOATE), 13 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours fluphz decan Favours other depot
205Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.19. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 19 Adverse effects: 1e. Movement disorders - tremor.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 19 Adverse effects: 1e. Movement disorders - tremor
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Feng 1990 9/15 8/15 72.7 % 1.13 [ 0.60, 2.11 ]
Frangos 1978 6/25 3/25 27.3 % 2.00 [ 0.56, 7.12 ]
Subtotal (95% CI) 40 40 100.0 % 1.36 [ 0.76, 2.46 ]
Total events: 15 (FLUPHENAZINE DECANOATE), 11 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
2 medium term (6 months to 1 year)
Leong 1989 2/30 3/30 14.0 % 0.67 [ 0.12, 3.71 ]
Schlosberg 1978 15/30 11/30 51.2 % 1.36 [ 0.76, 2.46 ]
Wistedt 1983 7/15 8/17 34.9 % 0.99 [ 0.47, 2.08 ]
Subtotal (95% CI) 75 77 100.0 % 1.14 [ 0.73, 1.78 ]
Total events: 24 (FLUPHENAZINE DECANOATE), 22 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
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Analysis 3.20. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 20 Adverse effects: 1f. Movement disorders - endpoint scores (short term - 6 weeks to 5 months).
Adverse effects: 1f. Movement disorders - endpoint scores (short term - 6 weeks to 5 months)
Study Intervention mean SD N
TESS (high = poor) TESS (high = poor)
Ju 2000 Fluphenazine decanoate 10.2 8.1 49
Ju 2000 Pipothiazine palmitate 2.6 3.9 103
RSESE (high = poor) RSESE (high = poor)
Ju 2000 Fluphenazine decanoate 7.5 7 49
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Adverse effects: 1f. Movement disorders - endpoint scores (short term - 6 weeks to 5 months) (Continued)
Ju 2000 Pipothiazine palmitate 1.0 2.1 103
Analysis 3.21. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 21 Adverse effects: 2. Blurred vision.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 21 Adverse effects: 2. Blurred vision
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 medium term (6 months to 1 year)
Wistedt 1983 7/15 9/17 100.0 % 0.88 [ 0.44, 1.78 ]
Subtotal (95% CI) 15 17 100.0 % 0.88 [ 0.44, 1.78 ]
Total events: 7 (FLUPHENAZINE DECANOATE), 9 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
2 longer term (more than 1 year)
Pinto 1979 9/33 0/31 100.0 % 17.88 [ 1.08, 294.82 ]
Subtotal (95% CI) 33 31 100.0 % 17.88 [ 1.08, 294.82 ]
Total events: 9 (FLUPHENAZINE DECANOATE), 0 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
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Analysis 3.22. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 22 Adverse effects: 3. Dry mouth: longer term (more than 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 22 Adverse effects: 3. Dry mouth: longer term (more than 1 year)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wistedt 1983 7/15 11/17 100.0 % 0.72 [ 0.38, 1.37 ]
Total (95% CI) 15 17 100.0 % 0.72 [ 0.38, 1.37 ]
Total events: 7 (FLUPHENAZINE DECANOATE), 11 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 3.23. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 23 Adverse effects: 4. General adverse effects.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 23 Adverse effects: 4. General adverse effects
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Frangos 1978 22/25 16/25 55.9 % 1.38 [ 0.99, 1.91 ]
Javed 1991 18/20 12/18 44.1 % 1.35 [ 0.94, 1.93 ]
Subtotal (95% CI) 45 43 100.0 % 1.36 [ 1.07, 1.74 ]
Total events: 40 (FLUPHENAZINE DECANOATE), 28 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
2 medium term (6 months to 1 year)
Dencker 1973 29/35 25/32 44.6 % 1.06 [ 0.84, 1.34 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leong 1989 6/30 2/30 3.4 % 3.00 [ 0.66, 13.69 ]
Magnus 1979 15/26 4/24 7.1 % 3.46 [ 1.33, 8.98 ]
Russell 1982 3/13 8/20 10.8 % 0.58 [ 0.19, 1.78 ]
Walker 1983 9/20 19/19 34.1 % 0.46 [ 0.29, 0.75 ]
Subtotal (95% CI) 124 125 100.0 % 1.04 [ 0.83, 1.32 ]
Total events: 62 (FLUPHENAZINE DECANOATE), 58 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 20.14, df = 4 (P = 0.00047); I2 =80%
Test for overall effect: Z = 0.34 (P = 0.73)
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Analysis 3.24. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 24 SENSITIVITY ANALYSIS Global state: 2. Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 24 SENSITIVITY ANALYSIS Global state: 2. Relapse
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 medium term (6 months to 1 year)
Chouinard 1984 1/36 0/36 1.0 % 3.00 [ 0.13, 71.28 ]
Cookson 1986 0/9 2/10 4.9 % 0.22 [ 0.01, 4.05 ]
Dencker 1973 6/35 3/32 6.4 % 1.83 [ 0.50, 6.71 ]
Kelly 1977 3/28 3/26 6.3 % 0.93 [ 0.21, 4.20 ]
Leong 1989 0/30 1/30 3.1 % 0.33 [ 0.01, 7.87 ]
Lundin 1990 9/30 11/28 23.2 % 0.76 [ 0.37, 1.56 ]
Magnus 1979 1/26 1/26 2.0 % 1.00 [ 0.07, 15.15 ]
McLaren 1992 0/24 6/23 13.5 % 0.07 [ 0.00, 1.24 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANOATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Russell 1982 3/13 2/20 3.2 % 2.31 [ 0.44, 11.98 ]
Schlosberg 1978 9/30 8/30 16.3 % 1.13 [ 0.50, 2.52 ]
Sharma 1991 6/29 10/30 20.0 % 0.62 [ 0.26, 1.49 ]
Subtotal (95% CI) 290 291 100.0 % 0.82 [ 0.56, 1.18 ]
Total events: 38 (FLUPHENAZINE DECANOATE), 47 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 8.59, df = 10 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
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Analysis 4.1. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs
STANDARD, Outcome 1 Global state: 1. Relapse (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome: 1 Global state: 1. Relapse (medium term - 6 months to 1 year)
Study or subgroup
FLUPHZ
DECAN HIGH
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kreisman 1988 30/66 6/66 57.2 % 5.00 [ 2.23, 11.21 ]
McClelland 1976 2/25 3/25 42.8 % 0.67 [ 0.12, 3.65 ]
Total (95% CI) 91 91 100.0 % 2.11 [ 0.30, 14.91 ]
Total events: 32 (FLUPHZ DECAN HIGH DOSE), 9 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: Tau2 = 1.57; Chi2 = 4.40, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs
STANDARD, Outcome 2 Global state: 2. Needing additional antispsychotic treatment (medium term - 6
months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome: 2 Global state: 2. Needing additional antispsychotic treatment (medium term - 6 months to 1 year)
Study or subgroup
FLUPHZ
DECAN HIGH
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McClelland 1976 5/25 3/25 100.0 % 1.67 [ 0.45, 6.24 ]
Total (95% CI) 25 25 100.0 % 1.67 [ 0.45, 6.24 ]
Total events: 5 (FLUPHZ DECAN HIGH DOSE), 3 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs
STANDARD, Outcome 3 Global state: 3. Not improved (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome: 3 Global state: 3. Not improved (medium term - 6 months to 1 year)
Study or subgroup
FLUPHZ
DECAN HIGH
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 nurse rated
Lehmann 1980 19/20 12/20 100.0 % 1.58 [ 1.09, 2.30 ]
Subtotal (95% CI) 20 20 100.0 % 1.58 [ 1.09, 2.30 ]
Total events: 19 (FLUPHZ DECAN HIGH DOSE), 12 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.015)
2 psychiatrist rated
Lehmann 1980 15/20 13/20 100.0 % 1.15 [ 0.77, 1.74 ]
Subtotal (95% CI) 20 20 100.0 % 1.15 [ 0.77, 1.74 ]
Total events: 15 (FLUPHZ DECAN HIGH DOSE), 13 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 4.4. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs
STANDARD, Outcome 4 Leaving the study early (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome: 4 Leaving the study early (medium term - 6 months to 1 year)
Study or subgroup
FLUPHZ
DECAN HIGH
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lehmann 1980 1/20 2/20 40.0 % 0.50 [ 0.05, 5.08 ]
McClelland 1976 2/25 3/25 60.0 % 0.67 [ 0.12, 3.65 ]
Total (95% CI) 45 45 100.0 % 0.60 [ 0.15, 2.36 ]
Total events: 3 (FLUPHZ DECAN HIGH DOSE), 5 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs
STANDARD, Outcome 5 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score =
poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome: 5 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score = poor)
Study or subgroup
FLUPHZ
DECAN HIGH
DOSE
FLUPHZ
DECAN
STANRD DOSE
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McClelland 1976 25 34.65 (11.48) 25 34.68 (9.19) 100.0 % -0.03 [ -5.79, 5.73 ]
Total (95% CI) 25 25 100.0 % -0.03 [ -5.79, 5.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs
STANDARD, Outcome 6 Adverse effects: Movement disorders - needing anticholinergic drugs (medium term -
6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD
Outcome: 6 Adverse effects: Movement disorders - needing anticholinergic drugs (medium term - 6 months to 1 year)
Study or subgroup
FLUPHZ
DECAN HIGH
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McClelland 1976 5/25 3/25 100.0 % 1.67 [ 0.45, 6.24 ]
Total (95% CI) 25 25 100.0 % 1.67 [ 0.45, 6.24 ]
Total events: 5 (FLUPHZ DECAN HIGH DOSE), 3 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs
STANDARD, Outcome 1 Global state: Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD
Outcome: 1 Global state: Relapse
Study or subgroup
FLUPHZ
DECAN LOW
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 medium term (6 months to 1 year)
Kane 1983 26/62 3/64 30.5 % 8.95 [ 2.85, 28.05 ]
Kreisman 1988 30/66 6/66 33.5 % 5.00 [ 2.23, 11.21 ]
Schooler 1997 27/107 27/106 36.0 % 0.99 [ 0.62, 1.57 ]
Subtotal (95% CI) 235 236 100.0 % 3.33 [ 0.77, 14.51 ]
Total events: 83 (FLUPHZ DECAN LOW DOSE), 36 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: Tau2 = 1.51; Chi2 = 21.86, df = 2 (P = 0.00002); I2 =91%
Test for overall effect: Z = 1.60 (P = 0.11)
2 longer term (more than 1 year)
Asarnow 1988 3/22 1/14 12.2 % 1.91 [ 0.22, 16.58 ]
Hogarty 1988 16/37 14/33 66.2 % 1.02 [ 0.59, 1.75 ]
Marder 1987 2/35 6/31 21.6 % 0.30 [ 0.06, 1.36 ]
Subtotal (95% CI) 94 78 100.0 % 0.84 [ 0.38, 1.89 ]
Total events: 21 (FLUPHZ DECAN LOW DOSE), 21 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: Tau2 = 0.18; Chi2 = 2.78, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.42 (P = 0.68)
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Analysis 5.2. Comparison 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs
STANDARD, Outcome 2 Leaving the study early.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD
Outcome: 2 Leaving the study early
Study or subgroup
FLUPHZ
DECAN LOW
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 longer term (more than 1 year)
Asarnow 1988 3/22 1/14 7.6 % 1.91 [ 0.22, 16.58 ]
Hogarty 1988 7/37 8/33 52.7 % 0.78 [ 0.32, 1.92 ]
Marder 1987 2/35 6/31 39.7 % 0.30 [ 0.06, 1.36 ]
Subtotal (95% CI) 94 78 100.0 % 0.67 [ 0.33, 1.36 ]
Total events: 12 (FLUPHZ DECAN LOW DOSE), 15 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: Chi2 = 2.12, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 5.3. Comparison 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs
STANDARD, Outcome 3 Adverse effects: 1. Movement disorders (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs STANDARD
Outcome: 3 Adverse effects: 1. Movement disorders (medium term - 6 months to 1 year)
Study or subgroup
FLUPHZ
DECAN LOW
DOSE
FLUPHZ
DECAN
STANRD DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tardive dyskinesia
Kane 1983 2/62 4/64 100.0 % 0.52 [ 0.10, 2.72 ]
Subtotal (95% CI) 62 64 100.0 % 0.52 [ 0.10, 2.72 ]
Total events: 2 (FLUPHZ DECAN LOW DOSE), 4 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
2 Needing anticholinergic drugs
Marder 1987 6/22 3/28 100.0 % 2.55 [ 0.72, 9.05 ]
Subtotal (95% CI) 22 28 100.0 % 2.55 [ 0.72, 9.05 ]
Total events: 6 (FLUPHZ DECAN LOW DOSE), 3 (FLUPHZ DECAN STANRD DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
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Analysis 5.4. Comparison 5 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - LOW DOSE vs
STANDARD, Outcome 4 Adverse effects: 2. Continuous data - skewed data (endpoint scores, high = poor).
Adverse effects: 2. Continuous data - skewed data (endpoint scores, high = poor)
Study Intervention mean SD N
Kane 1983 Fluphenazine decanoate
(low dose)
0.52 1.00 62
Kane 1983 Fluphenazine decanoate
(standard dose)
1.04 2.42 64
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Analysis 6.1. Comparison 6 FLUPHENAZINE ENANTHATE vs PLACEBO, Outcome 1 Adverse effects:
Movement disorders - general.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 6 FLUPHENAZINE ENANTHATE vs PLACEBO
Outcome: 1 Adverse effects: Movement disorders - general
Study or subgroup
FLUPHENAZINE
ENANTHATE PLACEBO Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Needing anticholinergic drugs (short term - 6 weeks to 5 months)
Van Praag 1970 4/12 0/13 100.0 % 9.69 [ 0.58, 163.02 ]
Subtotal (95% CI) 12 13 100.0 % 9.69 [ 0.58, 163.02 ]
Total events: 4 (FLUPHENAZINE ENANTHATE), 0 (PLACEBO)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
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Analysis 7.1. Comparison 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 1
Global state: No clinically important global change (immediate - 0 to 5 weeks).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS
Outcome: 1 Global state: No clinically important global change (immediate - 0 to 5 weeks)
Study or subgroup
FLUPHENAZINE
ENANTHATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chien 1973 5/16 7/15 100.0 % 0.67 [ 0.27, 1.66 ]
Total (95% CI) 16 15 100.0 % 0.67 [ 0.27, 1.66 ]
Total events: 5 (FLUPHENAZINE ENANTHATE), 7 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 2
Adverse effects: Movement disorders - general.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS
Outcome: 2 Adverse effects: Movement disorders - general
Study or subgroup
FLUPHENAZINE
ENANTHATE
ORAL
NEU-
ROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 movement disorders: immediate (0 to 5 weeks)
Chien 1973 5/16 2/15 100.0 % 2.34 [ 0.53, 10.30 ]
Subtotal (95% CI) 16 15 100.0 % 2.34 [ 0.53, 10.30 ]
Total events: 5 (FLUPHENAZINE ENANTHATE), 2 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2 side effects: immediate (0 to 5 weeks)
Chien 1973 9/16 3/15 100.0 % 2.81 [ 0.94, 8.45 ]
Subtotal (95% CI) 16 15 100.0 % 2.81 [ 0.94, 8.45 ]
Total events: 9 (FLUPHENAZINE ENANTHATE), 3 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
3 parkinsonism: immediate (0 to 5 weeks)
Chien 1973 7/16 1/15 100.0 % 6.56 [ 0.91, 47.21 ]
Subtotal (95% CI) 16 15 100.0 % 6.56 [ 0.91, 47.21 ]
Total events: 7 (FLUPHENAZINE ENANTHATE), 1 (ORAL NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
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Analysis 8.1. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 1 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 1 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Albert 1980 4/11 13/22 59.1 % 0.62 [ 0.26, 1.45 ]
Chouinard 1978 2/16 6/16 40.9 % 0.33 [ 0.08, 1.41 ]
Total (95% CI) 27 38 100.0 % 0.50 [ 0.24, 1.05 ]
Total events: 6 (FLUPHENAZINE ENANTHATE), 19 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 2 Global state: 2. Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 2 Global state: 2. Relapse
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Malm 1974 6/26 3/31 100.0 % 2.38 [ 0.66, 8.61 ]
Subtotal (95% CI) 26 31 100.0 % 2.38 [ 0.66, 8.61 ]
Total events: 6 (FLUPHENAZINE ENANTHATE), 3 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 medium term (6 months to 1 year)
Chouinard 1978 1/16 3/16 100.0 % 0.33 [ 0.04, 2.87 ]
Subtotal (95% CI) 16 16 100.0 % 0.33 [ 0.04, 2.87 ]
Total events: 1 (FLUPHENAZINE ENANTHATE), 3 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 8.3. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 3 Leaving the study early.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 3 Leaving the study early
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Jain 1975 1/15 11/15 100.0 % 0.09 [ 0.01, 0.62 ]
Subtotal (95% CI) 15 15 100.0 % 0.09 [ 0.01, 0.62 ]
Total events: 1 (FLUPHENAZINE ENANTHATE), 11 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
2 short term (6 weeks to 5 months)
Malm 1974 6/26 3/31 100.0 % 2.38 [ 0.66, 8.61 ]
Subtotal (95% CI) 26 31 100.0 % 2.38 [ 0.66, 8.61 ]
Total events: 6 (FLUPHENAZINE ENANTHATE), 3 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 medium term (6 months to 1 year)
Chouinard 1978 1/16 3/16 100.0 % 0.33 [ 0.04, 2.87 ]
Subtotal (95% CI) 16 16 100.0 % 0.33 [ 0.04, 2.87 ]
Total events: 1 (FLUPHENAZINE ENANTHATE), 3 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 8.4. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 4 Mental state: 1. BPRS - endpoint scores (medium term - 6 months to 1 year) (high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 4 Mental state: 1. BPRS - endpoint scores (medium term - 6 months to 1 year) (high score = poor)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singh 1979 15 2.3 (0.05) 15 1.9 (0.1) 100.0 % 0.40 [ 0.34, 0.46 ]
Total (95% CI) 15 15 100.0 % 0.40 [ 0.34, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.86 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 5 Mental state: 2. Depression (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 5 Mental state: 2. Depression (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Singh 1979 3/15 0/15 100.0 % 7.00 [ 0.39, 124.83 ]
Total (95% CI) 15 15 100.0 % 7.00 [ 0.39, 124.83 ]
Total events: 3 (FLUPHENAZINE ENANTHATE), 0 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 8.6. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 6 Adverse effects: 1a. Movement disorders - general (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 6 Adverse effects: 1a. Movement disorders - general (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Albert 1980 0/11 1/22 14.6 % 0.64 [ 0.03, 14.52 ]
Singh 1979 10/15 6/15 85.4 % 1.67 [ 0.81, 3.41 ]
Total (95% CI) 26 37 100.0 % 1.52 [ 0.75, 3.07 ]
Total events: 10 (FLUPHENAZINE ENANTHATE), 7 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours fluphz enanthate Favours other depot neuro
224Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.7. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 7 Adverse effects: 1b. Movement disorders - needing additional anticholinergic drugs.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 7 Adverse effects: 1b. Movement disorders - needing additional anticholinergic drugs
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 short term (6 weeks to 5 months)
Malm 1974 12/26 5/31 100.0 % 2.86 [ 1.16, 7.06 ]
Subtotal (95% CI) 26 31 100.0 % 2.86 [ 1.16, 7.06 ]
Total events: 12 (FLUPHENAZINE ENANTHATE), 5 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
2 medium term (6 months to 1 year)
Albert 1980 0/11 3/22 14.2 % 0.27 [ 0.02, 4.88 ]
Chouinard 1978 16/16 14/16 85.8 % 1.14 [ 0.92, 1.41 ]
Subtotal (95% CI) 27 38 100.0 % 1.02 [ 0.76, 1.35 ]
Total events: 16 (FLUPHENAZINE ENANTHATE), 17 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 8.8. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 8 Adverse effects: 1c. Movement disorders - tardive dyskinesia: medium term (6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 8 Adverse effects: 1c. Movement disorders - tardive dyskinesia: medium term (6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chouinard 1978 8/16 9/16 100.0 % 0.89 [ 0.46, 1.71 ]
Total (95% CI) 16 16 100.0 % 0.89 [ 0.46, 1.71 ]
Total events: 8 (FLUPHENAZINE ENANTHATE), 9 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 8.9. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 9 Adverse effects: 1d. Movement disorders - tremor (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 9 Adverse effects: 1d. Movement disorders - tremor (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Albert 1980 5/11 10/22 32.3 % 1.00 [ 0.45, 2.21 ]
Chouinard 1978 9/16 8/16 38.7 % 1.13 [ 0.59, 2.16 ]
Singh 1979 10/15 6/15 29.0 % 1.67 [ 0.81, 3.41 ]
Total (95% CI) 42 53 100.0 % 1.24 [ 0.82, 1.87 ]
Total events: 24 (FLUPHENAZINE ENANTHATE), 24 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 8.10. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 10 Adverse effects: 2. Blurred vision (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 10 Adverse effects: 2. Blurred vision (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Singh 1979 1/15 0/15 100.0 % 3.00 [ 0.13, 68.26 ]
Total (95% CI) 15 15 100.0 % 3.00 [ 0.13, 68.26 ]
Total events: 1 (FLUPHENAZINE ENANTHATE), 0 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 8.11. Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS,
Outcome 11 Adverse effects: 3. Dry mouth (medium term - 6 months to 1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS
Outcome: 11 Adverse effects: 3. Dry mouth (medium term - 6 months to 1 year)
Study or subgroup
FLUPHENAZINE
ENANTHATE
OTHER DEPOT
NEUROLEPTICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chouinard 1978 4/16 9/16 90.0 % 0.44 [ 0.17, 1.15 ]
Singh 1979 4/15 1/15 10.0 % 4.00 [ 0.50, 31.74 ]
Total (95% CI) 31 31 100.0 % 0.80 [ 0.36, 1.76 ]
Total events: 8 (FLUPHENAZINE ENANTHATE), 10 (OTHER DEPOT NEUROLEPTICS)
Heterogeneity: Chi2 = 3.78, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours fluphz enanthate Favours other depot neuro
227Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.1. Comparison 9 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs
INTERMEDIATE/HIGH DOSE, Outcome 1 Global state: Relapse (short term - 6 weeks to 5 months).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 9 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE
Outcome: 1 Global state: Relapse (short term - 6 weeks to 5 months)
Study or subgroup
FLUPHZINE
ENANTH LOW
DOSE
FLUPHZ ENAN
INT/HIGH DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goldstein 1978 18/51 2/53 100.0 % 9.35 [ 2.28, 38.29 ]
Total (95% CI) 51 53 100.0 % 9.35 [ 2.28, 38.29 ]
Total events: 18 (FLUPHZINE ENANTH LOW DOSE), 2 (FLUPHZ ENAN INT/HIGH DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs
INTERMEDIATE/HIGH DOSE, Outcome 2 Leaving the study early (short term - 6 weeks to 5 months).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 9 FLUPHENAZINE ENANTHATE - DOSAGE STUDIES - LOW DOSE vs INTERMEDIATE/HIGH DOSE
Outcome: 2 Leaving the study early (short term - 6 weeks to 5 months)
Study or subgroup
FLUPHZINE
ENANTH LOW
DOSE
FLUPHZ ENAN
INT/HIGH DOSE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goldstein 1978 6/51 2/53 100.0 % 3.12 [ 0.66, 14.74 ]
Total (95% CI) 51 53 100.0 % 3.12 [ 0.66, 14.74 ]
Total events: 6 (FLUPHZINE ENANTH LOW DOSE), 2 (FLUPHZ ENAN INT/HIGH DOSE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 1 Global state: 1. Needing additional antipsychotic treatment.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 1 Global state: 1. Needing additional antipsychotic treatment
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Van Praag 1973 5/17 12/16 100.0 % 0.39 [ 0.18, 0.86 ]
Subtotal (95% CI) 17 16 100.0 % 0.39 [ 0.18, 0.86 ]
Total events: 5 (FLUPHENAZINE DECANAOTE), 12 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.020)
2 mediium term (6 months to 1 year)
Chouinard 1982 2/24 2/24 100.0 % 1.00 [ 0.15, 6.53 ]
Subtotal (95% CI) 24 24 100.0 % 1.00 [ 0.15, 6.53 ]
Total events: 2 (FLUPHENAZINE DECANAOTE), 2 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 10.2. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 2 Global state: 2. Relapse.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 2 Global state: 2. Relapse
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Altamura 1985 2/6 2/5 51.4 % 0.83 [ 0.18, 3.96 ]
Van Praag 1973 1/17 2/16 48.6 % 0.47 [ 0.05, 4.70 ]
Subtotal (95% CI) 23 21 100.0 % 0.66 [ 0.18, 2.43 ]
Total events: 3 (FLUPHENAZINE DECANAOTE), 4 (FLUPHENAZINE ENANTHATE)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 short term (6 weeks to 5 months)
Donlon 1976 6/14 3/16 100.0 % 2.29 [ 0.70, 7.48 ]
Subtotal (95% CI) 14 16 100.0 % 2.29 [ 0.70, 7.48 ]
Total events: 6 (FLUPHENAZINE DECANAOTE), 3 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
3 medium term (6 months to 1 year)
MacCrimmon 1978 7/24 3/25 100.0 % 2.43 [ 0.71, 8.32 ]
Subtotal (95% CI) 24 25 100.0 % 2.43 [ 0.71, 8.32 ]
Total events: 7 (FLUPHENAZINE DECANAOTE), 3 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 10.3. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 3 Behavioiur: Leaving the study early.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 3 Behavioiur: Leaving the study early
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Altamura 1985 2/6 2/5 51.4 % 0.83 [ 0.18, 3.96 ]
Van Praag 1973 1/17 2/16 48.6 % 0.47 [ 0.05, 4.70 ]
Subtotal (95% CI) 23 21 100.0 % 0.66 [ 0.18, 2.43 ]
Total events: 3 (FLUPHENAZINE DECANAOTE), 4 (FLUPHENAZINE ENANTHATE)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 short term (6 weeks to 5 months)
Donlon 1976 6/14 3/16 100.0 % 2.29 [ 0.70, 7.48 ]
Keskiner 1971 0/6 0/6 Not estimable
Subtotal (95% CI) 20 22 100.0 % 2.29 [ 0.70, 7.48 ]
Total events: 6 (FLUPHENAZINE DECANAOTE), 3 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
3 medium term (6 months to 1 year)
MacCrimmon 1978 7/24 3/25 100.0 % 2.43 [ 0.71, 8.32 ]
Subtotal (95% CI) 24 25 100.0 % 2.43 [ 0.71, 8.32 ]
Total events: 7 (FLUPHENAZINE DECANAOTE), 3 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 10.4. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 4 Mental State: BPRS medium term (6 months to 1 year - high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 4 Mental State: BPRS medium term (6 months to 1 year - high score = poor)
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
MacCrimmon 1978 17 26 (7) 22 26 (5) 100.0 % 0.0 [ -3.93, 3.93 ]
Total (95% CI) 17 22 100.0 % 0.0 [ -3.93, 3.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 5 Adverse effects: 1a. Movement disorders - general.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 5 Adverse effects: 1a. Movement disorders - general
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Immediate (0 to 5 weeks)
Kane 1978 (1) 9/26 3/23 100.0 % 2.65 [ 0.82, 8.64 ]
Subtotal (95% CI) 26 23 100.0 % 2.65 [ 0.82, 8.64 ]
Total events: 9 (FLUPHENAZINE DECANAOTE), 3 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
2 short term (6 weeks to 5 months)
Donlon 1976 12/14 13/16 92.8 % 1.05 [ 0.77, 1.45 ]
Kurland 1966 2/9 1/10 7.2 % 2.22 [ 0.24, 20.57 ]
Subtotal (95% CI) 23 26 100.0 % 1.14 [ 0.79, 1.64 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 14 (FLUPHENAZINE DECANAOTE), 14 (FLUPHENAZINE ENANTHATE)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 1.80, df = 1 (P = 0.18), I2 =45%
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Analysis 10.6. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 6 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs.
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 6 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 immediate (0 to 5 weeks)
Van Praag 1973 4/17 13/16 100.0 % 0.29 [ 0.12, 0.70 ]
Subtotal (95% CI) 17 16 100.0 % 0.29 [ 0.12, 0.70 ]
Total events: 4 (FLUPHENAZINE DECANAOTE), 13 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0063)
2 short term (6 weeks to 5 months)
Donlon 1976 13/14 15/16 100.0 % 0.99 [ 0.82, 1.20 ]
Subtotal (95% CI) 14 16 100.0 % 0.99 [ 0.82, 1.20 ]
Total events: 13 (FLUPHENAZINE DECANAOTE), 15 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
3 medium term (6 months to 1 year)
Chouinard 1982 16/24 17/24 50.5 % 0.94 [ 0.64, 1.38 ]
MacCrimmon 1978 10/24 17/25 49.5 % 0.61 [ 0.36, 1.06 ]
Subtotal (95% CI) 48 49 100.0 % 0.78 [ 0.57, 1.07 ]
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(. . . Continued)
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 26 (FLUPHENAZINE DECANAOTE), 34 (FLUPHENAZINE ENANTHATE)
Heterogeneity: Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 1.53 (P = 0.12)
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Analysis 10.7. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 7 Adverse effects: 1c. Movement disorders - parkinsonism (short term - 6 weeks to 5 months).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 7 Adverse effects: 1c. Movement disorders - parkinsonism (short term - 6 weeks to 5 months)
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kurland 1966 0/9 1/10 100.0 % 0.37 [ 0.02, 8.01 ]
Total (95% CI) 9 10 100.0 % 0.37 [ 0.02, 8.01 ]
Total events: 0 (FLUPHENAZINE DECANAOTE), 1 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 10.8. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 8 Adverse effects: 1d. Movement disorders - akathisia (Immediate - 0 to 5 weeks).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 8 Adverse effects: 1d. Movement disorders - akathisia (Immediate - 0 to 5 weeks)
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kane 1978 7/26 1/23 100.0 % 6.19 [ 0.82, 46.62 ]
Total (95% CI) 26 23 100.0 % 6.19 [ 0.82, 46.62 ]
Total events: 7 (FLUPHENAZINE DECANAOTE), 1 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 10.9. Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE,
Outcome 9 Adverse effects: 2. General adverse effects (immediate - 0 to 5 weeks).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE
Outcome: 9 Adverse effects: 2. General adverse effects (immediate - 0 to 5 weeks)
Study or subgroup
FLUPHENAZINE
DECANAOTE
FLUPHENAZINE
ENANTHATE Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Altamura 1985 0/6 5/5 100.0 % 0.08 [ 0.01, 1.14 ]
Total (95% CI) 6 5 100.0 % 0.08 [ 0.01, 1.14 ]
Total events: 0 (FLUPHENAZINE DECANAOTE), 5 (FLUPHENAZINE ENANTHATE)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6
WEEKS, Outcome 1 Global state: 1. Relapse (1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6 WEEKS
Outcome: 1 Global state: 1. Relapse (1 year)
Study or subgroup
FLUPHZ
DECAN 2
WEEKS
FLUPHZ
DECAN 6
WEEKS Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Khazaie 2005 11/18 13/19 100.0 % 0.89 [ 0.55, 1.44 ]
Total (95% CI) 18 19 100.0 % 0.89 [ 0.55, 1.44 ]
Total events: 11 (FLUPHZ DECAN 2 WEEKS), 13 (FLUPHZ DECAN 6 WEEKS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6
WEEKS, Outcome 2 Leaving the study early (1 year).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6 WEEKS
Outcome: 2 Leaving the study early (1 year)
Study or subgroup
FLUPHZ
DECAN 2
WEEKS
FLUPHZ
DECAN 6
WEEKS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Khazaie 2005 7/25 6/25 100.0 % 1.17 [ 0.46, 2.98 ]
Total (95% CI) 25 25 100.0 % 1.17 [ 0.46, 2.98 ]
Total events: 7 (FLUPHZ DECAN 2 WEEKS), 6 (FLUPHZ DECAN 6 WEEKS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6
WEEKS, Outcome 3 Mental state: 1. BPRS - endpoint scores (1 year) (high score = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6 WEEKS
Outcome: 3 Mental state: 1. BPRS - endpoint scores (1 year) (high score = poor)
Study or subgroup
FLUPHZ
DECAN 2
WEEKS
FLUPHZ
DECAN 6
WEEKS Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Total
Khazaie 2005 18 19 2.72 (1.9799) 100.0 % 2.72 [ -1.16, 6.60 ]
Subtotal (95% CI) 18 19 100.0 % 2.72 [ -1.16, 6.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 Thought disorder
Khazaie 2005 18 19 -0.39 (0.5728) 100.0 % -0.39 [ -1.51, 0.73 ]
Subtotal (95% CI) 18 19 100.0 % -0.39 [ -1.51, 0.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 2.28, df = 1 (P = 0.13), I2 =56%
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Analysis 11.4. Comparison 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6
WEEKS, Outcome 4 Adverse effects: 1. Movement disorders - MPRC (1 year, high = poor).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6 WEEKS
Outcome: 4 Adverse effects: 1. Movement disorders - MPRC (1 year, high = poor)
Study or subgroup
FLUPHZ
DECAN 2
WEEKS
FLUPHZ
DECAN 6
WEEKS Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Parkinsonian symptoms
Khazaie 2005 18 19 1.3 (0.6801) 100.0 % 1.30 [ -0.03, 2.63 ]
Subtotal (95% CI) 18 19 100.0 % 1.30 [ -0.03, 2.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Dyskinesia
Khazaie 2005 18 19 2.4 (2.126) 100.0 % 2.40 [ -1.77, 6.57 ]
Subtotal (95% CI) 18 19 100.0 % 2.40 [ -1.77, 6.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 11.5. Comparison 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6
WEEKS, Outcome 5 Quality of life: Quality of life scale (1 year) (high score = good).
Review: Fluphenazine decanoate (depot) and enanthate for schizophrenia
Comparison: 11 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - 2 WEEKS vs 6 WEEKS
Outcome: 5 Quality of life: Quality of life scale (1 year) (high score = good)
Study or subgroup
FLUPHZ
DECAN 2
WEEKS
FLUPHZ
DECAN 6
WEEKS Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Khazaie 2005 18 19 1.42 (5.6639) 100.0 % 1.42 [ -9.68, 12.52 ]
Total (95% CI) 18 19 100.0 % 1.42 [ -9.68, 12.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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A D D I T I O N A L T A B L E S
Table 1. Suggested design of future trials
Methods Allocation: randomised - clearly described generation of sequence and concealment of allocation.
Blindness: double - described and tested.
Duration: 12 months minimum.
Participants Diagnosis: schizophrenia (operational criteria).
N = 300*
Age: any.
Gender: both.
History: any.
Interventions 1. Fluphenazine decanoate/enanthate: clinically acceptable dose. N = 150
2. Oral antipsychotic: clinically acceptable dose. N = 150.
Outcomes Death and all causes of mortality**
Clinical global state - relapse**; clinically significant change in global state**; leaving the study early**
Service utilisation outcomes - hospital admission**, time in hospital.
Adverse effects: extrapyramidal adverse effects**, other adverse effects.
Economic outcomes.
Notes * The number of participants needed to gain sufficient power to highlight about a 10% difference between groups
for primary outcome depends on the primary outcome used and the prevalence/magnitude of this outcome. N =
300 is approximately the size of study to detect a 10% difference in improvement with 80% certainty
** Primary outcome
A P P E N D I C E S
Appendix 1. Previous search strategies
1. We updated previous searches in May 2002 using the Cochrane Schizophrenia Group’s Register search phrase:
[ fluphen* or *fluphen* or *modec* or *moditen* or *eutimox* or *flufen* or *prolixin* or *siqualone* or *anaten* or *dapotum* or
*decazate* or *lyoridin* in title, abstract, index terms of [REFERENCE] or [(fluphenaz* AND depot*) in interventions of STUDY]
2. Details of previous electronic searches.
2.1 Electronic searching
Relevant randomised trials were identified by searching several electronic databases (the Cochrane Schizophrenia Group’s Register of
Trials, the Cochrane Library, Biological Abstracts, EMBASE, MEDLINE, PsycLIT and SCISEARCH).
2.2 We searched the Cochrane Schizophrenia Group’s Register (1998) using the phrase:
(FLUPHEN* and DECANOATE or ENANTHATE ) or ((DEPOT* or (LONG and ACTING) or (DELAY* and ACTION)) and
(FLUPHEN* or MODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SIQUALONE* or ANATEN* or
DAPOTUM* or DECAZATE* or LYORIDIN*) or (#44=2 and #44=230) or #44=549)
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2.3 We searched the COCHRANE LIBRARY (Issue 2, 1998) using the Cochrane Schizophrenia Group’s phrase for schizophrenia (see
Group search strategy) combined with the phrase:
(FLUPHEN* and DECANOATE or ENANTHATE) or ((DEPOT* or (LONG and ACTING) or (DELAY* and ACTION)) and
(FLUPHEN* or MODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SIQUALONE* or ANATEN* or
DAPOTUM* or DECAZATE* or LYORIDIN*)) or (FLUPHEN* ME and DELAYED-ACTION-PREPARATIONS* ME))]
2.4 We searched BIOLOGICAL ABSTRACTS (January 1982 to June 1998 - current disc issue) using the Cochrane Schizophrenia
Group’s phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
[and (FLUPHENAZINE near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2
ACTION)) near (FLUPHENAZINE orMODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SIQUALONE*
or ANATEN* or DAPOTUM* or DECAZOTE* or LYONRIDIN*)]
2.5 EMBASE (January 1980 to June 1998 - current disc issue): we searched this database using the Cochrane Schizophrenia Group’s
phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
(FLUPHEN* near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION))
near (FLUPHEN* or MODITEN* or MODEC* or FLUFEN* or EUTIMOX* or PROLIXIN* or SIQUALONE* or ANATEN* or
DAPOTUM* or DECAZATE* or LYORIDIN*) or “FLUPHENAZINE-DECANOATE”/ all subheadings]
2.6 We searched MEDLINE (January 1966 to June 1998 - current disc issue) using the Cochrane Schizophrenia Group’s phrase for
randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
(FLUPHEN* near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION))
near (FLUPHEN* or MODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SEQUALONE* or ANATEN*
or DAPOTUM* or DECAZATE* or LYORIDIN*) or (“FLUPHENAZINE”/ all subheadings and explode “DELAYED-ACTION-
PREPARATIONS”/ all subheadings))]
2.7 We searched PsycLIT (January 1974 to June 1998 - current disc issue) using the Cochrane Schizophrenia Group’s phrase for
randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:
(FLUPHEN* near1 DECANOATE or ENANTHATE) or ((DEPOT* or (LONG near4 ACTING) or (DELAY* near2 ACTION))
near (FLUPHEN* or MODEC* or MODITEN* or EUTIMOX* or FLUFEN* or PROLIXIN* or SIQUALONE* or ANATEN* or
DAPOTUM* or DECAZATE* or LYORIDIN)
Appendix 2. Previous methods: data collection and analyses
1. Study selection
In the original review, all the studies we identified were inspected by the principal reviewer (SQ). A randomly selected sample of
10% of all reports was re-inspected by AD in order to ensure selection was reliable. Where disagreement occurred, we resolved this
by discussion, where there was still doubt, we acquired the full article for further inspection. Once we had obtained the full articles,
SQ and AD independently decided whether they met the review criteria. We resolved disagreement by discussion and when this was
not possible sought further information. We added these trials to the list of those awaiting assessment pending acquisition of further
information. For the updated version of this review, JR inspected and data extracted all studies.
2. Assessment of methodological quality
We allocated trials to three quality categories, as described in The Cochrane Collaboration Handbook (Alderson 2004). Again, we
resolved disputes by discussion. When this was not possible and further information was necessary to clarify which category to allocate
a trial to, we did not enter data and allocated the trial to the list of those awaiting assessment. We included only trials in Category A
or B in the review.
3. Data collection
In the first version of this review SQ and AD independently extracted data from selected trials. JR did this for the updated version.
Again, we resolved disputes by discussion. When this was not possible and further information was necessary to resolve the dilemma,
we did not enter data and added this outcome of the trial to the list of those awaiting assessment.
4. Data synthesis
4.1 Incomplete data.
Where more than 30% of those randomised were lost to follow-up by six months, or 50% by beyond that time, we felt data to be too
prone to bias and did not used these outcomes.
4.2 Dichotomous - yes/no - data.
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4.2.1 Statistics: For binary outcomes, for example, ’admitted’ or ’not admitted’, we estimated a Relative Risk with 95% confidence
interval. Where possible, we calculated the number needed to treat statistic (NNT) taking into account the event rate in the control
group.
4.2.2 Intention-to-treat: We present data on a ’once-randomised-always-analyse’ basis. Those who were lost to follow-up are all assumed
to have the negative outcome, with the exception of death, which was coded separately. For example, for the outcome of relapse, we
considered those who were lost to follow-up all to have relapsed.
4.2.3 Data reporting
4.3 Continuous - scale - data
4.3.1 Normal data: Mental health continuous data are often not ’normally’ distributed. To avoid the pitfall of applying parametric
tests to non-parametric data we applied the following standards to all data before inclusion: i. standard deviations and means had to be
reported in the paper or had to be obtainable from the authors; ii. when a continuous outcome started from a finite number (such as
0), the standard deviation, when multiplied by 2, had to be less than the mean (as otherwise the mean is unlikely to be an appropriate
measure of the centre of the distribution - Altman 1996). We did not enter data not meeting the second standard into the RevMan
calculator (which assumes a normal distribution). However, data not meeting these standards can be reported in the ’Other data types’
of the results section if they have been analysed with appropriate non-parametric tests. If continuous data were recording change, where
the finite parameters of the measure were unclear, the reviewers decided whether the data were usable or not.
4.3.2 Rating scales: A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality
and many are not valid, or are ad hoc. For outcome instruments some minimum standards have to be set. They could be that: i. the
psychometric properties of the instrument should have been described in a peer-reviewed journal; ii. not written or modified by one of
the trialists; iii. the instrument should either be: (a) a self report, or (b) completed by an independent rater or relative (not the therapist);
and iv. the instrument should be a global assessment of an area of functioning (Marshall 1998).
4.3.3 Endpoint versus change data: where possible we presented endpoint data and if both endpoint and change data were available
for the same outcomes then we only reported the former in this review.
4.3.4 Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a ’unit of analysis’
error (Divine 1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated.
This causes type I errors (Bland 1997; Gulliford 1999).
Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a
probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class
correlation co-efficients of their clustered data and to adjust for this using accepted methods (Gulliford 1999). If clustering had been
incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but
would have adjusted for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design
effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999).
5. Heterogeneity
Firstly, we considered all the included studies within any comparison to judge clinical heterogeneity. We then used visual inspection
of graphs to investigate the possibility of statistical heterogeneity. This was supplemented using, primarily, the I-squared statistic. This
provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate
was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (Higgins 2003). If
inconsistency was high, we did not summate these data, but presented them separately and investigated reasons for heterogeneity. Data
were presented using a fixed-effect model for homogeneous data and a random-effects model for heterogeneous data.
6. Tables and figures
Where possible we entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable
outcome for the fluphenazine esters.
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WH A T ’ S N E W
Last assessed as up-to-date: 1 December 2013.
Date Event Description
25 February 2016 Amended The comparison interventions in five studies (Falloon 1978, McCreadie 1980, McCreadie 1982,
Quitkin 1978 & Rifkin 1977) were incorrectly described as IM for the comparison Fluphenazine
decanoate IM versus oral neuroleptics. All now are correctly described as oral. Leaving the study
early data from Magnus 1979 have been removed for this comparison. These corrections do not
change results
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 4, 1997
Date Event Description
1 May 2014 New citation required but conclusions have not
changed
Additional data from three new trials have been added
to the review, no change to overall conclusions of review
4 December 2013 New search has been performed Results from 2013 search added to the review. Method
sections amended to include new Cochrane methodol-
ogy
25 January 2011 Amended byline corrected
30 October 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
SeemaQuraishi - prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report
(2002, 2011).
Maurice Eisenbruch - prepared the protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced
reports (2002, 2011).
Anthony David - acquired funding, helped prepare protocol, select studies, extract data, and produce the report (2002, 2011).
Clive Adams - acquired funding, helped prepare protocol, undertook searches, selected and acquired studies, extracted and summated
data, produce the reports and prepared the updated review (2002, 2011, 2013).
John Rathbone - selected and acquired studies, extracted and summated data and prepared the updated review (2002, 2011).
Enhance Reviews - Nicola Maayan and Rosie Asher screened studies, extracted data for two new studies, assessed the risk of bias for all
included studies, prepared ’Summary of findings’ tables and prepared the updated review (2013).
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D E C L A R A T I O N S O F I N T E R E S T
The authors have declared no conflicts of interest.
Enhance Reviews: is a company that carries out systematic reviews mostly for the public sector, it currently does not provide services
for the pharmaceutical industry.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NHS-ROCD Health Technology Assessment Programme., UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have updated our methods since publication of the protocol to reflect advances in Cochrane methodology.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Antipsychotic Agents [administration & dosage; ∗therapeutic use]; Delayed-Action Preparations [administration
& dosage; therapeutic use]; Fluphenazine [administration & dosage; ∗analogs & derivatives; therapeutic use]; Injections, Intramuscular;
Randomized Controlled Trials as Topic; Schizophrenia [drug therapy]
MeSH check words
Humans
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